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ABSTRACT 
 International health has typically focused on remediation of infectious diseases in 
developing countries. However, recent reports from the International Agency for 
Research on Cancer (IARC) have highlighted the importance of cancer incidence/ 
mortality in the developing world. Foodborne mycotoxins produced by fungi, called 
aflatoxin (AF) and fumonisin (FB), have been associated with hepatocellular and 
esophageal carcinomas among other deleterious effects, such as growth faltering and 
immune dysfunction. Exposure to these toxins in Ghana is particularly high due to food 
insecurity, climate, and lack of regulatory infrastructures. Work to alleviate AF and FB 
contamination in Africa has focused on instituting good agricultural and storage 
practices however, exposures remain inextricable in many communities. Utilization of a 
calcium montmorillonite clay, UPSN, shows promise of tightly binding both AF and FB 
in the gastrointestinal tract, thereby reducing their bioavailability. The objectives of this 
research were to determine exposure susceptibility in Ghana and to assess efficacy and 
safety of UPSN treatment within vulnerable populations.    
Cross-sectional data from six different regions of Ghana indicated that AF 
exposure is associated with maize consumption and region of residence. However, food 
preparation practices were not correlated to AF levels in the present study. Therefore, 
future intervention strategies were focused on the end point of the food consumption 
chain by reducing AF exposure from maize immediately prior to ingestion (i.e. UPSN 
treatment). In a three-month trial an encapsulated montmorillonite clay was efficacious 
in reducing AF exposure. However, concern for sustainability and its applicability for 
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children led to an effort to alter the dose dissemination form. Inclusion of UPSN in 
common Ghanaian foods retained the efficacy of the clay, reducing a short-term 
biomarker (AFM1) by 55%, and was determined to be safe in children (ages 3-9). 
Importantly, daily assessment of AFM1 levels was successful in providing statistical 
significance of intervention effects within only five days of treatment. Initial results 
indicate that UPSN could efficiently to bind both AF and FB in the gastrointestinal tract, 
reducing biomarkers for both toxins in animal models. Thus, UPSN could positively 
impact health in developing communities at risk for AF and FB exposure.   
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1. INTRODUCTION 
 
Worldwide cancer patterns have been changing drastically over the past decade. 
Cancer was previously considered to be a more prevalent disease in the developed 
world; however, the cancer incidence and mortality in developing countries has been 
rising. The World Cancer Report (2002), produced by the International Agency for 
Research on Cancer (IARC), clearly delineates the rising concern for worldwide public 
health care expenses, mortality, and morbidity resulting from cancer incidence (Parkin et 
al. 2005). In 2002, global mortality from cancer was higher than that from HIV/AIDS, 
tuberculosis, and malaria combined; accounting for 7.6 million lives lost. Following 
current trends, it is estimated that cancer burden will increase from 10 million new cases 
per year in 2000 to 16 million in 2020; with the largest burden (70%) occurring in the 
developing world (Lingwood et al. 2008). Annual new cases of cancers in developing 
countries are highest among lung and bronchus, stomach, liver, colon, and esophagus for 
men (Ferlay et al. 2010). Breast, cervical, lung and bronchus, stomach, colon, and liver 
make up the primary cancer types in women from the developing world (Ferlay et al. 
2010). In particular, more than 1 million of these cases are suspected to occur in Sub-
Saharan Africa (Parkin et al. 2003). The risk of dying from cancer in Africa is almost 
double that of developed countries due to late-onset diagnosis, inadequate treatment 
facilities, and few effective cancer medicines that are affordable and do not require 
hospitalization (Lingwood et al. 2008; Parkin et al. 2008). Adoption of a western 
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lifestyle, longer life, and improved diagnosis has been implicated in the rise of cancer 
incidence observed in Sub-Saharan Africa (Jemal et al. 2011).  
Primary liver cancer is of particular interest in these populations as it typically 
carries a very poor prognosis and remains the second and third highest in incidence and 
mortality in men and women in Sub-Saharan Africa, respectively (Ferlay et al. 2010; 
Parkin et al. 2005). The median survival rate of primary liver cancer patients is less than 
one year (Nguyen et al. 2009). More than 80% of the liver cancer cases occur in the 
developing world. The highest risk is in populations of Africa and Asia due to various 
factors; including a high prevalence of Hepatitis B and C (HBV and HCV) infection, 
alcohol consumption, dietary aflatoxin (AF) exposure, tobacco smoking, obesity, fatty 
liver, and iron load (Parkin et al. 2005). Of these risk factors HBV infection and 
exposure to a carcinogenic mycotoxin, named AF, are the two variables primarily 
implicated in the development of hepatocellular carcinoma (HCC) in Africa and Asia 
(Parkin et al. 2005). HCC accounts for 80% of all primary liver cancer cases in the world 
and is attributed to the unregulated growth and cellular replication of hepatocytes. HBV 
transmission in Africa occurs typically through an unexplained route of horizontal 
transmission between toddlers, with exposure and subsequent infection arising before the 
age of 5 (Burnett et al. 2012). Association of HCC incidence with HBV occurs in 
individuals who are chronically infected, thus consistently testing positive for HBV 
surface antigen (HBsAg). Although, introduction of HBV vaccination programs are 
currently underway in Africa and Southeast Asia it will take many generations to 
positively affect change in HCC incidence. Moreover, it is estimated that 40% of the 
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HCC cases attributable to AF exposure alone, occur in Africa (Liu Y and Wu 2010) and 
thus would not be affected by HBV vaccination. Other factors contributing to HCC rates 
in Western Africa include similar environmental carcinogens, such as fumonisin (FB) 
mycotoxins. Therefore, the development of interventions that are economically feasible, 
culturally acceptable, and would be sustainable in rural African communities are 
important to help reduce the burden of mycotoxin-induced health effects.  
1.1 Aflatoxin           
1.1.1 Aflatoxin chemistry 
Since the discovery of AFs in the early 1960s there has been a constant interest in 
the toxic effects and prevention of AF exposure in animals and humans. The AF 
congeners were isolated, and characterized chemically in the lab of Dr. Gerald Wogan in 
1963 following reports of acute hepatotoxicity in turkey poults in England (Asao et al. 
1965; Blount 1961; Lancaster et al. 1961). Exposed animals all had similar physiological 
endpoints of toxicity including acute hepatic necrosis, bile duct hyperplasia, loss of 
appetite, wing weakness, and lethargy (Blount 1961). Reports of turkey “X” disease 
causing deaths of thousands of chickens, turkeys, and ducks were later linked to 
consumption of contaminated feeds containing high levels of peanut meal as a protein 
source (Cullen and Newberne 1994). The discovery of toxicity resulting from the feed 
led to the hypothesis that AFs were an environmental contaminant. Further research 
indicated that AFs were indeed products of certain fungal strains that commonly grow on 
grains and groundnuts, such as peanuts. Subsequently, AFs were then assessed for 
toxicological significance in multiple laboratory animal species. Although species 
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differences in susceptibility were apparent, the target of AF toxicity has been proven to 
be the liver in most animals (Cullen and Newberne 1994).  
AFs comprise one group of over 300 known mycotoxins (Shephard 2006) and 
exposure predominantly occurs through ingestion of foods or feeds contaminated with 
Aspergillus flavus and/or A. parasiticus fungi. These fungi can produce four structurally 
different congeners of AF: B1, B2, G1, and G2 (AFB1, AFB2, AFG1, and AFG2). 
Structurally, AFs are highly substituted coumarins containing a fused dihydrofuran 
moiety. AFB1 and AFB2 are so named due to an emission of blue fluorescence following 
ultraviolet light stimulation and are characterized by the fusion of a cyclopentenone ring 
to the lactone ring of the coumarin moiety. AFG1 and AFG2 emit a greenish yellow 
fluorescence under ultraviolet light and contain a fused lactone ring in the coumarin 
moiety (Figure 1).  AFB1 and AFG1 are the most toxic due to an unsaturated double 
bond at the 8,9 position on the terminal furan ring which can be metabolized in animals 
and humans to a toxic and mutagenic epoxide.  
1.1.2 Source of aflatoxin contamination 
Aspergillus flavus and A. parasiticus can inoculate and colonize different crops 
by three primary routes: 1) insect transfer, 2) airborne spores, and 3) soil contact. Maize 
crops are one of the major hosts for A. flavus and A. parasiticus colonization. It was first 
determined by Anderson et al. (1975) that these pathogenic fungi could colonize maize 
not only during storage, but also in the field. The main route of inoculation of the fungi 
occurs through the silk by insects acting as vectors between contaminated ears. It has 
been suggested that insects facilitate infection in pre-harvest maize by transporting 
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Aspergillus spores from silk to silk, disseminating inoculum within the ears, and creating 
a favorable environment for Aspergillus growth and colonization through injury of the 
protective pericarp of maize kernels (Marsh and Payne 1984; Payne 1992; Wilson and 
Payne 1994). Peanut crops, like maize, are a favorable host for Aspergillus, however the 
route of contamination most likely originates from the soil, as the fruit of this plant 
develops underground (Cole et al. 1989). Contamination of both crops may also occur 
through airborne spores inoculating the silk of the maize and the above ground flower of 
peanut plants as well (Griffin and Garren 1976; Wilson and Payne 1994). It is important 
to note that crops infected with Aspergillus fungi do not always contain AFs. Production 
of mycotoxins by different fungal species depends largely on the environment in which 
the fungi are growing. In particular, the temperature and moisture content during 
Aspergillus growth have an effect on production of AFs during both pre-harvest growth 
and post-harvest storage. Climates where temperatures are predominantly below 20°C 
tend to have a low likelihood of Aspergillus contamination, while tropical climates (i.e. 
temperature minimum is >25°C) have common contamination in the soils, air, and crop 
surfaces (Cotty and Jaime-Garcia 2007a; Shearer et al. 1992). Rises in temperature 
during drought, in tropical countries with semi-arid and arid climates, has been 
associated with increases in levels of AF contamination of developing crops (Sanders et 
al. 1984; Schmitt and Harburgh Jr. 1989). Following contamination of developing crops 
with Aspergillus species; warm, moist conditions (i.e. high humidity) can increase 
production of AFs in mature crops (Cotty 1991; Russell et al. 1976). High humidity 
results in a high water content of previously dry seeds, which is conducive to 
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contamination and fungal growth. This effect has been best portrayed by Jaime-Garcia 
and Cotty (2003), where AF contamination was highest when mature crops were rained 
on just prior to or during harvesting. The influence that climate has on AF production 
results in continued exposure in human populations inhabiting tropical and sub-tropical 
areas. 
1.1.3 Aflatoxin toxicity         
The toxicity of AFs has been exhaustively studied in multiple animal species. 
While AFB1, AFB2, AFG1, and AFG2 are considered the “major” congeners from A. 
flavus and A. parasciticus, AFB1 is the most toxic and prevalent in food-stuffs (CAST 
2003). Acute toxicity from AFB1 exposure, termed aflatoxicosis, typically involves 
symptoms of anorexia, depression, ataxia, dyspnea, anemia, and hemorrhaging from 
body orifices; these conditions are often followed by death. Sensitivity to AFB1 has been 
established in vertebrates, invertebrates, plants, and bacteria; however the range of toxin 
dosimetry is wide. Differences in species susceptibility could be attributed to three 
important metabolic factors: 1) activation of AFB1 to the toxic 8,9 epoxide relative to 
other less toxic metabolites, 2) conjugation pathways resulting in relatively nontoxic 
metabolites that are eventually excreted, and/or 3) differences in absorption from the gut. 
As previously stated, the metabolic activation of AFB1 across the 8,9 double bond forms 
a short-lived but highly reactive epoxide that is the principle mediator of cellular injury. 
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The LD50 value for acute toxicity among non-human species ranges from 0.3-18.0 
mg/kg, depending on species, sex, route of administration, and age difference (Cullen 
and Newberne 1994).  
1.1.4 Carcinogenicity 
Following discovery of acute toxicity mechanisms and doses in animals it 
became evident that AFB1 was hepatocarcinogenic. Variability in the LD50 values 
among species is important not only in determining acute susceptibility, but also in 
indicating species susceptibility for cancer development. For instance, some of the most 
sensitive species to AFB1 are ducks and rabbits, while chickens are highly resistant. 
Chickens appear to be resistant to AF-induced carcinoma (Roebuck and Maxuitenko 
1994), while ducks develop HCC following treatment with levels as low as 0.02 
mg/kg/month over a 2 year period (Cova et al. 1990). A similar trend is observed in 
mouse and rat sensitivity. One of the most important findings among variations in 
species susceptibility has been delineated in the differences in conjugation of the 
carcinogenic AFB1-8,9-epoxide with glutathione (GSH) in rat and mouse models 
(Monroe and Eaton 1987; O'Brien et al. 1983; Quinn et al. 1990). Mice are relatively 
insensitive to induction of tumors in the liver following AFB1 treatment, even though 
epoxidation of AFB1 is high compared to rats. A high level of glutathione S-transferase 
(GST) activity has been reported to be important for species resistance to AFB1 (Eaton et 
al. 1994). Specific GST activity for AFB1-8,9-epoxide conjugation by homologous rat 
and mouse forms was 100-times higher in the mouse than the rat (Eaton et al. 1994). 
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These differences in metabolism are likely to result in the over five-times higher 
susceptibility observed in the rat.    
The carcinogenic potency of the AFs is highest for the AFB1 congener. 
Development of lesions in the liver has been thoroughly studied in multiple animal 
species; however rat and trout models have been the most frequently used. The first 
study to demonstrate effects of chronic AF exposure in a laboratory animal was 
conducted by Wogan et al. (1974). Rats fed levels of 1, 5, 15, 50, and 100 ng/g AF 
developed tumors at incidences of 9, 4.5, 19, 80, and 100% (Kensler et al. 2011; Wogan 
et al. 1974). This work indicated that HCC could develop at doses as low as micrograms 
per day, implicating the carcinogenic potential of AF consumption in human 
populations. Extrapolation of animal model carcinogenicity to risk assessment in human 
populations has been most useful in various studies with the monkey and rainbow trout, 
whose sensitivity is most closely related to humans. In a model utilizing three separate 
species of monkeys, (rhesus, cynomolgus, and African green) liver tumors developed in 
64% of animals treated with AFB1 for 6 months when doses were steadily increased 
from 0.2 to 0.8 mg/kg (Thorgeirsson et al. 1994). Studies in rats and rainbow trout 
exhibit a dose-response relationship between AFB1 exposure levels and DNA adduct 
formation even at levels relative to chronic human exposures (Buss et al. 1990; 
Dashwood et al. 1988). Therefore, it is widely accepted that AFB1 has no threshold level 
at which it would not pose a genotoxic risk.  
Carcinogenicity of AFB1 is dependent on activation through biological 
metabolism to the AFB1-8,9-epoxide. Following ingestion and absorption, AFB1 is 
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biotransformed predominantly by hepatocytes by both phase I and phase II metabolic 
enzymes. The AFB1-8,9-epoxide can react with biological nucleophiles, such as DNA, 
RNA, and proteins causing disruption of normal cellular function and DNA mutations. 
AFB1 is considered a complete carcinogen due to its ability to both induce and promote 
cancer development ((IARC) 1993, 2002). The ability of AFB1 to act as an initiator 
stems from its bioactivation to a direct-acting mutagen and subsequent disruption of 
several genes involved in carcinogenesis. The AFB1-8,9-epoxide reacts with guanine at 
the N-7 position resulting in an AFB1-DNA adduct and G:CT:A transversions. This 
adduct, 8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-N
7-Gua), is the most 
abundant occurring in animal models (Croy et al. 1978; Croy and Wogan 1981a, b; 
Essigmann et al. 1977; Lin JK et al. 1977). The importance of guanine as a target for 
AFB1 genotoxicity has been further solidified through various carcinogenicity studies 
showing G:C to T:A or G:C to A:T point mutations in AFB1 induced tumors (McMahon 
et al. 1987; McMahon et al. 1986; Sinha et al. 1988). These transversions were all 
observed at codon 12 of the K-ras gene. K-ras, a protooncogene, has been suggested as a 
target gene for AFB1 induced point mutations of the DNA. Evidence from a rat study 
conducted by Soman and Wogan (1993) showed point mutations in all AF related 
adenomas and carcinomas at the K-ras gene. High frequency of mutations at codon 249 
of the p53 tumor suppressor gene in human HCC cases has been reported in areas with 
chronic AF exposure (Bressac et al. 1991; Hsu et al. 1991). However, these studies were 
conducted in populations that are also afflicted with endemic HBV infection and 
therefore the observed mutations could not be solely attributed to AF. Multiple animal 
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models have failed to support the evidence of selective p53 mutations, on a codon 249 
equivalent, from AFB1-induced carcinogenicity (Wild and Montesano 2009). Human 
liver epithelial cells that were transfected with HBx gene and treated with AFB1 were 
more sensitive to the cytotoxicity of AFB1 and were sensitive to induction of mutations 
at codon 249 of p53 (Sohn et al. 2000). Thus, it is speculated that the codon 249 hotspot 
mutations observed in epidemiological studies is dependent on having both active HBV 
surface antigen and AFB1 present (Wild and Montesano 2009).  
The International Agency for Research on Cancer (IARC) has classified AFB1 as 
a Group 1 human carcinogen based on multiple epidemiological studies in populations 
with high HCC incidence ((IARC) 1993, 2002). Heterogeneity of AF contamination in 
crops and food-stuffs, differences in food intake, and metabolism between individuals 
makes exposure assessment difficult through analysis of food samples. Thus, use of 
biological metabolites resulting from AFB1 exposure, termed biomarkers, are the current 
standard for evaluating exposure in human populations and subsequent correlations with 
endpoints of disease. A thorough review of AFB1 biomarkers of exposure is discussed in 
subsequent sections; here biomarkers will only be referred to in the context of 
correlating human AFB1 exposure with HCC. Some of the first work to determine 
associations of AFB1 consumption with HCC development in humans involved case-
control studies in Mozambique, Swaziland, and the Philippines (Bulatao-Jayme et al. 
1982; Linsell and Peers 1977; Peers and Linsell 1977; Van Rensburg et al. 1985). These 
studies estimated dietary intake of AFs, retrospectively, for HCC cases and compared 
them with age and gender matched controls. Results from all three studies indicated that 
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mean AF exposure was positively correlated with HCC, with daily AF exposure in HCC 
cases estimated to be 4.5 times higher than in controls. Similarly, in Taiwan, detectable 
levels of AFB1 biomarkers were a risk factor for HCC, with an odds ratio of 1.5 
compared to controls (Lunn et al. 1997). The population of Qidong, China has been 
investigated over numerous years for AF, hepatitis B viral infection (HBV), and HCC 
incidence. This particular population has been a keystone in discovering effects of 
chronic AF exposure in humans, due to the seemingly inextricable contamination of 
foods and endemic HBV and HCC incidence. Sun et al. (1999) concluded that the 
attributed relative risk for HCC from AFB1 was 0.55 and thus, AF exposure accounted 
for a substantial portion of HCC cases in the screened population even in the presence of 
HBV (Sun Z et al. 1999). Individuals with HBV positive surface antigen (HBsAg) had a 
10-fold increased rate of HCC, when they also were consuming large amounts of AF 
compared to those with positive HBsAg and low exposure levels to AFs (Yeh et al. 
1985, 1989). Importantly, populations that are most at risk for AF exposure are often 
also populations with endemic HBV infection. Therefore, the epidemiology of AF 
induced HCC often cannot be considered without also accounting for chronic HBV 
infection.  
Like AFB1, chronic hepatitis infection has been categorized by IARC as 
hepatocarcinogenic in humans (IARC 1994). It is estimated that there are 400 million 
chronic HBV carriers worldwide (Parkin et al. 2005). DNA insertion by HBV under 
chronic infection conditions would result in genomic instability and ultimately liver 
disease and/or HCC. Also, chronic inflammation and generation of reactive oxygen 
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species resulting from HBV infection could have promoter-like activity, thereby 
increasing the incidence of AFB1 induced cell proliferation leading to tumor 
development. Multiple epidemiological studies have investigated the effect of the 
complex paradigm of chronic AF exposure and HBV infection on HCC development. It 
has been shown that the presence of HBV infection coupled with AFB1 exposure 
increases the risk of hepatocellular carcinoma (HCC) by up to 3.5-fold when compared 
to those who are seropositive for HBV in the absence of AFB1 exposure (Ming et al. 
2002; Sun Z et al. 1999). The activities of HBV and AF biomarkers as independent and 
interactive variables for risk of HCC were studied in a cohort of 18,244 men in Shanghai 
(Qian GS et al. 1994; Ross et al. 1992b). This duo of studies showed increases of HCC 
by, 3.4-fold when AF biomarkers were detected in the urine alone, 7.3-fold when 
participants tested positive for HBsAg alone, and 59.4-fold when participants tested 
positive for both HBsAg and AF biomarkers, respectively. These results and other 
studies have clearly established the synergistic interaction between AFB1 and HBV that 
occurs in the development of HCC. Wang LY et al. (1996) confirmed these findings in 
Taiwan, where HCC incidence in HBV carriers with detectable AF biomarkers had an 
odds ratio of 2.8 compared to those with non-detectable biomarkers. Similarly, when 
participants were classified as either having high or low AFB1 exposure, the odds ratio 
(5.5) clearly suggested that high exposure was a risk factor in HCC cases. HCC risk in 
HBsAg positive participants revealed a dose-dependent relationship with urinary AF 
biomarkers (Yu et al. 1997); providing further evidence of a causal relationship between 
AF exposure and HCC risk in human populations in both the presence and absence of 
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chronic HBV. Importantly, a recent risk assessment for global burden of AF-induced 
HCC attributed from 25,200 to 155,000 of the 550,000 annual cases of HCC to AF 
exposure alone (Liu Y and Wu 2010).  
1.1.5 Nutritional modulation 
    Although the vast majority of AF based research focuses on the genotoxicity and 
carcinogenic properties of AFB1 the first sign of exposure in all animal species is 
decreased growth and loss of appetite. This observation has led to the investigation of 
the role AF has in growth faltering and nutritional status. Food conversion efficiency is 
consistently decreased in animals exposed to AF versus those on control diets. Following 
administration of AF to broiler chicks and barrows, vitamin A levels were decreased in 
serum and liver (Harvey et al. 1994; Pimpukdee et al. 2004). AF-contaminated corn (500 
ng/g AFB1) also decreased serum vitamins A and E by half in young pigs exposed for 21 
days (Harper et al. 2010). Alternatively, vitamin E levels significantly increased as AF 
levels decreased in a Ghanaian clinical trial designed to mitigate exposure (Afriyie-
Gyawu et al. 2008b), and vitamin A levels were not correlated with AF-alb biomarkers 
in another human trial (Turner et al. 2003). These findings were contradictory to a study 
conducted in 2010 in Ghana, where individuals with high AF-alb levels had a 2.64-fold 
greater risk of vitamin A deficiency compared with those people with low AF-alb 
(Obuseh et al. 2010). A similar trend was observed for vitamin E deficiency; however it 
was not statistically significant. These differences could be a result of study design, 
population size, and/or HBV infection. For example, Obuseh et al., (2010) utilized a 
cross-sectional design with 147 adult participants; however Turner et al. (2003) 
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conducted a cohort study with 472 children ages 6-9. It is also important to note that 
high AF-alb levels were associated with an increased relative risk (odds ratio, 5.88) for 
HBsAg (Obuseh et al. 2010). The other two studies conducted in humans did not report 
HBV infection. Interestingly, Pan et al. (1993) observed an inverse correlation between 
serum vitamin A levels and development of HCC in HBsAg positive participants. 
Therefore, it is a possibility that HBV infection may play a role in lowered vitamin A 
levels in these human populations along with AF exposure. Vitamin A may also have a 
protective effect on exposure to carcinogens, like AF, by inhibiting their metabolic 
activation and preventing the initial steps of carcinogenesis (Huang et al. 1982). Thus, 
more research needs to be conducted to investigate the observed differences in serum 
vitamins A and E. Although AF-alb levels appear to be associated with vitamin A and 
vitamin E levels it is still unclear if this correlation is a result of changes in AFB1 
metabolism via vitamin A mediated mechanisms or if AF exposure directly affects 
vitamin absorption and/or metabolism. 
Vitamin D, zinc, and selenium were affected by AF exposure in animal models; 
however reports of these effects are limited. Broiler chickens had decreased vitamin D 
levels following treatment with 1 ppm AF for 5 days (Glahn et al. 1991). Aflatoxicosis 
studies in chickens demonstrated an inverse correlation between AF exposure and serum 
selenium levels (Hegazy and Adachi 2000). Chen et al. (2000) also observed a negative 
correlation between selenium and AF-alb levels from a Chinese population. Maternal AF 
exposure in pigs resulted in decreased zinc content in offspring, although there were no 
significant changes in the maternal zinc concentrations (Mocchegiani et al. 2001). 
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Lowered zinc in the piglets resulted in decreased cellular immunity due to lowered 
thymulin activity. Reduced zinc concentrations following AF exposure has also been 
observed in rats (Doyle et al. 1977; Ikegwuonu 1984). Influences of AF on all of these 
nutrients could have negative impacts on the immune system and growth. Other reports 
indicate that AF exposure can lead to obstructed biliary flow (Neeff et al. 2013; Wouters 
et al. 2013), in conjunction with dose-dependent increases of bilirubin and alkaline 
phosphatase in rats (Clifford and Rees 1967), goats (Clark et al. 1984), monkeys (Rao 
and Gehring 1971), and pigs (Cardeilhac et al. 1970). Results from these studies suggest 
that fat-soluble vitamins may not be fully absorbed from food due to decreased bile 
release from the liver. Recently, Gong YY et al. (2012) reported that, after adjusting for 
parasitic infection, AF exposure significantly contributed to the incidence of 
hepatomegaly in Kenyan school children, a condition which can be caused by a variety 
of ailments in children including biliary obstruction and anemia (Wolf and Lavine 2000). 
In addition to hepatic damage, AF also causes toxicity of the intestinal mucosa, resulting 
in decreased nutrient uptake (Applegate et al. 2009; Yunus et al. 2011a; Yunus et al. 
2011b). Although the concept of AF acting as an anti-nutrient is commonly accepted 
among mycotoxin researchers, the mechanisms behind these effects are still not well 
established and consequently cannot be applied to risk assessment for human 
populations. 
1.1.6 Growth suppression 
AF exposure has been strongly associated with growth impairment in various 
animal species (Cheng et al. 2001; Giambrone et al. 1985; Harvey et al. 1995, 1989a, 
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1989b; Kocabas et al. 2003; Pimpukdee et al. 2004). Overall, research has not only 
indicated reduced feed intake and lowered weight gain in mice, chickens, pigs, ducks, 
and turkeys, but has also shown that AF exposure correlates with lower feed conversion 
efficiency (Khlangwiset et al. 2011). In 30 animal studies designed to assess deleterious 
effects of AF on growth, 29 out of 30 reported that exposed animals exhibited either 
reduced weight gain or decreased feed conversion efficiency. Furthermore, multiple 
studies investigating the effects of AF on in utero development have reported reduced 
fetal weight and/or length (Khlangwiset et al. 2011). Turner et al. (2007) followed the 
growth of 138 Gambian infants from birth to 12 months and compared growth status 
with maternal AF exposure during pregnancy. In this study, a higher mean maternal AF-
alb concentration was significantly correlated with lower weight-for-age and height-for-
age z-scores. Maternal cord blood and infant blood samples were also assessed for AF-
alb, yielding detectable biomarker levels in 48.5% and 11% of samples, respectively. 
Furthermore, children ages 16-37 months from Benin exhibited a significant negative 
correlation between AF exposure (AF-alb) and height increase over 8-months (Gong YY 
et al. 2004). The growth stunting observed in children from Benin and Togo had a 
distinct dose-response relationship with AF-alb levels in the serum. A height-for-age z-
score of ≤ -2 had 30-40% higher AF-alb when compared to children not classified as 
stunted (Gong YY et al. 2002, 2003). Relationships observed between AF exposure and 
impaired growth are hypothesized to work through a complex mechanism that results in 
impaired gut health and function, decreased nutrient absorption, and chronic 
inflammation (Smith LE et al. 2012). Definition of the threshold for effect on growth, 
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nutritional health, and immunology is important in the effort to provide effective 
intervention strategies to reduce health consequences from AF exposure in developing 
countries.  
1.1.7 Immune suppression  
Nutritional interference resulting from AF exposure can have further influences 
on the immune status and overall health in those chronically exposed. AFs have been 
implicated as immune-toxicants in multiple animal species. Research has demonstrated 
deleterious effects on the innate immunity, such as phagocytic cell function following 
AF treatment in laboratory and domestic animals. Negative effects on human immunity 
are still inconclusive and more research needs to be conducted to make conclusions 
about possible health effects in high-risk populations. Communities that are frequently 
exposed to AFs are often also highly exposed to infectious pathogens. Low dose levels 
of AFB1 have diminished delayed-type of hypersensitivity, which is an important aspect 
of cell-mediated immunity. Both T and B cell responses have been reported to be 
lowered following AFB1 treatment. However, the findings from AFB1 related immune 
studies should be interpreted carefully as results have proven inconsistent. Different 
models, doses, and exposure duration seem to add variability to results, leading to some 
conclusions that AFB1 stimulates the immune response while others indicate a 
suppression of immunity. However, there is significant evidence in multiple domestic 
animal species that AFB1 suppresses T-cell mediated immunity, particularly in cattle 
(Bodine et al. 1984; Brown RW et al. 1981), poultry (Ghosh et al. 1990; Giambrone et 
al. 1985), and swine (Liu BH et al. 2002; Mocchegiani et al. 1998). A recent study in 
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rats following a short (i.e. one-week) or long exposure (i.e. five-weeks) to AFB1 has 
concluded that short-term exposures may act to suppress cell-mediated immunity while 
the long-term exposure may act to enhance cytokine excretion and an increase in 
inflammation and apoptosis (Qian G et al. 2013a).       
Following the one-week dose period, 25 µg AFB1/kg body weight decreased 
cytotoxic T cells (CD8+), and CD3-CD8a+ natural killer (NK) cells. Expression of 
interleukin (IL)-4 and interferon (IFN)-ɣ by CD4+ and CD8a+ T cells was inhibited by 
AFB1 treatment. However, many of these effects were differential following the five-
week dose period, depending on AFB1 dose. IL-4 expression by CD4+ T cells was 
consistently decreased with one and five weeks of treatment. IFN-ɣ and tumor necrosis 
factor (TNF)-α expression was elevated following five weeks of AFB1 treatment and this 
is in contradiction to the inhibition observed after one week of AFB1 (Qian G et al. 
2013a). The authors of this study concluded that short-term exposure to AFB1 can dose-
dependently lower the number of splenic CD8+ lymphocytes and NK cells and 
subsequent production of cytokines by CD4+, CD8+, and NK cells. Inversely, long-term 
exposure can result in stimulatory effects on such lymphocytes and expression of IFN-ɣ 
and TNF-α at low dose levels. IL-4 contains anti-inflammatory properties while IFN-ɣ 
and TNF-α are pro-inflammatory (Niiro et al. 1997). This would suggest that chronic 
and sub-chronic exposure to AFB1 could play a role in the establishment of a chronic 
inflammatory environment as a result of cytokine excretion. Similarly, Bruneau et al. 
(2012) showed, in vitro, that murine macrophages would decrease expression of anti-
inflammatory cytokine IL-10, but increase in pro-inflammatory IL-6 following pre-
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treatment with AF for 72 hr.  AFB1 exposure reduced helper T cells in the spleen and 
antibody response in mice (Hatori et al. 1991), inhibited excretion of IL-2, IL-3 and IFN-
ɣ by macrophages (Dugyala and Sharma 1996), and decreased murine macrophage 
phagocytosis and production of TNF-α in multiple cellular and animal models (Moon et 
al. 1999a, b). Dietary exposure to AFB1 in rats at levels from 0.01-1.6 mg/kg inhibited 
production of IL-1, IL-2, and IL-6 as well as increased the percentages of T cells but 
lowered B cells following 12 weeks of treatment (Hinton et al. 2003).  
Human populations that are at high-risk for AFB1 exposure are also likely to 
have frequent insults to their immune system from infectious pathogens or bacterial 
disease and therefore, it is difficult to ascertain effects of AF on human immunity. One 
human study in Ghana assessed correlations between AF-alb serum biomarkers and 
percentages of leukocyte immunophenotypes in peripheral blood (Jiang et al. 2005). 
Participants in this study with high levels of AF-alb had significantly lower levels of 
CD3+ and CD19+ cells, with activation marker CD69+, than those people with low AF-
alb. CD8+ T cells were also significantly lower in participants classified in the high 
AFB1 exposure group. Implications for the effects immunomodulation could have on 
such populations are demonstrated in a report on immune dysfunction in AFB1 exposed 
individuals infected with human immunodeficiency virus (HIV). Results from this study 
indicated that high AFB1 consumption may heighten some HIV associated changes in T-
cell and B-cell phenotypes, possibly accelerating the development of acquired 
immunodeficiency syndrome (AIDS) (Jiang et al. 2008). A cohort of children from 
Gambia showed a negative correlation in AF-alb levels and secretory immunoglobulin A 
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(IgA) from the saliva (Turner et al. 2003). IgA in mucosal barriers acts as a barrier for 
mucosal immunity to protect the body from potential infections. In populations 
frequently exposed to infectious insults an AFB1-mediated decrease in IgA could 
influence one’s susceptibility to infection.  
Importantly, lymphoid cells such as cytotoxic T-cells, NK cells, and other T-
lymphocytes function to directly or indirectly kill tumor cells. Therefore the inhibitory 
effects of AFB1 on such cells could have a pronounced effect not only on overall 
immunity, but also on tumor progression (Raisuddin et al. 1991). Effects on the immune 
system from AFB1 could also affect cancer progression through the development of 
chronic inflammation, which can stimulate cellular mitosis and promotion of initiated 
cancer cells. The complex dichotomous relationship of AFB1 with immune suppression 
and/or increased inflammatory response has serious implications for human health in 
populations that are frequently exposed to infectious diseases or at risk for carcinoma.               
1.1.8 Human exposure in Africa 
     AF exposure is most common in Southeast Asia, China, Africa, and the Caribbean. 
Human exposure most commonly occurs through frequent consumption of staple foods 
containing low levels of AFs. With global changes in climate over the past century it has 
been hypothesized that populations living between 40° N and S latitude are at risk for 
AF exposure, which includes the southern half of the United States (Williams et al. 
2004). However, the United States Food and Drug Administration (FDA) regulates 
levels of AFs in commercially available foods. Populations living in agricultural or low 
income communities are at higher risk of chronic exposure due to food instability, which 
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results in the consumption of a low-grade, homogenous diet. Crops produced and stored 
in tropical and sub-tropical regions are vulnerable for contamination, where humidity 
and drought are common and conducive for Aspergillus growth (Williams et al. 2004). 
Historically, acute aflatoxicosis in humans has resulted in multiple deaths. Two different 
reports from India, during 1974, indicated that the deaths of 106 and 97 people were 
associated with consumption of contaminated maize (Krishnamachari et al. 1975; 
Tandon et al. 1977). Africa, in particular, has a high incidence of AF exposure and 
continues to report multiple clusters of aflatoxicosis cases in humans. In 2004, a severe 
outbreak occurred in Kenya where 317 clinical cases were registered and 125 people 
died after consumption of maize contaminated with AF at levels as high as 1000 ppm 
(CDC and Prevention 2004). In October of 2011, the Kenya Red Cross recalled 360 tons 
of contaminated relief foods containing sub-lethal levels of AFs. It was estimated that 
60,000 children were put at risk after ingesting the contaminated food before the recall 
occurred (allAfrica 2011). 
Crop contamination and subsequent consumption of AF is commonly observed 
in staple cereal grains, such as, maize, rice, wheat, and groundnuts, such as peanuts 
(CAST 2003). These crops are typically a primary food source in developing countries, 
resulting in high-risk for both acute and chronic exposure in much of the population in 
developing countries. African populations in particular consume some of the highest 
amounts of maize and peanuts per person per day (Liu Y and Wu 2010). Studies 
utilizing biomarkers of exposure in West Africa have indicated on-going, extensive 
exposure (Egal et al. 2005; Njumbe Ediage et al. 2013; Shephard 2008; Wild et al. 1992; 
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Zarba et al. 1992). Exposure in a particular community, in the Ashanti Region of Ghana, 
has been well documented for numerous years, indicating chronic exposure over the past 
10 years (Jolly et al. 2006; Kumi et al. 2011; Mitchell NJ et al. 2013; Wang P et al. 
2008). AF exposure in this community, like others in Western Africa, can occur in 
humans in utero and continue through life. Detectable levels of AFs have been observed 
in umbilical cord blood samples taken at birth in populations where mothers are highly 
exposed (De Vries et al. 1989; Lamplugh et al. 1988; Turner et al. 2007). Importantly, a 
recent study conducted to assess the transfer and metabolism of AFB1 in human 
placentas was undertaken in Finland (Partanen et al. 2010). Researchers conducted 
perfusions of human placenta samples immediately following birth and provided the first 
direct evidence of the actual transfer of AFB1 across the placenta and into the fetal 
circulation. Based on this research the sole AFB1 metabolite produced by xenobiotic 
enzymes present in the placenta is thought to be aflatoxicol (AFL). AFs have also been 
detected in human breast milk (Adejumo et al. 2013; Coulter et al. 1984; Elzupir et al. 
2012; Jonsyn et al. 1995; Lamplugh et al. 1988; Wild et al. 1987; Zarba et al. 1992) and 
weaning foods (Gong YY et al. 2003; Gong YY et al. 2004; Kumi et al. 2011; Oyelami 
et al. 1996). Estimated exposure of adults in African populations ranges from 3.5 to 850 
ng/kg body weight/day (Liu Y and Wu 2010; Shephard 2008). Some of the highest 
exposure estimates in Africa are reported by Shephard (2008). During this risk 
assessment it was proposed that the highest exposure in Africa occurs in Ghana due to 
the large consumption of maize. Based on the assumption of an average 60 kg adult 
eating 1000 g/day of maize, exposure could be as high as 850 ng/kg body weight/day; 
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this accounts for a population risk of 70 liver cancer cases per 100,000 people/year in 
Ghana (Shephard 2008). Similarly, Liu and Wu have estimated that HCC cases 
attributable to AF consumption is highest in Africa accounting for 40% of those 
worldwide, with 2,150 to 9,300 annual incidences in Africa (Liu Y and Wu 2010). 
However, it is important to note that these extrapolations are typically based on levels of 
contamination in samples of food-stuffs and averages of total food consumption per day. 
In applying such evaluations of exposure to human risk assessment there are certain 
factors that should be recognized. First, levels of Aspergillus and subsequently AF 
contamination are temporally variable and typically result in heterogeneous or “hot spot” 
confluence of food-stuffs. Although analysis of AF levels in food is a critical tool for 
exposure assessment, it should be acknowledged that the values reported from these 
methods have the potential to grossly over or under estimate true exposure in the 
population of interest.  
AF associated health burdens in Africa are considerably higher once growth 
faltering, suppressed immunity, and incidences of acute aflatoxicosis are taken into 
account. Multiple factors contribute to the etiology of AF related disease outcomes in 
Africa. For example, AF exposure has been inversely correlated with various 
socioeconomic factors, such as income, education level, employment, and number of 
dependents in a household (Adejumo et al. 2013; Jolly et al. 2006; Shuaib et al. 2012). 
All of these factors could negatively influence the diversity of the diet and the quality of 
food consumed. However, it is important to note that there are reports of such 
socioeconomic statuses having no influence on AF exposure in Kenya and Malaysia 
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(Leong et al. 2012; Yard et al. 2013). A lack of effect observed in these studies could 
indicate that AF contamination is universally prevalent in the food supply and thus, 
effects health across all economic classes. Other contributors to the etiology of AF 
exposure are climate and cultural practices. As stated previously, Aspergillus growth and 
production of toxic AF metabolites is heavily influenced by drought, insect damage, and 
humidity. Sub-Saharan Africa is afflicted with cases of severe drought and famine. 
Drought negatively effects plant health and ability to stave off insect and fungal 
infestation. Although drought is common in sub-Saharan Africa, there is also high 
humidity content, which can create an optimal environment for fungal growth during 
storage of crops. Many storage and eating habits are culturally based. For instance, many 
African communities eat a high quantity of fermented maize. The traditional 
fermentation process in Ghana, in particular, occurs without addition of an accelerant. 
Typically maize is mixed with water until moist and allowed to ferment naturally for 
three days. The average household will make enough of this fermented dough to supply 
the family with meals for a week and store at room temperature until consumed. This 
practice results in growth of various fungi on the dough, which is desirable for taste and 
textural preferences. These types of cultural practices could potentiate AF contamination 
and are difficult if not impossible to change.  
1.1.9 AFB1 metabolism  
Approximately 50% of an orally administered dose of AFB1 is absorbed from the 
duodenal region of the small intestine (Hsieh and Wong 1994). Although there is a lack 
of research published on the mechanisms of AF absorption, one study indicated that the 
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uptake of AFB1 in the intestine occurs through passive diffusion (Kumagai 1989). The 
authors made this conclusion following the observation that the rate of AFB1 absorption 
increases nearly in proportion to an increase in AFB1 concentration. Interestingly, this 
study also indicated that the rate of absorption of AF was dependent on the lipophilicity 
of the compound. The rate of AFG1 absorption, a less lipophilic compound, was 
significantly lower than the rate for AFB1 following perfusion of the duodenum 
(Kumagai 1989). A recent in vitro study with human intestinal Caco-2 cells seems to 
support passive diffusion as the mechanism for AF absorption (Caloni et al. 2012). The 
uptake and efflux ratios of an AFB1 metabolite present in breast milk (AFM1) were <2, 
suggesting that AFM1 was passively transported. Furthermore, intracellular 
concentrations of AFM1 were very low and not dose dependent, indicating that Caco-2 
cells do not actively absorb AFM1.  
Following absorption to the vasculature, the majority of AF is concentrated in the 
liver, where AFB1 biotransformation by phase I and II enzymes results in the production 
of both activated and detoxified metabolites. Oxidation of AFB1 by Cytochrome P450 
enzymes (CYPs) is the primary mechanism of phase I AF metabolism. Epoxidation of 
the double bond on the terminal furan ring of AFB1 and AFG1 produces a genotoxic 
metabolite that can alkylate with nucleic acids (Eaton and Gallagher 1994; Essigmann et 
al. 1977; Swenson et al. 1977). Human CYPs: 1A2, 2A3, 2B7, 3A3, and 3A4 have all 
been implicated in the oxidative metabolism of AFB1 (Massey et al. 1995). CYP1A2 and 
3A4 are the predominant phase I enzymes that facilitate formation of the carcinogenic 
AFB1 exo-8,9-epoxide metabolite. When compared to CYP3A4 activity, CYP1A2 was 
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found to have a higher-affinity for AFB1 activation at low substrate concentrations 
relevant to human exposures (Gallagher et al. 1994). However, liver samples from 
Thailand showed a stronger correlation with CYP3A4 expression and AFB1 epoxidation 
at intermediate AFB1 concentrations relative to correlations with CYP1A2 expression 
(Kirby et al. 1993). Furthermore, it appears that CYP3A4 is constitutively expressed at 
higher levels than CYP1A2 in the human liver and could thus be the primary enzyme for 
AFB1 activation in humans (Gallagher et al. 1994; Kirby et al. 1993). The AFB1-epoxide 
is highly unstable and capable of covalently binding with DNA, resulting in irreparable 
adducts at the N-7 guanine position (Essigmann et al. 1977; Lin JK et al. 1977; Martin 
and Garner 1977).  
In addition to epoxidation of AFB1, phase I metabolism includes hydroxylation 
and demethylation, forming the M1 (AFM1), Q1 (AFQ1), P1 (AFP1), B2a (AFB2a), and 
aflatoxicol metabolites. These products exhibit less than 4% of the mutagenic activity of 
AFB1 in Salmonella assays (Coulombe et al. 1982; Essigmann et al. 1982; Gurtoo et al. 
1978; Wong and Hsieh 1976), therefore metabolism to the hydroxylated and 
demethylated metabolites is considered a detoxification process. Hydroxylation of AFB1 
to AFQ1 is increased following treatment with glucocorticoid-type inducers, implicating 
CYP3A subtypes as the active enzymes in formation of AFQ1 (Halvorson et al. 1988; 
Raney et al. 1992b). In contrast, AFM1 formation is catalyzed by the CYP1A subfamily 
of P450 enzymes (Koser et al. 1988; Metcalfe et al. 1981; Raina et al. 1985; Santhanam 
et al. 1989). An interesting epidemiological finding in a human population with high 
incidence of HCC and AF exposure in the Fujian Province of China further supported 
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the CYP1A mediated detoxification of AFB1 to AFM1 (Lin L et al. 1991). A higher 
incidence of hepatomas was found in participants who were nonsmokers compared to 
smokers over the age of 50 (odds ratio 2.06). It was hypothesized that the polycyclic 
aromatic hydrocarbons (PAHs) in cigarette smoke could induce CYP1A enzymes, 
leading to increased formation of AFM1, pushing AFB1 metabolism into the 
detoxification pathway.  
Phase II metabolism further transforms the phase I metabolites to higher 
molecular weight products for excretion. Conjugation of the epoxide with glutathione 
(GSH) and the hydroxylated metabolites with glucaronic acid are the major metabolites 
produced from phase II detoxification. Production of an AFB1-8,9-epoxide-GSH 
conjugate is catalyzed by glutathione S-transferases (GSTs) and has been identified as 
the primary metabolite in the bile following AFB1 treatment (Degen and Neumann 1978; 
Holeski et al. 1987; Raney et al. 1992a). Conjugation with GSH is typically followed by 
conversion to an AF-mercapturic acid residue by acetylases and peptidases; this 
metabolite is then excreted in the urine (Wild and Turner 2002). As previously discussed 
in section 1.3.1, GSH conjugation and GST activity are important in the susceptibility of 
different species to AFB1 toxicity. For instance, oral doses as high as 10,000 ppb AFB1 
do not cause liver cancer in mice while levels as low as 15 ppb cause increased tumors in 
rats (Wogan and Newberne 1967). This difference in susceptibility can be explained by 
the fact that mice constitutively express murine GST A3-3, which catalyzes conjugation 
to 50 times faster than in sensitive species (Eaton and Gallagher 1994). Humans are 
thought to have a metabolic capacity similar to that of the rat with regard to AFB1 
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detoxification. Human GSTs do not readily conjugate the epoxide metabolite, resulting 
in a longer half-life and increased exposure in vivo. Glucuronidation of AFM1, AFP1, 
and aflatoxicol are important steps that enhance their rates of elimination from the body. 
Conjugation with glucuronide appears to occur at a higher rate with AFP1 compared to 
the other hydroxylated metabolites (Eaton et al. 1994). Many of the AFB1 metabolites 
are utilized in human studies as biomarkers to assess exposure and effect (Figure 2).    
1.1.10 Biomarkers of exposure           
As previously indicated, mycotoxin exposure assessment in human populations is 
difficult through food screening due to the heterogeneous nature of mycotoxin 
contamination and human dietary habits. Similarly, predictions and associations with AF 
consumption and health outcomes are difficult to assess in humans due to the latent 
nature of AF-induced disease. Therefore an effort to discover biomarkers that correlate 
with xenobiotic ingestion was initiated over 20 years ago for use in human based 
epidemiological and chemoprevention trials (Turner et al. 2012; Wild and Turner 2001, 
2002). Primary metabolites excreted in the urine, such as AFM1, AFP1, and AFQ1, were 
some of the first metabolites investigated as potential biomarkers of exposure in diverse 
human populations (Gan et al. 1988; Groopman et al. 1992c; Ross et al. 1992a, 1992b; 
Zhu et al. 1987). During a cross-sectional survey in Zimbabwe, AFM1 was found in the 
urine at a higher rate than any other metabolite from 1200 human samples (Nyathi et al. 
1987). Following this report Zhu et al. (1987) demonstrated that urinary AFM1 excretion 
was also linearly related to AFB1 consumption. This study collected daily urine samples 
and food samples from 32 households in Fushui County of the Guangxi Autonomous 
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Region of the People’s Republic of China and analyzed each for AFM1 and AFB1, 
respectively. Results indicated a strong positive correlation (correlation coefficient of 
0.66) between dietary AFB1 intake and urinary AFM1 excretion (Zhu et al. 1987). 
Dosimetry analysis in a rat model confirmed the linear relationship between AFM1 in the 
urine and AFB1 intake with an even stronger correlation coefficient of 0.93 (Riley et al. 
1993). Data from this study and Groopman et al. (1992c) estimated that between 1.2 and 
2.2% of the total AFB1 intake is excreted as AFM1 in the urine. Excretion of AFM1 
occurs rapidly, following an oral dose of AFB1, typically peaking in the first 12 hr and 
decreasing to undetectable levels within 48 hr (Dalezios et al. 1973; Groopman et al. 
1988; Mitchell NJ et al. 2013; Sarr et al. 1995). Thus, level of urinary AFM1 is 
indicative of AF exposure within the past two days. Interestingly, AFM1 received its 
name due to its presence and discovery in breast milk from AF exposed mothers. 
Although this marker can be used to determine mother-child exposure, it is not 
commonly used in exposure assessment for adults. Total excretion of AFM1 in breast 
milk has been estimated to account for only 0.09 to 0.43% of AFB1 intake of the mother 
(Zarba et al. 1992). Urinary AFP1 and AFB1 are not linearly correlated with AF intake in 
humans or rats (Groopman et al. 1992a, 1992b. 1992c). 
Scholl PF et al. (1997) investigated the use of AFB1-mercapturic acid as a 
biomarker of carcinogenic susceptibility in rats. Because the AFB1-mercapturic acid is a 
product of the GST mediated detoxification pathway for the AFB1 epoxide, it was 
speculated that this marker could be utilized in intervention therapy trials intended to 
induce the rate of GST activity. Although there was a dose-dependent relationship 
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between AF treatment and excretion of mercapturic acid conjugates, this biomarker has 
not been extensively utilized.     
AFM1 is an important tool for assessing exposure in human populations; 
however, AFB-N7-guanine excretion in the urine is a useful biomarker of effect. AFB-
N7-guanine is the primary AFB1-DNA adduct excised from the DNA and present in 
urine (Croy et al. 1978; Essigmann et al. 1977). This biomarker is removed rapidly from 
the DNA and has a half-life of 8-10 hr in rats (Bennett et al. 1981; Groopman et al. 
1980). A correlation coefficient of 0.99 was found in rats indicating a strong relationship 
between a p.o. dose of AFB1 and urinary concentration of the genotoxic metabolite 
(Groopman et al. 1992b). This correlation was also observed in a genetically diverse 
human population from China (correlation coefficient: 0.65) (Groopman et al. 1992c). 
One of the most striking studies that provides evidence for AFB-N7-guanine use as a 
biomarker of biological effect was determined in a prospective study, which is the most 
rigorous test for association between a suspected causal agent and disease outcome. Ross 
et al. (1992b) conducted a prospective study in Shanghai with 18,244 male participants 
starting in 1986 and concluding three and a half years later. Of the study participants, 22 
developed HCC within the study duration. Analysis of urine samples indicated that the 
presence of AF biomarkers carried a relative risk of 3.8 for development of liver cancer. 
AFB-N7-guanine in particular showed a highly significant increase in relative risk (RR= 
4.9) for cancer development (Ross et al. 1992b). Interestingly, the relative risk for liver 
cancer in participants with positive AF markers and HBsAg was 60. This study was the 
first to show both a synergistic interaction between HBsAg and AF for liver cancer 
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development, and a positive relationship between an AFB1 genotoxic metabolite and 
disease outcome.  
Although the use of urinary biomarkers such as AFM1 and AFB-N
7-guanine have 
been useful in epidemiology based research, their short half-lives make exposure 
assessment a moving target due to high variability in AF intake and subsequent 
excretion. Thus, studies utilizing these markers require large population sizes and 
multiple samplings for strength of data analysis. The AFB1-albumin adduct (AFB1-alb) 
however has a half-life equivalent to that of serum albumin (Sabbioni et al. 1987), which 
is 20 days in humans and 2.6 days in rats (Peters 1970; Schreiber et al. 1971). During 
AFB1 metabolism, the epoxide can be hydrolyzed spontaneously in the presence of water 
to produce an 8,9-dihydrodiol which is reactive with proteins and binds to one or more 
lysine residues in serum albumin, which can be quantified in animals and humans 
(Sabbioni et al. 1990; Sabbioni et al. 1987; Skipper et al. 1985; Wild et al. 1986). The 
extant scientific literature labels this biomarker as either AFB1-albumin (AFB1-alb) or 
AFB1-lysine depending on the context; here AFB1-alb will be used in reference to this 
metabolite. Molecular dosimetry of AFB1-alb and AF intake in humans was first 
described by Gan et al. in 1988. During this study linear regression models demonstrated 
a strong positive correlation between the biomarker and exposure (Gan et al. 1988). Data 
from this study also indicated that the AFB1-alb adduct levels represent approximately 
1.4 to 2.3% of a daily dose of AFB1. This is similar to rat (1 to 2%) (Sabbioni et al. 
1987; Wild et al. 1986) indicating the rat as an appropriate model for human excretion. 
Due to the 20 day turnover rate in humans for albumin it has been estimated that AFB1-
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alb levels are 30 times higher than that produced by a one-day exposure and can reach a 
steady state in chronically exposed populations (Gan et al. 1988; Groopman et al. 1994; 
Sabbioni et al. 1987). AFM1, AFB1-alb, and AFB-N
7-guanine have been integral to 
epidemiological surveys and risk assessment as well as determining efficacy in 
intervention trials in human populations.  
1.1.11 Regulation 
Governmental regulations to reduce AF exposure in animals and humans have been 
enacted in the United States and Europe due to the concern for AF-induced toxicity. 
Feed for mature, non-lactating animals has been assigned an FDA action limit of 100 
ppb total AFs in the U.S. and commodities destined for human consumption cannot 
exceed 20 ppb. Due to high consumption of milk by infants and children the FDA action 
level for AFM1 in milk products, has been lowered to 0.5 ppb. Although regulations on 
AF content have been beneficial in U.S. and European markets, such regulations are 
lacking in most African countries. It is also important to note that strict European and 
U.S. regulations have influenced exportation of grains and oilseeds from Africa, 
resulting in farmers keeping the lower quality produce for their own consumption. 
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1.2 Fumonisin   
1.2.1 Fumonisin chemistry 
Fumonisins (FBs) are a recently discovered family of mycotoxins, consisting of 
15 structurally similar analogs produced by Fusarium verticilliodies (moniliforme) and 
F. proliferatum (Marin S et al. 2004). While Fusarium fungi, identified by John Sheldon 
in 1904, was known to cause adverse health effects in animals, the toxic agent was not 
elucidated until many years later. During an investigation of increased esophageal cancer 
incidence in South Africa, scientists elucidated the structure of FBs and implicated them 
as the source of toxicity (Gelderblom et al. 1988). It was later discovered that the source 
of the described FBs was F. verticilliodies. FBs contain a long carbon-chain backbone 
with two tricarboxylic acid groups esterified at C14 and C15. The tricarboxylic acid and 
amine groups on the carbon-chain make the compounds highly water soluble (Figure 3). 
The fumonisin B1 (FB1) isoform is the most studied and is frequently implicated in the 
manifestation of multiple animal and human diseases and thus will be the toxin of 
interest in this text. The stereochemistry of FBs is still unknown. However, it has been 
proposed that the acid side chains can act with the backbone, causing the molecule to 
fold on itself creating a spherical globular model. This model suggests that FB1 could be 
a potential chelator of ions important for cellular function, such as potassium and 
calcium (Beier and Stanker 1997). 
1.2.2 Source of fumonisin contamination 
Ear rot and kernel disease in maize most frequently results from infection with 
Fusarium fungi (Marasas et al. 1984). Fusarium species are primarily associated with 
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infection of maize crops but can also affect wheat and other cereal grains (Marasas 
1995). Two factors that contribute to the growth of F. verticilliodies and F. proliferatum, 
and the production of FBs, are water activity (aw) and temperature (Doohan et al. 2003). 
Climate affects not only growth and germination, but production and dispersal of 
Fusarium species as well. F. verticilliodies and F. proliferatum are known to reproduce 
both sexually and asexually (Leslie 1996; Parry et al. 1995). Optimal temperatures for 
germination are between 25-37°C, and a minimum aw of 0.88 is required (Marin S et al. 
1996). Water activity defines the intensity of association between water and a non-
aqueous substance and typically rises with temperature. It is calculated as a ratio of 
vapor pressure of water in a solid material (i.e. maize) to vapor pressure of pure water, 
thus an aw of 0.88 means the vapor pressure of the maize is 88% that of pure water. A 
high aw value indicates a high-risk for bacterial, yeast, and fungal growth. Optimal 
conditions for growth of F. verticilliodies and F. proliferatum on maize were reported at 
30°C and an increasing aw (>0.925) (Marin S et al. 1995). Although Fusarium is one 
fungi that is often attributed to global contamination, the two species known to produce 
FBs, F. verticilliodies and F. proliferatum, grow best in high temperatures (Keller et al. 
1997; Kostecki et al. 1999; Marin S et al. 1999a; Miller 2001). FB production by these 
fungi is more highly dependent on aw than temperature; the temperature range for 
optimal FB production can range between 15-30°C (Cahagnier et al. 1995; Marin S et al. 
1999a). In general, F. verticilliodies FB production is greatest at 20-25°C and aw 0.98, 
however F. proliferatum prefers lower temperatures around 15°C (Marin S et al. 2004). 
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Thus, reports of high prevalence of Fusarium infection and FB exposure in tropical and 
sub-tropical climates, where the relative humidity is highest, are not unexpected.  
1.2.3 Fumonisin toxicity 
FB1 has a complex mode of action and biological effects have been difficult to 
extrapolate to other species, particularly humans, due to gender, strain, and species 
differences in effects (Muller et al. 2012). The complexity of FB toxicity can be fully 
appreciated when assessing variability in species sensitivity to the toxin. Horses and 
swine are the most sensitive species to FB exposure. Horses may develop equine 
leukoencephalomalacia (ELEM) following the ingestion of as little as 5-10 ppm. ELEM 
is characterized by necrosis of the brain white matter leading to signs such as ataxia, 
trembling, anorexia, and death (Kellerman et al. 1990; Marasas et al. 1988; Uhlinger 
1997). However, toxicity manifests differently in swine with the development of porcine 
pulmonary edema following FB1 ingestion, frequently resulting in death. The exact 
mechanism by which pulmonary edema develops in swine is unknown; however, there is 
evidence that FB1 acts as a cardiotoxin through the increased production of TNF-α (He 
et al. 2001; Soriano et al. 2005). It is also suggested that the disruption of sphingolipid 
metabolism by FB1 causes collapse of cell to cell junctions leading to degradation of the 
endothelial barrier and formation of “leaky” vessels, which results in hypertension 
(Ramasamy et al. 1995). 
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Figure 3. Fumonisin chemical structure. A) fumonisin B1, B) sphinganine, C) 
sphingosine 
 
  
 39 
 
During multiple rodent toxicity assays conducted by the U.S. Department of 
Health National Toxicology Program, the most common toxic endpoints identified 
following FB1 treatment was renal carcinogenicity and nephrotoxicity (NTP 2001). 
Target organs for FB1 toxicity are the kidney and liver in rodent models. Acute toxicity 
of FB1 appears to be low but at a dose of 150 ppm, for 4 weeks in Sprague-Dawley rats, 
significant increases in triglycerides, cholesterol, and alkaline phosphatase (ALP) were 
observed indicating hepatotoxicity under this treatment regimen (Voss et al. 1993a). 
Cortical nephrosis was also observed in animals given lower doses of FB1, however this 
study also indicated that males were more sensitive to FB1-induced renal toxicity than 
female Sprague-Dawley rats. The same kidney lesions, tubular epithelial basophilia and 
cell degeneration in the proximal convoluted tubules, did not occur in females until a 
dose of 50 ppm, while males developed these histopathological effects after 15 ppm FB1. 
Although Fischer-344 rats (F344) demonstrated similar sex-linked sensitivities to FB1 
nephrotoxicity as the Sprague-Dawley rats, hepatic apoptosis occurred more frequently 
in females of this breed (NTP 2001). In contrast, it was reported that FB1 treatment in 
B6C3F/Nctr BR mice, at the same doses given to rats (up to 56 mg/kg), does not result 
in nephrotoxicity, but causes hepatocellular effects such as, necrosis, periportal 
hypertrophy, and centrilobular and bile duct hyperplasia (NTP 2001). Increased levels of 
alanine aminotransferase (ALT) and ALP in the serum also indicated hepatotoxic effects 
of FB1 and, like rats; females were more sensitive to the hepatic toxicity than males. 
Interestingly, male BDIX mice, dosed with F. moniliforme culture, showed signs of 
hepatotoxicity but not nephrotoxicity. Gelderblom et al. (1991) discovered fibrosis, 
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degeneration, and proliferation of the hepatobiliary tract in male mice given FB 
treatment but found minimal changes in the kidney. Although, the toxins produced from 
the F. moniliforme cultures used in this study were not defined, this is one of the first 
studies to demonstrate the possible carcinogenicity of FB. Gender-differences in 
susceptibility are also prevalent among other species. Male pigs are more highly affected 
by FB1 exposure than females. FB1 treatment in weanling pigs decreased antibody levels 
following vaccination and expression of IL-10 in males only (Marin DE et al. 2006). 
Similarly, males were more sensitive to toxicity as evidenced by higher levels of free 
sphingolipids in the lungs (the target organ in swine) when compared to effects in 
females (Rotter et al. 1996). Sub-chronic exposure assessment in F344 rats confirmed 
the kidney as a target organ in this species and its gender-specific variability (Voss et al. 
1995).  
Evidence of renal carcinogenicity in F344 rats occurred in males following a two 
year treatment protocol (NTP 2001). Doses of 50 and 150 ppm FB1 included in the diet 
resulted in renal tubular adenomas, carcinomas, and increases in preneoplastic lesions. 
Renal carcinomas were highly metastatic; metastasis to the lung occurred in 50% of rats 
at the highest dose of FB1. Renal tubular carcinomas showed a malignant anaplastic 
phenotype that was highly invasive and mitotic (Hard et al. 2001). The incidence of 
hepatocellular neoplasms were higher in females than males in a study conducted by the 
same group utilizing B6C3F/Nctr mice (NTP 2001). FB1-mediated toxicity studies 
lasting for two years in BDIX mice resulted in increased hepatocyte nodules and HCC 
(Gelderblom et al. 1991; Gelderblom et al. 1996b). Interestingly, the authors also 
 41 
 
reported hepatotoxic and nephrotoxic non-neoplastic lesions at lower doses that did not 
induce carcinogenic effects. Based on these chronic studies a no observed effect level 
(NOEL) of 0.67 mg/kg b.w. per day was defined for tumor induction in rats and 0.22 
mg/kg for renal toxicity (Howard et al. 2001; NTP 2001).     
1.2.4 Mechanism of action 
FB1 is poorly absorbed by the GI tract, only 4% of an orally administered dose 
was recovered in the plasma and tissues of rats (Martinez-Larranaga et al. 1999). FB1 is 
rapidly distributed to the liver and kidney and eliminated with a plasma half-life of only 
3.15 hr Treatment of Sprague-Dawley rats for ten days showed accumulation of FB1 in 
the kidney and liver, although the concentration in the kidney was 10-fold higher than 
the liver (Riley and Voss 2006). Importantly, the concentration of FB1 in the kidney 
positively correlated with histopathological changes observed in the kidneys. Multiple 
studies designed to assess the metabolism and biotransformation of FB1, in vitro and in 
vivo, have indicated that FB1 is not biologically activated or deactivated following 
ingestion. Unlike AFB1, CYP450 enzymes do not metabolize FB1. However, a 
hydrolyzed form of FB1 (HFB1) is excreted in the feces (Shephard et al. 1995, 1994). 
The HFB1 excreted product is not a result of direct biological metabolism; it results from 
microbial deesterification of the tricarboxylic acid groups in the gut and not well 
absorbed. Therefore, although HFB1 is more toxic than FB1 following intraperitoneal 
administration (Seiferlein et al. 2007), it is not thought to contribute to FBs toxicity 
outside of possible GI effects (Humpf et al. 1998). Absorbed FB1 primarily remains in 
its non-metabolized form and is rapidly excreted in the feces (primary route) or urine.    
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Structurally, the 3,5-dihydroxy, 2-aminoalkane backbone of FB1 is similar to 
endogenous sphingolipids, sphinganine and sphingosine; this likeness is believed to be 
the basis of their toxicity (Merrill et al. 1996) (Figure 4). The backbone similarity to 
natural substrates of sphinganine N-acetyltransferase (ceramide synthase) led to research 
involving the inhibition of this important enzyme by FB1. Its suspected mode of action is 
described in Figure 4. Ceramide synthase is an integral enzyme in cellular sphingolipid 
metabolism by acetylating free sphinganine to produce dihydroceramide during de novo 
sphingolipid synthesis. This enzyme also catalyzes deactylation of sphingosine to 
ceramide (Mullen et al. 2012; Pewzner-Jung et al. 2006). There is evidence that 
sphingolipids are not solely utilized as structural units of biological membranes, but are 
involved in various intracellular and extracellular functions including differentiation, 
growth, proliferation, senescence, apoptosis, and necrosis (Adam et al. 2002; Okazaki et 
al. 1989; Ruvolo 2003; Venable et al. 1995; Wang G et al. 2005). FB1 potency is 
influenced by the concentration of sphinganine, suggesting that FB1 most likely interacts 
with sphinganine binding sites within ceramide synthase (Merrill et al. 2001). Inhibition 
of ceramide synthase by FB1 results in an accumulation of free sphinganine in serum and 
tissues and decreases in ceramide and complex sphingolipids (Merrill et al. 2001; Riley 
et al. 2001; Wang E et al. 1991). Consequently, FB1 exposure has been correlated with 
increases in free sphinganine levels in the blood and urine resulting in an unbalanced 
sphingolipid ratio (Gelderblom et al. 1996a; Riley et al. 1993, 1994; Wang E et al. 
1992). Importantly, Riley et al. (1994) observed a strong dose-response relationship 
between FB1 treatment in rats and sphingoid base levels in the kidney prior to the onset 
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of renal toxicity, indicating a possible mechanistic basis for disrupted sphingolipid 
metabolism and FB1-induced toxicity. Sphinganine and sphingosine are known to cause 
cytotoxic, apoptotic, and inhibitory effects on cells when applied exogenously, therefore 
accumulation of these sphingoid bases following FB1 exposure could be responsible for 
apoptosis observed during toxicity studies (Muller et al. 2012). Although there is 
evidence to support the hypothesis that FB1-mediated toxicity is a result of inhibition of 
ceramide synthase activity and accumulation of sphingoid bases and decreases of more 
complex sphingolipids, more recent work suggests that additional targets also contribute 
to the cellular response from FB1 exposure (He et al. 2001; Riley and Voss 2006; 
Seefelder et al. 2003).  
The potential carcinogenicity of FB1 stimulated research on the genotoxicity of 
FB and there is evidence that although FB1 is not a genotoxic compound it does acts as 
an indirect carcinogen. Mutagenicity studies with Escherichia coli and Salmonella 
typhimurium have repeatedly shown negative results (Aranda et al. 2000; Gelderblom 
and Snyman 1991; Knasmuller et al. 1997). However, DNA damage, including strand 
breaks, have been observed by the comet assay in numerous mammalian cell lines and in 
vivo in both liver and kidney of rats (Atroshi et al. 1999; Domijan A et al. 2006, 2007, 
2008; Ehrlich et al. 2002; Galvano et al. 2002a, 2002b). The lack of FB1 reactivity with 
DNA has led to conclusions that the DNA damage observed in these studies are 
mediated through oxidative stress resulting from FB1 exposure. In rats, FB ingestion 
causes accumulation of fatty acids in the liver, which are subject to lipid peroxidation, 
free radical formation and damage leading to cell transformation (Gelderblom et al. 
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1996a).  Reactive oxygen species (ROS) act as highly reactive electrophiles and can 
cause damage to proteins, lipids, and DNA. FB1-mediated ROS production has been 
implicated as the causative agent in DNA damage and carcinogenic potential of FB1 in 
biological systems (Abel and Gelderblom 1998; Domijan A et al. 2007, 2008; Kouadio 
et al. 2007). FB1 treated rats had DNA lesions in their kidney in addition to signs of 
oxidative stress (i.e. increases in protein carbonyls and malondialdehyde). In vitro 
studies have supported these findings; porcine and monkey kidney cells showed 
increased levels of malondialdehyde following FB1 treatment (Abado-Becognee et al. 
1998; Klaric et al. 2007; Meca et al. 2010). Interestingly, FB1 has also been associated 
with depleted levels of an important cellular ROS scavenger, GSH, further supporting an 
increase in ROS species following FB1 induced toxicity (Atroshi et al. 1999; Bondy et 
al. 1995; Kang and Alexander 1996). However, there is still no conclusive evidence 
whether lipid peroxidation and oxidative stress is an indirect or direct consequence of 
FB1 toxicity (Abel and Gelderblom 1998; Muller et al. 2012). 
1.2.5 Human exposure in Africa 
Human exposure in Africa occurs through consumption of contaminated maize 
meal. Consumption of FB1, like AFB1, is highest in rural communities of South 
America, Africa, and Southeast Asia, due to a favorable climate for fungal growth, 
limited. 
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Figure 4. A model of de novo sphingolipid biosynthesis and inhibition by fumonisin B1.  The gray arrows indicate known 
effects of pools of metabolites resulting from fumonisin B1 inhibition of ceramide synthase. Reductions in complex 
sphingolipids can disrupt the integrity of the plasma membrane of cell. Adapted from Riley and Voss 2006. 
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variety in the diet, and unsuitable cultivation and storage practices. It has been estimated 
that dietary intake of FB1 could be as high as 354.9 µg/kg bw per day, in areas of Africa 
consuming large quantities of maize based foods (Muller et al. 2012). In humans, the 
most widely recognized effect associated with the consumption of FB1-contaminated 
corn is the development of esophageal squamous cell carcinoma (Alizadeh et al. 2012; 
Chu and Li 1994; Gong HZ et al. 2009; Rheeder et al. 1992; Williams et al. 2010). 
Although FB1 is associated with carcinomas in many species, it does not induce 
genotoxicity in cellular models, resulting in a 2B classification (possibly carcinogenic to 
humans) by the International Agency for Research on Cancer (IARC 2002). Lack of an 
appropriate biomarker of FB1 exposure has limited the findings and efforts of 
epidemiological based studies correlating FB1 with human based health effects. Thus, 
most reports are limited to generalizations of populations with a higher incidence of a 
specific disease who also consume large amounts of maize, or maize from the same 
region containing FB1 contamination. A recent report in China showed no correlation 
between FB1 levels in the toe nails of participants and HCC incidence, following 
adjustments for HBsAg positive, sex, age, and alcohol consumption status (Persson et al. 
2012). However, the biomarker utilized in this study was not validated for linearity with 
FB1 exposure in humans or animal models. While epidemiological evidence for 
carcinogenic potential of FB1 in human populations is lacking, animal models indicate 
that FB1 could be a contributing variable and additional risk factor for development of 
cancer, particularly in populations at high-risk for cancer development due to other 
environmental factors. Of concern is FB exposure in populations in Ghana, where HBV 
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infection and AF exposure is endemic. Up to 72.1% of participant urine samples were 
positive for FB1 in a rural community of Ghana (Robinson et al. 2012), demonstrating a 
high incidence of exposure to this mycotoxin in communities at high-risk for HCC 
development.    
Recently, FBs have also been proposed as a risk factor for neural tube defects 
(NTDs) in areas where populations consume large quantities of corn and corn based 
foods (Gelineau-van Waes et al. 2009; Missmer et al. 2006; Suarez et al. 2012). The 
incidence of NTDs is heightened in areas where corn is a dietary staple and FB 
contamination is common, such as in Guatemala, Northern China, and the Transkei 
region of South Africa. These areas have reported an incidence of NTDs that is 6-10 
times higher than the global average (Hendricks K 1999; Marasas et al. 2004; Moore et 
al. 1997; Ncayiyana 1986; Xiao et al. 1990). In the U. S., corn crops along the Texas-
Mexico border registered unusually high levels of FB contamination during 1990-1991, 
which correlated with substantially higher NTDs (2.7/1000 live births) compared to the 
same area in 1986-1989 (1.5/1000 live births) (Hendricks K 1999; Missmer et al. 2006). 
While a mechanism of action has not yet been delineated, FB1 appears to inhibit uptake 
and metabolism of folic acid, a vitamin essential for normal fetal NT development.  
Like AF, FBs have been implicated in a myriad of biological endpoints that are 
not fully understood. Potential health effects of FBs in humans are still being assessed. 
For example, Kimanya et al. (2010) recently reported that children from Tanzania 
consuming foods contaminated with greater than 2 µg/kg bw FB were significantly 
shorter and lighter than children with lower FB1 exposure. This implies that FB1 
 48 
 
exposure may have a possible association with growth faltering in Africa. Development 
of an appropriate biomarker and further research in the mechanism of action for FB1 
would improve the quality of epidemiological based studies. 
1.2.6 Biomarkers of exposure 
Development of a stable, linear, dose-dependent biomarker of FB exposure has 
proven difficult due to its short half-life in the serum and urine as well as a lack of 
detectable metabolites. FB1 is known to affect sphingoid base concentrations as a result 
of ceramide synthase inhibition and was thus the first biomarker to be investigated. An 
increase in the sphingolipid ratio (sphinganine/sphingosine) is linear with increased 
consumption of FB1 in various animal models and has often been utilized to assess 
exposure in animal species (Cai et al. 2007; Shephard et al. 1996). However, this 
biomarker of exposure is not linear within humans (Qiu and Liu 2001; Solfrizzo et al. 
2004; van der Westhuizen et al. 1999), which is likely due to genetic variations in lipid 
production. Parent FB1, was proposed as a biomarker for determining FB exposure in 
humans (Shephard et al. 1995, 2007). Cai et al. (2007) concluded that excretion of parent 
FB1 in the urine following repeated dosing was strongly correlated with urinary 
sphingolipid metabolites and serum sphinganine/sphingosine ratio and should be further 
assessed for linearity with human FB1 intake. The first human study to report a method 
for urinary FB1 analysis that showed a positive correlation with FB exposure and FB1 
excretion was conducted in a Mexican population consuming large quantities of maize-
based tortillas (Gong YY et al. 2008). Following this study, researchers from the 
PROMEC Unit in South Africa confirmed this correlation, with a correlation coefficient 
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of 0.4254 and p-value<0.01 (van der Westhuizen et al. 2011). Interestingly, the 
percentage of FB1 consumed that was excreted in the urine ranged from 0.054 to 0.104% 
per day, significantly lower than that proposed from animal studies (up to 2%). Riley et 
al. (2012) investigated the kinetics of urinary FB1 excretions in humans consuming 
maize based diets from Guatemala. Average excretion of FB1 in this study accounted for 
0.12 to 0.9% of the FB1 intake, however a correlation between intake and excretion was 
not reported. Variability in FB1 excretion was high between individuals and was cleared 
within 72 hr of exposure. Therefore, use of urinary FB1 levels in epidemiological based 
studies should consist of large population sizes and multiple samplings from the same 
participant to account for inter-individual variations in excretion.           
1.2.7 Regulation 
The occurrence of FBs in corn is ubiquitous, causing concern for populations 
where corn is a staple commodity used in a variety of foods. Currently there is 
insufficient information to adequately assess risk in populations that consume high 
amounts of corn. However, the U.S. FDA has established recommended maximum 
levels for FBs in animal and human foods, which are much higher than those established 
for AFs. A 60 ppm action level has been recommended for feeds for ruminant slaughter 
animals. Corn products for human consumption have been limited to 4 ppm for total 
FBs. JECFA has set a provisional maximum tolerable daily intake (PMTDI) for FB1, 
FB2, and FB3 combinations of 2 ppm per day.  
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1.3 AFB1/FB1 co-exposure 
Discovery of similar biological endpoints, such as liver toxicity, immunotoxicity, 
and growth faltering for AFB1 and FB1 exposure has led to public health concerns in 
communities that are dually exposed to FBs and AFs. A high-risk for AF and FB co-
contamination in maize-based products is common in climates favorable for growth of 
both aspergillus and fusarium. Surveys of maize flour from markets and households in 
Ghana have reported mixtures of both AFs and FBs (Kimanya et al. 2008; Kpodo et al. 
2000; Kumi et al. 2011). Additionally, biomarkers for both toxins were found in high 
frequency in an adult population residing in rural Ghana (Robinson et al. 2012; Wang P 
et al. 2008). Dual exposure risk has led to a recent assessment of possible antagonistc, 
additive, or synergistic effects of AFB1/FB1 mixtures on toxicity. Acute toxicity 
evaluation of combinations of AFB1 and FB1 demonstrated an additive effect in 
mortality in F344 rats (McKean et al. 2006). During this study various fractions (1.0, 
3/4, 1/2, 3/8, 1/4, 1/8) of the AFB1 LD50 value (2.71 mg/kg) for these rats was mixed 
with 25 mg/kg FB1 and dosed by gavage. Acute toxic effects such as depression and 
diarrhea occurred within a few hr of the treatment in the four highest doses, while no 
effect was observed in the two lowest doses. Importantly, mortality was 100% in the two 
highest doses (2.71 mg/kg AFB1 + 25 mg/kg FB1 and 2.03 mg/kg AFB1 + 25 mg/kg 
FB1) 72 hr after treatment, while treatment of 2.15 mg/kg AFB1 alone only had a 20% 
mortality rate during a one week study period (McKean et al. 2006). An interaction 
index (K) of 1.98 was calculated for combined toxicity indicating an additive interaction 
of AFB1 and FB1. Similarly, the same research group found a K value of 1.98 in 
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AFB1/FB1 combinative toxicity analysis in mosquito fish as well. Results from 
AFB1/FB1 toxicity in Hydra vulgaris, showed the combination to be more toxic than 
either mycotoxin alone (Brown KA et al. 2012). Following exposure to the mixture of 
AFB1 and FB1, all hydra had disintegrated. Although the single AFB1 or FB1 treatments 
caused morphological alterations the hydra were still viable. Male Wistar rats fed 
AFB1/FB1 contaminated diets had higher numbers of tubular apoptotic cells in the 
kidney compared to those treated with either FB1 or AFB1 alone (Theumer et al. 2010; 
Theumer et al. 2008). Additive effects were also observed in the liver; only the mixture 
group had signs of cellular mitosis and apoptosis after treatment. It is interesting to note 
that the increase in mitotic and apoptotic conditions in the liver of AFB1/FB1 supports 
evidence found by Gelderblom et al. (2002) even though the treatment protocols were 
vastly different. Theumer et al. (2008) dosed animals with AFB1 and FB1 at the same 
time, while Gelderblom and associates designed a sequential dosing regimen due to the 
cancer initiation and promotion potentials of AFB1 and FB1, respectively. AFB1 and FB1 
sequentially treated F344 rats had higher weight gain and relative liver weights than 
those treated with FB1 alone, however the AFB1 group had similar weights compared to 
the mixture group (Gelderblom et al. 2002). The AFB1/FB1 treatment increased the size 
and number of the placental form of glutathione-S-transferase positive (GSTP+) foci in 
the liver compared to either individual mycotoxin following promotion with 2-
acetylaminofluorene and partial hepatectomy (2-AAF/PH). Co-treatment also induced 
larger amounts of cellular apoptosis and mitoses and cirrhotic livers with numerous 
dysplastic nodules. The authors concluded that not only can FB1 act as a promoter of 
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AFB1-induced hepatocytes, but AFB1 enhanced the potency of FB1, presumably by 
increasing the susceptibility of the liver to fumoinsin’s toxicity (Gelderblom et al. 2002).  
One study conducted in weaned swine showed no additive effects of FB1/AFB1 
co-exposure except for a decrease in feed consumption and feed conversion (Dilkin et al. 
2003). However, the dose of AFB1 given in this study was very low (50 ug/kg) 
considering the LD50 value in weanling swine is 620 ug/kg (Cullen and Newberne 1994). 
Additionally, the species differences in effects of FB1 exposure in pigs would indicate 
that AF and FB may not act additively or synergistically in this species due to a 
difference in target organs (i.e. lung and liver, respectively). An alternate study in swine 
utilizing 2.5mg/kg AFB1 and 100 mg/kg FB1 did indicate additive and possible 
synergistic effects of the combination (Harvey et al. 1995). Additive effects included 
increases in body weight and hematologic measurements, while cholinesterase and ALP 
levels were synergistically elevated. The authors concluded that the combination diet of 
AFB1 and FB1 was at least additive for toxicity, and particularly for incidence of liver 
disease.  
1.4 Methods to reduce exposure in human populations        
AF toxicity, exposure, and intervention strategies have been investigated for over 
50 years. However, there is still approximately 4.5-5 billion of the world’s population 
exposed to AFs (Strosnider et al. 2006; Williams et al. 2004). Intervention strategies to 
reduce this exposure have been an important topic in mycotoxicology for 20 to 30 years. 
Although there have been numerous proposed mechanisms, humans and animals are 
frequently exposed to high levels of AFs, particularly in rural areas of developing 
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countries. Strategies to reduce mycotoxin exposure in these high risk areas can be 
categorized into one of three approaches: 1) Pre-harvest (agricultural), 2) Post-harvest 
(storage), and 3) Chemoprotective. Pre-harvest interventions include technologies that 
are utilized in the field to reduce or eliminate Aspergillus contamination and growth. 
Development of transgenic strains of maize and peanut crops resistant to Aspergillus has 
been developed and may provide both health and economic benefits in communities at 
risk (Guo et al. 2008; Holbrook et al. 2009; Menkir et al. 2006). Insect damage in the 
field is a main factor that can predispose maize crops to fungal contamination via 
promoting colonization through kernel injury and acting as vectors for fungal spores. 
Transgenic maize that is insect resistant has also been applied in areas of high AF 
incidence, however there were mixed results in its efficacy (Wu 2006). Similar, pre-
harvest control includes atoxigenic strains of Aspergilli that reduce Aspergillus 
colonization on crops through competition. These competitive fungi have shown a 
decrease of 70 to 99% following co-inoculation of African maize (Atehnkeng et al. 
2008). Good agricultural practices for post-harvest storage in the industrialized world 
prevent accumulation of mycotoxins. However, in developing countries storage practices 
tend to be rudimentary and can promote the growth of fungi and production of 
mycotoxins. Education of farmers in different agricultural processes can be effective in 
reducing levels of mycotoxins. In particular, early harvesting, proper drying, proper 
storage (proper ventilation), and insect management have shown improvement in 
contamination (Wagacha and Muthomi 2008; Wu 2008). Hand sorting of AF 
contaminated kernels can also be effective in reducing exposure in high-risk areas 
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(Kabak et al. 2006). Although these types of interventions improve food quality, 
implementation is often short lived in rural areas after research teams exit the 
community. Strategies to utilize crops that have been contaminated in the field or during 
storage are often of concern for mycotoxicologists working in Africa and Southeast 
Asia. Communities that are at highest risk for mycotoxin exposure are often forced to 
consume lower quality crops due to food insecurity. Disposing of any food is both 
culturally unacceptable and economically unfeasible.  
Chemoprotective interventions would allow for either human or animal 
consumption of foods that would otherwise be considered unsuitable for consumption by 
decreasing the toxic effects of ingested mycotoxins. Chemoprotective interventions 
include chemical compounds that alter the metabolic activation of AFB1. Three of the 
most studied strategies; green tea polyphenols (GTP), chlorophyllin, and a form of 
dithiolethiones named oltipraz are reviewed by Groopman et al. (2008). GTPs have been 
implicated as inhibitors of carcinogenesis from various chemical compounds in animal 
models as reviewed by Yang et al. (2006). Inclusion of GTP in the water of AFB1 treated 
rats decreased the number of preneoplastic lesions in the liver by 60-70% and inhibited 
AFB1-DNA binding by 20-30% (Qin et al. 1997). Similarly, GTP reduced oxidative 
DNA damage during a Phase IIa clinical trial in a population at high-risk for AF 
exposure in China (Luo et al. 2006). Chlorophyllin has been effective in inhibiting HCC 
in AFB1-treated trout (Breinholt et al. 1995a) and appears to both sequester AF and 
induce metabolic enzymes (Breinholt et al. 1995b; Fahey et al. 2005). Reductions in 
AFB1 biomarkers have confirmed efficacy of chlorophyllin in rats and a human 
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intervention trial (Egner et al. 2001; Simonich et al. 2007). Oltipraz acts to modify drug-
metabolizing enzymes through the Keap1-Nrf2 complex (Groopman et al. 2008). Nrf2 is 
a transcription factor that acts through the antioxidant response element. Keap1 acts to 
sequester Nrf2 in the cytoplasm; dissociation of the Keap1-Nrf2 complex results in 
translocation of Nrf2 to the nucleus and induction of transcription of various phase II 
detoxifying enzymes (Dinkova-Kostova et al. 2005; Kwak et al. 2004). One month 
intervention with Oltipraz in a human population reduced the urinary AFM1 biomarker 
by 51% and increased AF conjugation through GSTs (Kensler et al. 1998; Wang JS et al. 
1999). However, all these methods take numerous weeks, months, or even years to 
reduce AF exposure and would not be useful for acute outbreaks such as that seen in 
Kenya in 2004. Research in our laboratory has focused on the safety and efficacy of 
inclusion of a natural clay product that acts to bind AF and possibly FB, reducing their 
bioavailability in the GI tract. Thus, it is proposed that this product would be useful 
during instances of high AF exposure in populations presented with epidemics of 
jaundice, lethargy, or acute death from hemorrhaging of the liver.                     
1.4.1 Enterosorption with dioctahedral smectite clays  
 Smectite is one of the major mineral groups of phylosillicate clay fractions from 
soils (Reid-Soukup and Ulery 2002). They occur naturally in environments with high 
silicon and basic cation activities and are widely distributed around the world. Smectites 
have unique layered structures often described as a deck of cards randomly thrown on a 
table. Generally, they consist of two tetrahedral sheets (silicon oxide) and one octahedral 
sheet (aluminum oxide) to comprise a 2:1 lattice layer with interlayer regions between 
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each 2:1 lattice (Figure 5). The tetrahedral sheet is comprised of a Si4+ ion coordinated 
by four O2- ions and the octahedral sheet contains Al3+ ions coordinated by six O2- or 
OH- ions. The oxygen units of these tetrahedral and octahedral structures can be shared 
creating a variety of structures (Schulze 1989). Their structure makes them highly 
adsorbent materials that are often utilized as cleaning or purifying agents. The groups of 
smectites include montmorillonite, beidellite, nontronite, hectorite, saponite, and 
sauconite. Montmorillonites are dioctahedrally coordinated; meaning that they are 
composed of one octahedral unit and two tetrahedral units on either side of the 
octahedral unit creating a sheet that is around 10 Å thick (Segad et al. 2010). One 
aluminum atom shares oxygen with the two silica sheets. Importantly, montmorillonites 
also naturally undergo isomorphic substitutions in the octahedral layer often exchanging 
Al3+ ions with Mg2+ and/or Fe2+, creating a negative change on the platelets (Segad et al. 
2010). Water and exchangeable cations, predominantly Ca2+ and/or Na+, occupy the 
interlayer space between the platelets to equalize the negative charge. The physical and 
behavioral properties can change drastically depending on the major cation present in the 
interlayer space. Na+ montmorillonites generally have a larger swelling capacity than 
Ca2+ saturated clays. This is caused by stronger attractions of the platelet layers to the 
interlayer Ca2+ ions than the Na+ ions, resulting in less distance between the repeating 
platelets and reduced expansion of the interlayer space (Sato et al. 1992). Smectites have 
constant cation exchange capacities (charge on the surface of the clay platelet) ranging 
from 47 to 162 cmolc/kg (Borchardt 1989) due to the isomorphic substitutions present in 
the octahedral and tetrahedral sheets (Reid-Soukup and Ulery 2002). The particle size of 
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smectites is <0.2µm, comprising most of the fine clay fraction of soils, resulting in a 
large external surface area. Small particle size and interlayer expansion (swelling) 
promotes ion exchange and an increased surface area ranging from 600 to 800 m2/g 
(Reid-Soukup and Ulery 2002). An interesting way to visualize the massive surface area 
of these types of clays was provided by Mitchell JK (1993). They calculated that 10 g of 
a dispersed Na-montmorillonite would cover an entire football field. All of these 
properties make montmorillonites good materials for absorbing positively charged 
materials, as seen by their ability to act as macronutrient reservoirs in soils; sequestering 
K+, NH4
+, Ca2+, Mg2+, Cu2+, and Zn2+ (Reid-Soukup and Ulery 2002). The sorbent 
properties of montmorillonites and the observation that populations at high-risk for 
exposure commonly engaged in geophagy (the consumption of soils) led to an 
investigation for the potential to bind mycotoxins with various natural clay materials. 
Pioneering work by Phillips et al. in the 1980s reported efficacy of a Ca-
montmorillonite, NovaSil (NS) to decrease the negative health effects from AF exposure 
in multiple animal species. Further, molecular sorption analysis has proven that NS has a 
high binding capacity for AFB1 in vitro. 
1.4.2 Interaction between mycotoxins (AFB1 and FB1) and smectite  
 Isothermal analysis is a common method to investigate the sorption 
characteristics of a ligand on the surface of homogenous materials. Irving Langmuir 
developed a mathematical equation in 1916 that could describe the adsorption of gas 
molecules onto a solid surface, thereby significantly advancing the research of material 
sciences and adsorption (Langmuir 1916). The concepts of this modeling and 
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determination of binding capacity are described in detail by Kinniburgh (1986) and 
modified for mycotoxins by Grant (1998). Briefly, an isotherm is a plot of the 
concentration of a ligand left in solution versus the concentration bound to the surface of 
a solid. The shapes of the plots have been given classifications that describe the types of 
binding occurring (Giles et al. 1974a; Giles et al. 1960; Giles et al. 1974b). The plots can 
then be utilized in the Langmuir equation to determine the capacity (Qmax), affinity (Kd), 
and thermodynamics of adsorption.  
 AF binding analysis initially involved the use of 14C or 3H labeled AFB1 to 
determine the binding capacity of NS clay at various pH values and temperatures. The 
AFB1/NS complex was found to be stable at a variety of pH values and temperatures 
(Phillips et al. 1988). Following washing with various solvents, less than 10% of AFB1 
was extracted from the AFB1/NS complex, suggesting a chemisorption reaction between 
AFB1 and the surfaces of NS clay. Further research describing the mechanism of 
sorption indicated a high binding affinity and capacity of AFs on the surfaces of NS clay 
(Phillips et al. 1995). The index of chemisorption (Cα) was calculated from the initial 
concentration of AF, the amount bound, and amount desorbed and found to be relatively 
high (0.93). Similarly, calculation of enthalpy of the reaction was near or above -40 
kJ/mol (Grant and Phillips 1998). In general, adsorption of materials onto solid surfaces 
can be classified as physisorption or chemisorption depending on the enthalpy of 
adsorption value (ΔH). Enthalpy values of less than -20 kJ/mol suggest a physisorption 
binding mechanism and chemisorption can be described as those reactions with a ΔH 
greater than -20 kJ/mol (Guo et al. 1994). Recent studies have reported that AFB1 
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binding to smectite clays similar to NS involves direct ion-dipole interactions and 
electron sharing which explains the large heat of sorption described previously for NS 
(Deng et al. 2010). The maximum amount of AFB1 able to bind with the surfaces of NS 
based on the Langmuir model has been calculated as 0.461 mol/kg (Qmax). Grant and 
Phillips (1998) demonstrated an actual binding capacity (Qmax) of 0.336 mol/kg. This 
indicates that a majority of the space available for binding is occupied by AFB1, leading 
the authors to conclude that NS not only has a high binding capacity but also a high 
affinity for AFB1. Importantly, the surface area of NS clay available for binding was 
determined to be 848 ± 11 m2/g. AFB1 binding with NS clay occurs primarily within the 
interlayer space of the clay platelets. Collapsing of the interlayer through heating the 
clay at 125° C for 12 hr resulted in a significant decrease in sorption of AFB1 (Grant and 
Phillips 1998). Further work showed a similar AF binding capacity and affinity for a 
uniform particle size NS clay, or UPSN (Marroquín-Cardona et al. 2011). 
1.4.3 Uniform Particle Size NovaSil (UPSN) 
 UPSN was developed by Texas Enterosorbents (Bastrop, TX, USA) as a refined 
NS clay for human use. The purification of parent NS was designed to selectively 
minimize the amount of particles >100µm in size (Marroquín-Cardona et al. 2011). This 
process was designed to reduce batch to batch variations in the crude NS clay 
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Figure 5. Montmorillonite structure: Al2Si4O10 (OH)2. Schematic representation of 2:1 
layer-lattice montmorillonite clay showing hydrated calcium as the predominant 
interlayer cation. Common substitutions: Mg2+ for Al3+; Al3+ for Si4+; and Fe3+ for Al3+. 
Key: Si4+ (yellow), Al3+ (blue), O (red), H (white), C (light blue), and Ca2+ (green). A) 
Three-dimensional structure, B) Spatial structure demonstrating propping of the 
interlayer, C) AF bound structure.
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making it more suitable for human consumption. In the dry state, UPSN contains a 
higher fraction of its particles in the 45-100 µm range (67%), while NS has a majority of 
particles smaller than 45 µm (50%) (Marroquín-Cardona et al. 2011). There were major 
differences in the distribution of particle sized between UPSN and NS, but Qmax and Kd 
parameters following isothermal analysis were similar for the two materials. Due to the 
similarities observed in vitro, it was speculated that UPSN would have comparable 
efficacy and safety in vivo. The majority of work presented in this dissertation will focus 
on human intervention strategies with UPSN.         
1.4.4 Efficacy in animal and human models 
 The first studies showing efficacy of NS clay in reducing animal toxicity were 
conducted by a team at Texas A&M University and involved a variety of domestic farm 
animals. There is an extensive amount of literature describing the efficacy of 
montmorillonite clays to ameliorate the toxicity of various mycotoxins. A summary of 
these reports is shown in Table 1. For example, young broiler chicks administered 5 ppm 
AFB1 and 0.5% (w/w) NS clay were protected from the growth inhibitory effects of AF 
observed in controls (Pimpukdee et al. 2004). In growing barrows, NS prevented toxicity 
of AF over a 4-week period, as determined by recovery of weight gain, serum alkaline 
phosphatase (ALP), and ɣ-glutamyl transferase (GGT) values as compared with control 
group levels (Harvey et al. 1994, 1989c). In another study, AF and AF+NS-treated lambs 
gained 8 and 92% of the weight that control animals gained over the course of the trial, 
indicating a protective index of 75% from NS treatment (Harvey et al. 1991a). Similarly, 
vitamin A levels in chicks were diminished following AFB1 exposure, however 0.25 and 
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0.5% clay inclusion in the diet prevented AFB1 effects on vitamin A levels in the liver 
(Pimpukdee et al. 2004). Leghorn chicks were also protected from the effects of 7.5 
mg/kg AFB1 with 0.5% clay inclusion (Phillips et al. 1988). Inclusion of a 
montmorillonite clay decreased the growth inhibitory effects of AFB1 and gross 
pathological changes observed in the liver, such as a friable and pale appearance. A 
similar study conducted in Mexico confirmed these results. During this study chicks fed 
AF contaminated diets weighed 46% less than those receiving both AF and 
montmorillonite clay in their diet (Marquez Marquez and Tejada de Hernandez 1995). A 
montmorillonite clay (trademarked as Milbond-TX) was effective at a 1% dose in 
preventing reduced performance, changes in organ weights, serum chemistry changes, 
and gross pathology observed in broiler chicks fed 4 mg/kg AFB1 for 21 days (Ledoux et 
al. 1999). Kubena et al. (1998) reported a decrease in the toxic effects of 5 mg/kg AFB1 
on weight gain in chicks by 43% with only 0.375% clay inclusion. Effects of AFB1 on 
serum concentrations of cholesterol, albumin, triglycerides, calcium, glucose, and total 
protein were significantly reduced with 0.5% clay (Abo-Norag et al. 1995; Kubena et al. 
1990a, 1993a, 1993b). A study conducted with various clay binders investigated the 
efficacy of clay to rescue broiler chicks from the immunomodulation observed following 
AF exposure for 21 days (Kececi et al. 1998). The increases in white blood cell count, 
and percentages of lymphocytes and monocytes caused by AF exposure were not 
completely recovered to control levels with clay, but were significantly lower than those 
treated with AF alone.  
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 Turkey poults treated with 0.75 mg/kg AFB1 and 0.5% montmorillonite clay 
demonstrated an average reduction of 52% in excreted AFM1 when compared to the 
AFB1 control animals (Edrington et al. 1996). Acute toxicity of 1 mg/kg AFB1 was 
prevented in growing turkeys with treatment of clay at 0.5% (Kubena et al. 1991). The 
positive control group (1 mg/kg AFB1 alone) had a mortality rate of 88%, while no 
deaths occurred in those turkeys receiving AFB1 plus clay. One research group 
demonstrated acute toxicity of AFB1 in mink; inducing 100% mortality at 102 µg/kg 
AFB1 over 53 days of exposure (Bonna et al. 1991). Inclusion of 0.5% montmorillonite 
clay was effective in preventing mortality and toxic symptoms of aflatoxicosis. 
Weanling pigs have often been utilized as models for young children to assess possible 
health effects in humans. Studies have indicated that treatment with montmorillonite 
clay (NS) can reduce hepatic lesions, peripheral lobular lipidosis, peroportal and 
interlobular fibrosis, and bile duct hyperplasia induced by AFB1 exposure (Harvey et al. 
1989c). Impaired immune response following exposure to AFB1 including, reduced 
mitogen-induced lymphoblastogenesis and peritoneal macrophage activity and function, 
was prevented in barrows receiving 0.5% clay along with AFB1 (Harvey et al. 1994). 
Similar to the chicken studies described above, treatment with bentonite in AFB1 
exposed barrows, was effective in inhibiting growth stunting, decreased serum minerals, 
and decreased serum enzyme levels indicative of liver damage (AST, ALP, and gamma 
glutamyltransferase GGT) (Lindemann et al. 1993; Schell et al. 1993a, 1993b. Chestnut 
et al. (1992) and Harvey et al. (1991a) also showed positive results in sheep when 
consuming montmorillonite clays during AF exposure.  
  
 
64 
 Following identification of AFM1 excretion in the urine and milk of animals 
exposed to AFB1, exposure of the young through nursing has been investigated. 
Importantly, inclusioin of 1% montmorillonite clay was able to reduce excretion of 
AFM1 in the milk of dairy cows and goats by 44% and 51.9%, respectively (Harvey et 
al. 1991b; Smith EE et al. 1994). Reductions in the excretion of such biomarkers indicate 
a decrease in absorption of AFB1 in the GI tract due to binding with the clay treatment, 
resulting in reduced toxin bioavailability. The AFM1 biomarker has also been utilized in 
dogs and rodents to indicate efficacy of montmorillonites (Bingham et al. 2004; Sarr et 
al. 1995). Bingham et al. (2004) reported a reduction of 48.4% in urinary AFM1 
excretion in dogs, while Sarr et al. (1995) reported a much higher efficacy in rats 
(approximately 90% reduction in urinary AFM1). Importantly, pregnant rats treated with 
2 mg/kg AFB1 showed significant maternal and developmental toxicities in their 
offspring; however treatment with 0.5% NS resulted in development similar to absolute 
controls (Mayura et al. 1998). These studies indicated that treatment of montmorillonite 
clay can reduce the toxicity of AFB1 in multiple animal species, but its efficacy can 
differ between species due to differences in length of digestion, metabolism, dietary 
habits, and excretion. Importantly, based on results from short-term animal studies, it 
was calculated that the minimal effective dose to significantly reduce aflatoxicosis was 
0.5% montmorillonite clay (Phillips 1990; Phillips et al. 1990, 1995).  
 Determination of efficacy from human intervention trials is currently underway 
at Texas A&M University. However, there is one published report of the overall efficacy 
in an adult population from Ghana (Wang P et al. 2008). In this trial, the minimal 
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effective dose, 0.5% or 3 g NS, was taken daily, divided between a breakfast, lunch, and 
dinner meal for three months. Effect of NS treatment on AF bioavailability was assessed 
by both urinary and serum biomarkers, AFM1 and AFB1-alb, respectively. Urinary 
AFM1 levels were significantly reduced (58.7%) in the NS treated group when compared 
to a blinded placebo after three months of treatment. AFB1-alb levels were significantly 
lower in both the high-dose and low-dose NS treatment groups when compared to the 
placebo at the three month mark as well. Importantly, this significant difference was lost 
after treatment was discontinued (Wang P et al. 2008). This is the only published study 
to demonstrate efficacy of a montmorillonite clay to reduce bioavailability of AF in a 
human population at high-risk for exposure.                               
1.4.5 Safety evaluation                          
Safety assessment of both NS and UPSN has been conducted in animal and adult 
human trials. Due to the structural and physical characteristics it was postulated that 
montmorillonites could negatively affect the utilization of essential nutrients through 
cation exchange and possible sequestration of certain minerals like Zn, Mn, Na, and P in 
the interlayer. Studies specifically designed to determine the safety of smectite clay 
consumption are summarized in Table 2. 
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Table 1. Efficacy of montmorillonite clays to protect against mycotoxins 
Species Mycotoxin levels 
Clay in feed 
(duration) 
Major effects reported Reference 
Mice Zearalenone 
400 mg/kg bw; 5 
g/kg bw (48 h) 
Prevented the general toxicity 
of ZEN. 
Abbès et al. 
2006 
     
Mice Zearalenone 
400, 600 or 800 
mg/kg bw (48 h) 
Reduced erythrocytes, 
decreased the chromosomal 
aberration frequency and 
increased the number of 
polychromatic erythrocytes in 
bone-marrow cells. 
Abbès et al. 
2007 
     
Rats Aflatoxins 5g/kg (30 d) 
Prevented deleterious effects of 
aflatoxins. 
Abbès et al. 
2010 
     
Rats Aflatoxins 0.5% (21 d) 
Decreased growth inhibition in 
pregnant rats. 
Abdel-
Wahhab et al. 
1998 
     
Chickens Aflatoxins 0.5 % (28 d) 
Clay counteracted some of the 
toxic effects of AF in growing 
broiler chicks. 
Abo-Norag et 
al. 1995 
     
Chickens Afl/T-2 toxin          0.5% (21 d) 
No protection against T-2 toxin, 
variability in protection against 
growth inhibition 
Bailey et al. 
1998 
     
Pigs Aflatoxins 0.50% 
Decreased DNA adducts in the 
liver and reduced tissue 
residues of total aflatoxins.  
Beaver et al. 
1990 
     
Dogs Aflatoxins 0.5% (48 h) 
Significantly reduced the 
bioavailability of aflatoxins and 
excretion of M1 in urine. 
Bingham et 
al. 2004 
     
Mink Aflatoxins 0.5% (77 d) Mortality was prevented. 
Bonna et al. 
1991 
     
Mink Zearalenone 0.5% (24 d) 
Clay did not appreciably alter 
the hyperestrogenic effects. 
Bursian et al. 
1992 
     
Rats (& 
Sheep) 
Ergotamine Rats: 2.0% (28 d) 
HSCAS did not significantly 
protect rats or sheep from 
fescue toxicosis. 
Chestnut et 
al. 1992 
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     Table 1. Continued 
Species Mycotoxin levels 
Clay in feed 
(duration) 
Major effects reported Reference 
Pigs Aflatoxins 0.5% (35 d) 
Clay prevented hepatocellular 
changes normally associated 
with Aflatoxin consumption. 
Colvin et al. 
1989 
     
Chickens Cyclopiazonic acid 1.0% (21 d) 
Clay did not significantly 
prevent the adverse effects of 
clyclopiazonic acid. 
Dwyer et al. 
1997 
     
Turkeys Aflatoxins 0.5% (21 d) 
Decreased urinary excretion of 
aflatoxin M1. 
Edrington et 
al. 1996 
     
Chickens Aflatoxins 0.5% (3 weeks) 
Improved feed intake and 
weight gain. Alleviated the 
adverse effects of AFB1 on 
some serum chemistry. 
Gowda et al. 
2008 
     
Lambs Aflatoxins 2.0% (42 d) 
Diminished growth inhibition 
and immunosuppression. 
Harvey et al. 
1991a 
     Dairy 
Cows 
Aflatoxins 
0.5%; 1.0% (28 
d) 
Reduction of aflatoxin M1 in 
milk. 
Harvey et al. 
1991b 
     
Pigs Aflatoxins 
0.5%; 2.0% (28 
d) 
Decreased growth inhibition; 
prevention of serum effects and 
hepatic lesions. 
Harvey et al. 
1994 
     
Pigs Aflatoxins 
0.5%; 2.0% (28 
d) 
Diminished growth inhibition, 
hepatic lesions and 
immunosuppression. 
Harvey et al. 
1989 
     
Chickens Afl/Ochratoxin A  0.5% (21 d) 
Decreased growth inhibitory 
effects; no effect against 
ochratoxin. 
Huff et al. 
1992 
     
Chickens Aflatoxin  0.35, 0.5% (21 d) 
Reduced immune stimulation 
effects of Afl 
Kececi et al. 
1998 
     
Chickens Afl/Trichothecenes 0.5% (21 d) 
Growth inhibition diminished; 
no effect on trichothecens. 
Kubena et al. 
1990b 
     
Chickens Aflatoxin 0.5% (28 d) 
Growth inhibition diminished; 
decreased mortality.. 
Kubena et al. 
1990a 
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Table 1. Continued 
Species Mycotoxin levels 
Clay in feed 
(duration) 
Major effects reported Reference 
Turkeys Aflatoxins 0.5% (21 d) Decreased mortality. 
Kubena et al. 
1991 
     
Chickens Afl/Trichothecens         
0.25%; 0.37%; 
0.8% (21 d) 
Diminished growth inhibition; 
Alleviated the adverse effects of 
AFB1 on serum chemistry; no 
effect against trichothecenes. 
Kubena et al. 
1993a,b 
     
Chickens Aflatoxin, T-2                 
0.25, 0.375% (21 
d) 
Growth inhibition diminished; 
relative organ weights similar to 
controls 
Kubena et al. 
1998 
     
Chickens Aflatoxins  1.0% (21 d) 
Growth inhibition completely 
prevented. 
Ledoux et al. 
1999 
     
Pigs Aflatoxins 0.5% (42 d) Diminished growth inhibition. 
Lindemann et 
al. 1993 
     
Chickens Aflatoxin,  0.2% (42 d) 
Increased feed intake and 
apparent retention of 
phosphorus.  Prevented adverse 
effects to mycotoxins. 
Liu et al. 
2011 
     
Chickens Aflatoxin  0.5, 1.0% (21 d) 
Growth inhibition diminished; 
Ameliorated feed intake and 
feed efficiency effects 
Marquez-
Marquez et 
al. 1995 
     
Hydra Aflatoxin 
0.1 %; 0.3%; 
0.5% ( 92 hr) 
NS clay saved hydra from Afl-
induced toxicity 
Marroquin-
Cardona et al. 
2009 
     
Rats Aflatoxins 0.5% (21 d) 
Significant prevention of 
maternal and developmental 
toxicity. 
Mayura et al. 
1998 
     
Chickens Aflatoxins                      0.5% (28 d) 
Growth inhibition diminished; 
gross hepatic changes 
prevented. 
Phillips et al. 
1988 
     
Chickens Aflatoxins  
0.125%; 0.25%; 
0.5% (21) 
Protected against vitamin A 
depletion in the livers of chicks 
exposed to aflatoxins. 
Pimpukdee et 
al. 2004 
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Table 1. Continued 
Species Mycotoxin levels 
Clay in feed 
(duration) 
Major effects reported Reference 
Rats Fumonisin 2% (72 hr) 
Significantly reduced FB1 
biomarkers 
Robinson et 
al. 2012 
     
Rats Aflatoxins 0.5% (21 d) 
Decreased urinary excretion of 
Aflatoxin metabolites (M1 &  
P1). 
Sarr et al.  
1995 
     
Pigs Aflatoxins 1.0% (42 d) 
Lowered Mg and Na 
absorption, restoration of 
performance and liver function. 
Schell et al. 
1993 a 
     
Pigs Aflatoxins 0.5% (35 d) 
Growth inhibitory effects 
reduced. 
Schell et al. 
1993 b 
     Dairy 
Goats 
Aflatoxins 
1.0%; 2.0%; 
4.0% (12 d) 
Reduction of aflatoxin M1 in 
milk. 
Smith et al. 
1994 
     
Human Aflatoxin 
1.5 g/day; 3 
g/day (3 mo) 
Significantly reduced AFM1 
biomarker in urine and AFB1-
albumin biomarker in serum. 
Wang P et al. 
2008 
     
Rats Aflatoxins 
0.1%; 1% (8 
wks) 
Partial protection against 
lesions in the liver. 
Voss et al. 
1993 
     
Chickens  Aflatoxins 
0.1%; 0.2% (21 
d) 
Clay effectively alleviated the 
negative effect of AFB1 on 
growth performance and liver 
damage. 
Zhao et al. 
2010 
HSCAS-hydrated sodium calcium aluminosilicate, NS-NovaSil.  
Adapted from Johnson 2010.  
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Initial trials in chicks fed control diet with 0.5 or 1% montmorillonite clay 
showed no significant differences in weight gain or feed efficiency when compared to 
controls (Chung et al. 1990). The same was true for riboflavin, liver vitamin A 
concentrations, tibia weight, and manganese (Mn) concentrations (Chung et al. 1990). 
However, this same study did show a dose-dependent decrease in tibia zinc (Zn) 
concentration, with the 0.5 and 1% clay groups having 5 and 14% less Zn than the 
controls, respectively. To evaluate use of phosphorous (P) tibia ash weight and bone-
breaking force were analyzed in the presence of montmorillonite clay chickens fed diets 
containing P supplementation and 0.5 or 1% clay (Chung and Baker 1990). Results 
showed no significant differences between control groups supplemented with P and 
those receiving P and clay, indicating that montmorillonite clay does not impair the 
utilization of inorganic P (Chung and Baker 1990). Similarly, a form of montmorillonite 
clay given to broiler chicks at 0.5% w/w with nutrient deficient diets did not adversely 
affect percentage of tibia ash or Ca and P concentrations (Southern et al. 1994). A sub-
chronic treatment trial in Sprague-Dawley rats was conducted with NS inclusion ranging 
from 0.25-2% w/w feed for 6 months, following which the authors determined no 
significant differences in total body weight gain, feed conversion efficiency, histological 
abnormalities in target organs, or serum vitamin and nutrient levels (Afriyie-Gyawu et 
al. 2005). The authors thus concluded that ingestion of up to 2% NS was apparently safe 
in a sub-chronic treatment protocol. Similarly, UPSN was assessed for safety in 
Sprague-Dawley rats; however treatment in this study was reduced to a 3-month 
exposure time period (Marroquín-Cardona et al. 2011). Results from that research 
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indicated that, the serum Na, Na/K ratio, and Ca in UPSN treated groups were 
significantly higher than controls; however it was determined that the values were still 
within clinical ranges for these animals. Interestingly, this study also reported a 
significant increase in vitamin E values at both levels of UPSN inclusion. Other 
significant differences observed by Marroquin-Cardona et al. (2011) did not follow a 
dose-dependent relationship or were not consistent across both sexes. Therefore, the 
authors concluded that UPSN treatment at concentrations up to 2% resulted in no overt 
toxicity. Furthermore, Wiles et al. (2004) examined the gastrointestinal bioavailability of 
metals in pregnant rats following exposure to NS and concluded that the clay did not 
significantly leach or prevent absorption of the 11 metals analyzed.  
Results of Phase I and II clinical trials with NS clay suggested that ingestion of 
up to 3 g/day of NS in adults is safe for a 3 month period. There were no significant 
differences in clinical chemistry parameters, hematology, blood electrolytes, vitamins A 
and E, or serum Ca, Cu, Fe, K, Mg, Mn, Na, Ni, P, Pb, S, Se, Si, and Zn (Afriyie-Gyawu 
et al. 2008a, 2008b; Wang JS et al. 2005). The greatest hazard associated with acute 
ingestion of similar clay materials is intestinal obstruction. There have also been reports 
of increased fecal elimination of K and Fe resulting in clinical hypokalemia with Fe-
deficient anemia following chronic consumption of Al-silicate clays (Willhite et al. 
2012). However, it is important to note that these adverse event reports arose from 
studies in which adults consumed large quantities (0.5-1.0 kg/day) of various types of 
Al-silicate clays that were not assessed for metals or environmental contaminants 
(Reviewed by Willhite et al. 2012). Based on detailed studies conducted in animals and 
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humans for NS and UPSN, it was determined that ingestion of UPSN at levels 
efficacious for reducing AFB1 biomarkers would be reasonably safe. Results from 
mineralogical analyses of UPSN and NS indicated similar structural, morphological, and 
chemical characteristics (Marroquín-Cardona et al. 2011); therefore the two materials are 
thought to possess similar safety profiles. Importantly, Ca-montmorillonites, labeled as 
hydrated sodium calcium aluminosilicate (HSCAS) in the past literature, have been 
given GRAS (generally recognized as safe) status by the U.S. FDA for inclusion not 
exceeding a level of 2% w/w in feeds.  
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Table 2. Safety studies with montmorillonite clays 
 
Species 
Clay in feed 
(duration) 
Major effects reported Reference 
Chickens 0.5%; 1.0% (14 d) 
NS did not impair phytate or inorganic 
phosphorous utilization. 
Chung & 
Baker 1990 
    
Chickens 0.5% (19 d) 
Did not affect growth performance or tibial 
mineral concentrations of chicks. 
Southern et 
al. 1994 
    
Chickens 0.5%; 1.0% (14 d) 
NS did not impair utilization of riboflavin, 
vitamin A, or Mn; slight reduction of Zn.   
Chung et al. 
1990 
    
Human 
1.5 g/day; 3 g/day 
(3 mo) 
No significant effects in vitamins A & E and 
micronutrients, except for Strontium.  
Afriyie-
Gyawu et al. 
2008 
    
Rats 
0.25%; 2.0% (3 
mo) 
Increased serum Ca, Na, Vit. E. Reduced Zn 
in males %2 clay. Reduced serum K in 
males of clay groups.  
Marroquin-
Cardona et 
al. 2011 
    
Human 1.5 g; 3 g (2 wks) 
Mild GI effects, not significantly different. 
No difference in hematology, electrolytes, 
liver and kidney function. 
Wang JS et 
al. 2005 
    
Human 
1.5 g/day; 3 g/day 
(3 mo)  
Moderate effects, though not significant. No 
significant difference in hematology, 
electrolytes, liver and kidney function. 
Afriyie-
Gyawu et al. 
2008 
    
Rats 
0.25%; 0.5%; 1.0%; 
2.0% (6 mo) 
No adverse effects including vitamin 
utilization. 
Afriyie-
Gyawu et al. 
2005 
    
Rats  2.0% (16d) 
In pregnant rats, Rb was reduced in groups 
with clay. Neither NSP nor SWY-2 
influenced mineral intake. 
Wiles et al. 
2004 
    
Humans 
(children) 
6 g/day; 12 g/day 
(3d) 
Adverse events were not significantly 
different from placebo. Major complaints 
were vomiting, fever. 
Dupont et al. 
2009 
   
 
Humans 
(children) 
1.5 g/day (3 d) No adverse events were reported. 
Madkour et 
al. 1993 
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1.5 Research objectives 
 Mycotoxin contamination of staple crops is seemingly inextricable and exposure 
is inevitable in developing countries, where food insecurity results in consumption of 
lower quality grains (Williams et al. 2004). Assessment of linear biomarkers of exposure 
to mycotoxins in diverse human populations has shed light recently on the health 
burdens from AF and FB exposure in Western Africa. It is hypothesized that exposure of 
vulnerable, high risk populations to both mycotoxins could significantly impact health 
and disease outcomes. However, field-practical strategies to reduce mycotoxin exposures 
have proven difficult to maintain in rural communities of Africa. Thus, intervention 
strategies that are economically feasible, culturally acceptable, easily maintained, and 
can be implemented in communities at the highest risk for exposure during mycotoxin 
outbreaks are critically needed. Utilization of a natural product, like calcium 
montmorillonite clays, as a toxin enterosorbent in food could act as such an intervention. 
Work with multiple animal species has indicated a high efficacy of NovaSil in protecting 
animals from AF-induced health effects. However, minimal effective doses have not 
been delineated in humans and safety assessment is still ongoing. Recent work has 
indicated that NovaSil clay also binds FB in the interlayer to a lesser extent than AF 
(Robinson et al. 2012; Brown et al. 2012). Consequently, it is possible that NovaSil (and 
similar clays) may be used to mitigate (and reclaim) food-stuffs contaminated with both 
toxins. The work described in this dissertation focuses on utilizing mycotoxin 
biomarkers to establish exposures, efficacy, and safety of refined NovaSil clay (UPSN) 
in a high-risk community in Ghana. The work also aims to delineate effecitve dose 
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delivery methods and the ability of UPSN to alter the bioavailability of mixtures of 
AFB1 and FB1. The specific aims are fourfold: 
 1) to assess the average AF exposure across different regions of Ghana in relation 
to various sociodemographic, cultural, and health factors through the use of a 
comprehensive questionnaire and short-term analysis of AFM1 in the urine. 
 2) to evaluate the effectiveness of UPSN in a cross-over clinical intervention trial 
with treatment provided in the diets of Ghanaian participants to determine the ability of a 
short-term biomarker (AFM1) from urine as to be used as an early indicator of 
intervention efficacy.  
 3) to investigate the safety of UPSN during a Phase I clinical trial in children 
(ages 3-9) and provide initial evidence for aflatoxin exposure and UPSN efficacy. 
 4) to confirm the ability of UPSN to decrease the bioavailability of both AFB1 
and FB1 in the rat using short-term and long-term biomarkers of exposure.  
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2. EPIDEMIOLOGICAL SURVEY OF AFLATOXIN EXPOSURE ACROSS 
REGIONS OF GHANA   
2.1 Introduction 
 Previous work in Ghana has indicated that adults residing in the Ejura-
Sekyedumase district of the Ashanti region are chronically exposed to high levels of AFs  
via the diet (Jolly et al. 2006; Wang P et al. 2008). During the screening process for a 
three-month intervention trial, 100% of volunteers from this community tested positive 
for AFB1-alb in their serum. However, AF exposure in the rest of the country is not well 
established and may vary across socioeconomic classes and/or between regions based on 
differences in dietary intake. Previously, Jolly et al. (2006) observed significant 
correlations between AFB1-alb levels and education level, occupation, ethnic group, 
village of residence, number of individuals in the household, and number of children 
during a survey in the Ejura district. Recent risk assessment of AF burden in African 
countries has indicated that Ghanaian populations are at highest risk for exposure when 
compared to Kenya, Gambia, Botswana, Benin, and Tanzania (Shephard et al. 2008). 
During this risk assessment it was postulated that an average 60 kg adult in Ghana will 
consume as much as 1000 g of maize based foods per day, resulting in a total daily 
exposure of 850 ng/kg body weight. Further assessment indicated that HCC cases per 
100,000 population due to AF exposure in Ghana may be as high as 70. Thus, potential 
factors that could increase the relative risk for exposure in Ghana need to be determined. 
Identification of these risk factors would indicate areas (and communities) where 
intervention is most needed and would prove the most efficacious.  
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2.2 Materials and methods 
2.2.1 Materials 
 High Performance Liquid Chromatography (HPLC) grade methanol and ethanol, 
as well as reagent grade pH buffers (4.0, 7.0, and 10.0) were purchased from VWR 
(Atlanta, GA). AFM1 analytical standard was purchased from Sigma-Aldrich (Saint 
Louis, MO). AFM1 stock concentrations were verified by UV-visible spectrophotometry 
at a wavelength of 352 nm and molar absorptivity of Ɛ=18,815 M-1cm-1 (Shimadzu, 
Kyoto, Japan). AflatTest immunoaffinity columns were purchased from VICAM 
(Watertown, MA, USA). Ultrapure deionized water (18.2 MΩ) was generated within the 
laboratory using an Elga™ automated filtration system (Woodridge, IL). 
2.2.2 Participant recruitment, questionnaire, and data collection 
 Cross-sectional field surveys of demographic, food handling, consumption, 
health status, health history, and lifestyle choices were conducted in six different regions 
of Ghana (Ashanti, Brong Ahafo, Central, Eastern, Greater Accra, and Northern) by 
trained study monitors, June through August 2004. Only one adult participant from each 
household could participate in the survey and study monitors explained the purpose of 
the study to prospective participants prior to requesting consent. Consent and surveys 
were read to participants in their local language. A total of 801 participants completed 
the full survey and provided one urine sample to be analyzed for AFM1 levels. The 
number of participants from each region are as follows: Ashanti: 298, Brong Ahafo: 37, 
Central: 114, Eastern: 6, Greater Accra: 285, and Northern: 19. Variations in the number 
of participants recruited were calculated prior to initiation of the study and were based 
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on population size for each region. A greater number of recruits were desired from those 
regions with the largest portion of Ghana’s population, i.e. Accra and Ashanti.       
2.2.3  Determination of AFM1 in urine 
 Analysis of urinary AFM1 levels followed methods reported by Groopman et al. 
(1992b) and Sarr et al. (1995).  Urine samples were centrifuged at 2300 rpm, and 5.0 ml 
of supernatant was collected, acidified with 0.5 ml of 1.0 M ammonium formate (pH 
4.5) and diluted with water to a total volume of 10.0 ml. Samples were then loaded onto 
a 3 ml preparative Aflatest® WB immunoaffinity column (VICAM, Watertown, MA, 
USA) at a flow rate of 1 ml/min. Following washing of the column, the AF fraction was 
eluted with 2 ml of 80% methanol, dried under N2 and re-suspended in 200 µl of a 1:1 
solution of methanol:20 mM ammonium formate. Samples were analyzed using a 
Shimadzu HPLC system (Waters, Watertown, MA, USA) with fluorescence detection 
capabilities. A 250 x 4.6 mm LiCrospher RP-18 column with pore size 100 Å and 
particle size 5 µm (Alltech Associates, Deerfield, IL, USA) was used to resolve AF 
metabolites. The mobile phase consisted of 22% ethanol buffered with 20 mM 
ammonium formate (pH 3.0) in water. Isocratic elution of the mobile phase for 20 min at 
a rate of 1 ml/min allowed for proper chromatographic separation. External AFM1 
standards were prepared weekly and injected following every 5 injections of samples. 
The limit of detection for this method was 4.8 pg for AFM1. Urinary AFM1 
concentrations were expressed as pg/mg creatinine to correct for variations in urine 
dilution among samples. Urinary creatinine concentrations were measured by a Selectra 
E auto-analyzer (Vital Scientific, The Netherlands). 
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2.2.4 Statistical analysis 
 Statistical analyses were conducted by categorizing the participants into one of 
three groups based on the AFM1 level. The first group had an AFM1 level of 0.5 ppb or 
less, the second group had an AFM1 level greater than 0.5 ppb and less than or equal to 
the median AFM1 level of 43.2 ppb, and the third group had an AFM1 level of more than 
43.2 ppb. The analyses were then conducted separately for each of the three categories. 
Categorical variables were reported as counts and percentages. The chi-squared or 
Fisher’s exact tests were used to compare categorical variables. Variables with p-value ≤ 
0.10 in a bivariate model were included in the multivariable model. Odds ratios (OR) 
and the p-values for testing the significance of the variables in the model were obtained. 
All tests with a p-value less than or equal to 5% were deemed statistically significant and 
all analyses were done using SAS software version 9.2 (SAS Institute, Cary, NC, USA). 
2.3 Results 
2.3.1 Aflatoxin M1 concentration in urine 
 Urinary AFM1 was detected in 40.9% of the 801 samples tested. The median, 
mean, and range of AFM1 levels are presented in Table 3. Approximately one sixth of 
the population was above the mean level of 276 pg AFM1/mg creatinine. Concentration 
of AFM1 excretion ranged from 0 to 9,532 pg AFM1/mg creatinine and the distribution is 
represented in Figure 6. Estimates of AFB1 exposure levels were calculated from the 
median, 75th and 90th percentiles, and maximum AFM1 values (Table 4). Briefly, it was 
assumed that the average adult in the study would excrete 1500 ml of urine per day and 
2% of the total AFB1 consumed would be excreted as AFM1 in the urine (Zhu et al. 
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1987). The portion of the population above the 90th percentile was exposed to 
approximately greater than 43 µg of AFB1 per day.   
2.3.2 Sociodemographic characteristics 
 Table 5 shows the demographic and socio-economic characteristics of the 801 
participants by AFM1 level. Males and females were almost equally represented in the 
study, 49.7% and 50.3% respectively. However, a significant majority, 71.3%, of the 
heads of household were male. The majority of heads of households, 52.3%, were 50 
years or younger while the majority of the respondents, 53.8%, were 30 years or 
younger. A vast majority of participants, 86.8%, received a formal education and 
graduated. Most of them, 68.1%, went up to secondary school. Employment was high 
among the participants, 72.2%, and most of them neither drank nor smoked, 67.7% and 
96.8% respectively. However, none of these parameters showed a significant correlation 
to AFM1 excretion.   
Table 6 represents the levels of AFM1 excretion by region of residence. Most of 
the participants, 76.5%, were from the Ashanti and Greater Accra regions. This is 
reflective of the percent of HCC mortalities for each region. It is interesting to note that 
this does not correlate with population size. The Ashanti region is the most populated 
region accounting for 19.4% of the total population, followed by the Accra region, 
Eastern/Western, Northern, and Brong Ahafo. The Central region is the least populated 
based on the nation’s 2010 consensus (Ghana Statistical Service 2013). The region the 
participants came from had a significant association (p = 0.05) with their AFM1 levels. 
The Northern region had the highest percentage of its participants in the high AF group, 
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however there was only one more person reported than in the other two AFM1 levels. 
The Central region had 25.4% of its population within the high AF group followed by 
the Greater Accra region 23.5%. The Ashanti and Eastern groups had similar 
percentages within the high AF group, while the Brong Ahafo region had the lowest 
percentage (10.8%) of its participants in that group. 
2.3.3 Health factors 
Table 7 shows the health factors of the participants by AFM1 level. Most of the 
participants, 63.6%, reported being very healthy. To take care of their health care needs, 
most (59.7%) used orthodox means at government hospitals (54.6%) rather than use 
traditional means or self-medication. The majority had not been hospitalized recently, 
67.4%. When asked about their health condition, more than 80% of household members 
reported not having any of the health conditions present on the questionnaire: quick 
yellowing of skin, yellowing of eyes, dark brown urine, painful vomiting, and sore or 
swollen stomach. Most of the participants, more than 60%, also reported that they did 
not know whether their illness was related to foods such as peanuts, peanut products, 
maize, or maize products.  
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                 Table 3. Descriptive statistics of AFM1 levels 
AFM1 levels (pg/mg creatinine) 
   Number positive 328 
Mean ± SD 276 ± 883 
Median 
 
43 
Range 
 
0-9,532 
Percentiles 
 25 
 
15 
50 
 
43 
75 
 
136 
 
2.3.4 Food consumption and preparation practices 
 Table 8 shows the food consumption of main products most commonly 
associated with AF exposure by AFM1 level. On a weekly basis, 41, 93.3, and 26.8% of 
households consumed groundnut or groundnut products, maize or maize products, and 
millet or millet products, respectively, no more than once. Maize or maize products were 
consumed everyday by 61.8% of families. Of all the foods consumed, only maize or 
maize products had a significant association (p = 0.02) with AFM1 levels.  A great 
majority of participants (89.5%) could identify spoilt food. More than half of 
participants (50.2%) reported that a handful of their food was spoilt while a little less 
than half (47.6%) reported that a bucketful of their food was spoilt. Only a small portion, 
(2.27%) reported more than a bucketful of food spoilage. 
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Table 4. Estimated AFB1 exposure calculated from AFM1 excretion levels 
                                       µg AFB1/day 
Median (exposed) 2.5 
75
th
 Percentile 9.9 
90
th
 Percentile 43.1 
Maximum 614.1 
 
Table 9 shows the consumption behavior of the study participants by AFM1 
level. In general, most of the participants took the right actions with their grains or nuts. 
For example, 93.8% washed their grains or nuts before cooking and 97.7% cleaned their 
utensils before grinding grains or nuts. Also, 77.5% discarded discolored grains or nuts 
and only 36% used the discolored grains or nuts to feed animals. Participants also 
showed a lot of caution in buying what they consumed because 77.4% examined the 
grains or nuts for spoilage before buying them. None of the consumption behaviors had a 
significant association the AFM1 levels. 
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Table 5: Demographic and Socio-economic Information by AFM1 level 
 
 
  
All 
AFM1 ≤  
0.5 0.5 < AFM1 ≤  43.2 
AFM1 > 
43.2 
 Variable   n = 801 n = 473 n = 163 n = 165 pvalue 
Gender of respondent  
      Male  
 
378(49.7) 221(48.6) 67(45.3) 90(57.3) 0.08 
Female 
 
382(50.3) 234(51.4) 81(54.7) 67(42.7) 
 Age of respondent 
      Age ≤  30 
 
431(53.8) 244(51.6) 99(60.7) 88(53.3) 0.13 
Age > 30 
 
370(46.2) 229(48.4) 64(39.3) 77(46.7) 
 Gender of head of 
household   
      Male  
 
528(71.3) 313(70.7) 97(66.4) 118(77.6) 0.09 
Female 
 
213(28.7) 130(29.4) 49(33.6) 34(22.4) 
 Age of head of 
household   
      Age ≤  50 
 
383((52.3) 234(53.3) 74(51.8) 75(50.0) 0.77 
Age > 50 
 
349(47.7) 205(46.7) 69(48.3) 75(50.0) 
 Formal Education     
      Yes 
 
651(86.8) 393(87.7) 121(83.5) 136(87.2) 0.55 
No 
 
99(13.2) 55(12.3) 24(16.6) 20(12.8) 
 Level of Education   
      Primary 
 
49(7.45) 31(7.8) 9(7.2) 9(6.6) 
 Secondary 
 
448(68.1) 258(65.0) 91(72.8) 99(72.8) 0.26 
Tertiary 
 
142(21.5) 93(23.4) 22(17.6) 27(19.9) 
 Other 
 
19(2.9) 15(3.8) 3(2.4) 1(0.74) 
 Graduated             
      Yes 
 
568(86.7) 345(87.3) 106(85.5) 117(86.0) 0.94 
No 
 
87(13.3) 50(12.7) 18(14.5) 19(14.0) 
 Employed    
      Yes 
 
539(72.2) 317(71.1) 90(72.0) 114(74.0) 0.72 
No 
 
208(27.8) 129(28.9) 35(28.0) 40(26.0) 
 Drinking              
      Yes 
 
244(32.4) 152(33.7) 38(30.4) 51(32.7) 0.42 
No 
 
510(67.6) 299(66.3) 87(69.6) 105(67.3) 
 Smoking             
      Yes 
 
24(3.2) 14(3.1) 5(4.0) 5(3.2) 0.97 
No   730(96.8) 439(96.9) 119(96.0) 150(96.8)   
Data are presented as total number (n) and (%). * Statistical significance 
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Table 6.  AFM1 concentration by region 
  
Total 
AFM1 ≤  
0.5 
0.5 < AFM1 ≤  
43.2 
AFM1 > 
43.2  
  
n = 801 n = 473 n = 163 n = 165 pvalue 
     
 
0.05* 
Ashanti 
 
298 182(61.1) 67(22.5) 49(16.4) 
 
Brong Ahafo 
 
37 24(64.9) 9(24.3) 4(10.8) 
 
Central 
 
114 70(61.4) 15(13.2) 29(25.4) 
 
Eastern 
 
6 5(83.3) 0(0.0) 1(16.7) 
 
Greater Accra 
 
285 168(58.9) 50(17.5) 67(23.5) 
 
Northern 
 
19 6(31.6) 6(31.6) 7(36.8) 
 
        Data is represented as total number and (percent by region). * statistical significance 
 
2.4 Discussion 
 AF exposure in Ghana is an ongoing public health problem, which can contribute 
to the high morbidity and mortality in the country. However, until recently studies 
assessing the AF exposure pattern in Ghana have been lacking, with most occurring in a 
specified region (Ashanti) where chronic exposure is known to occur (Jolly et al. 2006; 
Wang P et al. 2008). Although efforts to control and reduce the AF exposure in Ghana 
have already been initiated more demographic information is needed. Demographics, 
socio-economic status, and food consumption practices in relation to AFB1 exposure 
would provide useful information about steps in the food production/consumption chain 
that are most likely contributing to exposure. This is the first study in Ghana to assess 
exposure across multiple regions of the country. Although total numbers of participants 
were highly variable between the regions, by classifying exposure status as low, 
medium, or high we were able to make comparisons between percentages of participants 
in a specific classification across regions. Through this method we are able to conclude 
that the Greater Accra and Central regions have very similar exposure patterns, which        
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Table 7: Health Factors by M1 level 
  
All 
AFM1 ≤  
0.5 
0.5 < AFM1 
≤  43.2 AFM1 > 43.2 
 Variable   n = 801 n = 473 n = 163 n = 165 pvalue 
Status of Health     
     
0.09 
Very Healthy 
 
473(63.6) 279(62.7) 87(60.0) 107(69.5) 
 Average 
 
235(31.6) 138(31.0) 53(36.6) 44(28.6) 
 Poor 
 
36(4.8) 28(6.3) 5(3.5) 3(2.0) 
 Type of 
Healthcare   
     
0.19 
Orthodox 
 
446(59.7) 275(61.4) 86(59.7) 85(54.8) 
 Traditional 
 
17(2.3) 9(2.0) 4(2.8) 4(2.6) 
 Spiritual 
 
2(0.3) 1(0.2) 0(0.0) 1(0.7) 
 Self Medication 
 
142(19.0) 84(18.8) 34(23.6) 24(15.5) 
 Combination  
 
133(17.8) 75(16.7) 20(13.9) 38(24.5) 
 None 
 
6(0.8) 4(0.9) 0(0.0) 2(1.3) 
 Other 
 
1(0.1) 0(0.0) 0(0.0) 1(0.7) 
 
       Type of 
Hospital    
     
0.45 
Government 
 
375(54.6) 228(55.2) 71(54.6) 76(52.8) 
 Private 
 
137(19.9) 86(20.8) 21(16.2) 30(20.8) 
 Both/Clinic 
 
97(14.1) 52(12.6) 20(15.4) 25(17.4) 
 Own Home 
 
71(10.3) 44(10.7) 17(13.1) 10(6.9) 
 Family 
 
7(1.0) 3(1.7) 1(1.8) 3(2.1) 
 
       Been  
Hospitalized 
     
0.08 
Yes 
 
238(32.7) 156(35.8) 41(29.3) 41(26.8) 
 No 
 
491(67.4) 280(64.2) 99(70.7) 112(73.2) 
 
       Health Condition of Household Members 
    
       Quick Yellowing of 
skin 
     
0.39 
Yes 
 
62(8.2) 41(9.1) 8(5.4) 13(8.3) 
 No 
 
693(91.8) 410(90.9) 139(94.6) 144(91.7) 
 
       Yellowing of eyes 
     
0.47 
Yes 
 
116(15.4) 72(16.1) 18(12.2) 26(16.7) 
 No 
 
636(84.6) 376(83.9) 130(87.8) 130(83.3) 
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Table 7. Continued 
  All 
AFM1 ≤  
0.5 
0.5 < AFM1 
≤  43.2 AFM1 > 43.2 pvalue 
Dark brown urine 
     
0.57 
Yes 
 
89(11.8) 58(12.9) 15(10.2) 16(10.2) 
 No 
 
665(88.2) 392(87.1) 132(89.8) 141(89.8) 
 
       
Swollen Legs 
     
0.04* 
Yes 
 
56(7.4) 41(9.1) 10(6.8) 5(3.2) 
 No 
 
700(92.6) 410(90.9) 137(93.2) 153(96.8) 
 
       Swollen Toes 
     
0.20 
Yes 
 
30(4.0) 23(5.1) 3(2.0) 4(2.5) 
 No 
 
725(96.0) 427(94.9) 144(98.0) 154(97.5) 
 
       Swollen Arms 
     
0.31 
Yes 
 
15(2.0) 12(2.7) 1(0.7) 2(1.3) 
 No 
 
740(98.0) 439(97.3) 146(99.3) 155(98.7) 
 
       Swollen Fingers 
     
0.74 
Yes 
 
17(2.3) 12(2.7) 2(1.4) 3(1.9) 
 No 
 
736(97.7) 437(97.3) 145(98.6) 154(98.1) 
 
       Painfull Vomiting 
     
0.63 
Yes 
 
71(9.4) 39(8.7) 16(10.9) 16(10.2) 
 No 
 
683(90.6) 411(91.3) 131(89.1) 141(89.8) 
 
       Sore or Swollen 
Stomach 
     
0.26 
Yes 
 
87(11.5) 45(10.0) 21(14.2) 21(13.5) 
 No 
 
667(88.5) 405(90.0) 127(85.8) 135(86.5) 
 
       Illness Relating to Food 
     
       Peanuts 
     
0.18 
Yes 
 
69(15.5) 46(16.6) 15(17.7) 8(9.6) 
 No 
 
104(23.4) 61(22.0) 16(18.8) 27(32.5) 
 Don't Know 
 
272(61.1) 170(61.4) 54(63.5) 48(57.8) 
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Table 7. Continued       
      All AFM1≤ 0.5 
0.5 < AFM1 
     ≤  43.2 AFM1 > 43.2 pvalue 
Peanuts Products 
     
0.17 
Yes 
 
69(15.5) 46(16.7)    15(17.7) 8(9.5) 
 No 
 
102(23.0) 59(21.5)    16(18.8) 27(32.1) 
 Don't Know 
 
273(61.5) 170(61.8)    54(63.5) 49(58.3) 
 
       Maize 
     
0.84 
Yes 
 
27(6.1) 16(5.8)    6(7.1) 5(6.0) 
 No 
 
120(27.0) 74(26.9)   20(23.5) 26(31.0) 
 Don't Know 
 
297(66.9) 185(67.3)   59(69.4) 53(63.1) 
 
       Maize Products 
      Yes 
 
27(6.1) 17(6.2) 5(5.9) 5(6.0) 0.79 
No 
 
121(27.2) 74(26.8) 20(23.5) 27(32.1) 
 Don't Know   297(66.7) 185(67.0) 60(70.6) 52(61.9)   
Data is represented as total number and (%). * Statistical significance 
  
happen to be some of the highest. Both Accra and Central regions are located on the 
coast and thus may engage in similar dietary habits more than other areas. Interestingly, 
in the Central region over half of its population, 52.9%, is located in rural areas while in 
Accra 90.5% of its population is in urbanized areas (Ghana statistical service 2013). 
However, they do have the two highest population densities of all the regions, albeit 
Accra is more densely populated than any other region, having 1,235.8 people per square 
kilometer of land. The Northern region had the highest percentage (68.4%) of its 
population test positive for AFM1 in the urine, which could be indicative of the 
heightened presence of agriculture in the area. The northern areas of the country tend to 
be more rural and are where the countries crops are primarily produced. Interestingly, 
this region is predominantly Islamic with three out of every five households indicating 
Islam as their religious affiliation (Ghana statistical service 2013).  
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Table 8: Percent Food Consumption by AFM1 level 
   
  
All AFM1<0.5 
0.5< AFM1 
≤  43.2 
AFM1> 
43.2 
 Variable   n = 801 n = 473 n = 163 n = 165 pvalue 
Frequency of food consumption by household/week 
Groundnut/Groundnut 
products  
     
0.24 
One or less 
 
53.1 53.2 54.4            51.2 
 Two to three 
 
29.1 29.7 32           24.4 
 Everyday 
 
11.9 11.3 10.2           15.4 
 Never 
 
6 5.8 3.4              9 
 
       
Maize/Maize products  
     
0.02* 
One time or less 
 
6.4 6.9 6.1           5.1 
 Two to three 
 
31.5 35.3 27.2           24.4 
 Everyday 
 
61.8 57.8 66           69.2 
 Never 
 
0.4 0 0.7           1.3 
 
       
Millet/Millet products  
     
0.52 
One time or less 
 
34.6 34.5 34           35.3 
 Two to three 
 
18 16.9 21.5           18 
 Everyday 
 
8.8 7.9 7.6           12.2 
 Never 
 
38.6 40.6 36.8           34.6 
  
In contrast to a previous report from the Ashanti region of Ghana (Jolly et al. 
2006) there were no significant associations with demographics or socio-economic 
factors and AF exposure. In that study the authors concluded that there was a correlation 
with education level, ethnic group, and number of individuals in a household and AFB1-
alb. The lack of associations described here could be caused by the variability in the 
AFM1 biomarker and its short half-life, thus indicating exposure within 24 to 48 hr of 
sampling. The AFB1-alb marker has a longer half-life, able to reach a plateau, which 
makes it more indicative of a person’s exposure over longer time periods. Therefore, the 
  
 
90 
AFB1-alb adduct may be a more accurate indicator of associations between biomarker 
levels and chronic social conditions, like demographics and socio-economic status. It is 
important to note however, that other work in Malaysia did not find associations 
between education, number of individual households, and other demographic factors 
with AFB1-alb levels (Leong et al. 2012). Thus, more work needs to be conducted to 
conclude whether the correlations observed by Jolly et al. (2006) are maintained across 
other countries and ethnic groups, or if they are specific to the particular community in 
the Ashanti region. Furthermore, the present work here would indicate that exposure is 
consistent across all demographic and socio-economic classes. As a result, interventions 
should target populations in specific areas of the country and be applicable to people 
across all ages, genders, economic, and educational backgrounds. 
 Health indicators did not show an association with AFM1 levels. This included 
reports of sickness from consumption of AF-prone foods. Calculations of AFB1 
ingestion from AFM1 levels would indicate that exposure during the time of sampling 
was not high enough to induce typical symptoms of acute exposure such as vomiting and 
other gastrointestinal irritation. The time of sampling could have influenced reports of 
illness and rates of AFM1 excretion. Ghana has its highest rainfall from April to July and 
AF exposure patterns have been associated with climatic changes in Africa, with higher 
biomarker levels observed during dry seasons compared to rainy seasons (Turner et al. 
2000; Wild et al. 2000). Consequently, participants could have been exposed to lower 
levels of AFs during the study period than at other times during the year.  
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Table 9: Food processing practices by M1 level 
   
  
All AFM1≤  0.5 0.5 <AFM1≤  43.2 AFM1> 43.2 
 Variable   n = 801 n = 473 n = 163 n = 165 pvalue 
Actions taken with grain/nuts 
           Sort before cooking   0.71 
No, no future plan 
 
59(9.6) 37(10.1) 13(10.6) 9(7.1) 
 No, have future 
plan 
 
27(4.4) 20(5.4) 3(2.4) 4(3.2) 
 
No, planning soon 
 
32(5.2) 16(4.4) 7(5.7) 9(7.1) 
 Yes, last time 
 
82(13.3) 46(12.5) 17(13.8) 19(15.1) 
 Yes, all the time 
 
417(67.6) 249(67.7) 83(67.5) 85(67.5) 
 
       Wash before cooking   0.22 
No, no future plan 
 
19(3.1) 7(1.9) 5(4.1) 7(5.7) 
 No, have future 
plan 
 
13(2.1) 10(2.7) 2(1.7) 1(0.8) 
 
No, planning soon 
 
6(1.0) 2(0.6) 2(1.7) 2(1.6) 
 Yes, last time 
 
52(8.5) 34(9.3) 7(5.8) 11(8.9) 
 Yes, all the time 
 
520(85.3) 313(85.5) 105(86.8) 102(82.9) 
 
       Grill before cooking   0.50 
No, no future plan 
 
219(38.4) 127(37.0) 50(44.3) 42(36.5) 
 No, have future 
plan 
 
63(11.0) 35(10.2) 15(13.3) 13(11.3) 
 
No, planning soon 
 
24(4.2) 13(3.8) 3(2.7) 8(7.0) 
 Yes, last time 
 
70(12.3) 44(12.8) 10(8.9) 16(13.9) 
 Yes, all the time 
 
195(34.2) 124(36.2) 35(31.0) 36(31.3) 
 
       
Clean utensils before grinding   0.57 
No, no future plan 
 
9(1.5) 6(1.6) 2(1.7) 1(0.8) 
 No, have future 
plan 
 
4(0.7) 3(0.8) 1(0.8) 0(0.0) 
 
No, planning soon 
 
1(0.2) 1(0.3) 0(0.0) 0(0.0) 
 Yes, last time 
 
64(10.5) 36(9.9) 9(7.4) 19(15.6) 
 Yes, all the time 
 
530(87.2) 319(87.4) 109(90.1) 102(83.6) 
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Table 9. Continued     
  All AFM1≤  0.5 0.5  <AFM1≤  43.2 AFM1> 43.2 pvalue 
Store in dry place  
     
0.62 
No, no future plan 
 
25(4.2) 18(5.0) 5(4.2) 2(1.7) 
 No, have future 
plan 
 
6(1.0) 5(1.4) 1(0.8) 0(0.0) 
 
No, planning soon 
 
4(0.7) 4(1.1) 0(0.0) 0(0.0) 
 Yes, last time 
 
58(9.7) 34(9.4) 14(11.7) 10(8.5) 
 Yes, all the time 
 
508(84.5) 302(83.2) 100(83.3) 106(89.3) 
 
       Discard discolored pieces   0.36 
No, no future plan 
 
105(17.3) 62(17.0) 21(17.5) 22(18.2) 
 No, have future 
plan 
 
16(2.6) 9(2.5) 3(2.5) 4(3.3) 
 
No, planning soon 
 
15(2.5) 10(2.7) 0(0.0) 5(4.1) 
 Yes, last time 
 
82(13.5) 46(12.6) 14(11.7) 22(18.2) 
 Yes, all the time 
 
388(64.0) 238(65.2) 82(68.3) 68(56.2) 
 
       Use discolored pieces for oil   0.66 
No, no future plan 
 
570(94.1) 342(94.0) 117(96.7) 111(91.7) 
 No, have future 
plan 
 
7(1.2) 5(1.4) 0(0.0) 2(1.7) 
 
No, planning soon 
 
4(0.7) 2(0.6) 1(0.8) 1(0.8) 
 Yes, last time 
 
7(1.2) 3(0.8) 1(0.8) 3(2.5) 
 Yes, all the time 
 
18(3.0) 12(3.3) 2(1.7) 4(3.3) 
 
       Use discolored pieces for animal feed   0.87 
No, no future plan 
 
350(58.0) 206(56.9) 75(62.5) 69(57.0) 
 No, have future 
plan 
 
21(3.5) 14(3.9) 4(3.3) 3(2.5) 
 
No, planning soon 
 
15(2.5) 9(2.5) 3(2.5) 3(2.5) 
 Yes, last time 
 
85(14.1) 48(13.3) 15(12.5) 22(18.2) 
 Yes, all the time 
 
132(21.9) 85(23.5 23(19.2) 24(19.8) 
 
       Use discolored pieces as seeds   0.06 
No, no future plan 
 
546(91.0) 332(92.5) 112(92.6) 102(85.0) 
 No, have future 
plan 
 
14(2.3) 8(2.2) 0(0.0) 6(5.0) 
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Table 9. Continued     
  All AFM1≤  0.5 0.5  <AFM1≤  43.2 AFM1> 43.2 pvalue 
No, planning soon 
 
2(0.3) 1(0.3) 0(0.0) 1(0.8) 0.06 
Yes, last time 
 
9(1.5) 4(1.1) 1(0.8) 4(3.3) 
 Yes, all the time 
 
29(4.8) 14(3.9) 8(6.6) 7(5.8) 
 
       Examine for spoilage before buying   0.87 
No, no future plan 
 
92(15.3) 52(14.4) 21(17.7) 19(15.6) 
 No, have future 
plan 
 
40(6.7) 26(7.2) 7(5.9) 7(5.7) 
 
No, planning soon 
 
22(3.7) 11(3.1) 4(3.4) 7(5.7) 
 Yes, last time 
 
105(17.5) 60(16.7) 21(17.7) 24(19.7) 
 Yes, all the time 
 
342(56.9) 211(58.6) 66(55.5) 65(53.3) 
 
       Inspect processed products before buying   0.91 
No, no future plan 
 
118(16.7) 73(17.2) 23(17.0) 22(15.2) 
 No, have future 
plan 
 
57(8.1) 34(8.0) 14(10.4) 9(6.2) 
 
No, planning soon 
 
35(5.0) 23(5.4) 7(5.2) 5(3.5) 
 Yes, last time 
 
102(14.5) 60(14.1) 19(14.1) 23(15.9) 
 Yes, all the time 
 
393(55.7) 235(55.3) 72(53.3) 86(59.3) 
 
       Consider source of processed products before buying  0.13 
No, no future plan 
 
253(36.0) 145(34.4) 55(40.4) 53(36.8) 
 No, have future 
plan 
 
132(18.8) 87(20.6) 28(20.6) 17(11.8) 
 
No, planning soon 
 
31(4.4) 22(5.2) 4(2.9) 5(3.5) 
 Yes, last time 
 
46(6.6) 25(5.9) 6(4.4) 15(10.4) 
 Yes, all the time 
 
240(34.2) 143(33.9) 43(31.6) 54(37.5) 
 Data appear as total number and (%). 
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Maize was the food commodity with the highest consumption. Only 0.4% of the 
participants answered “never” when asked how often they consume maize-based 
products on a weekly basis. Maize was also the only food that was associated with 
AFM1 excretion. Therefore, future intervention work should focus on treatment of maize 
based products, or populations with the highest maize consumption. Importantly, this 
work indicates that the majority of the population in Ghana can identify spoiled grains or 
nuts and discard those which are discolored. Large portions of the population also store 
their grain appropriately (94.2%), sort (80.9%), and wash foods before cooking (93.8%). 
Thus, educational and grain processing interventions are likely to provide little relief of 
AF exposure in this population. More comprehensive analysis with a larger cohort and 
AFB1-alb levels should be conducted across Ghana to further assess exposure patterns 
and possible indicators of risk. Currently, research indicates that exposure in Ghana is 
endemic and has been documented in several studies to be chronically affecting the 
population over the past ten years (Table 10). Intervention strategies that are safe, 
efficacious, and sustainable in individuals across all ages, education levels, and genders 
need to be developed for this population.  
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Table 10.  Descriptive statistics of AFM1 levels in Ghana 
from three separate time points 
 
AFM1 (pg/mg creatinine) 
 
June-Aug. 
2004 Sep. 2005 October 2010 
AFM1 Positive 40.9% 86.7% 100% 
Median 43 50 274 
Mean ± S.D. 276 ± 883 361 ± 1,246 818 ± 1,235 
Range 0 – 9,532 0 - 13,297 15-5,454 
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3. REDUTION IN THE URINARY AFLATOXIN M1 BIOMARKER AS AN 
EARLY INDICATOR OF THE EFFICACY OF DIETARY INTERVENTIONS 
TO REDUCE EXPOSURE TO AFLATOXINS
*
 
3.1 Introduction 
In Sub-Saharan Africa, hepatocellular carcinoma (HCC) is one of the most 
common malignancies (Ferlay et al. 2010). In Ghana, HCC mortality accounts for 21.15 
and 10.97% of all cancer related deaths in men and women, respectively (Wiredu and 
Armah 2006). Multiple factors play a role in the etiology of HCC; one major 
environmental risk factor is chronic exposure to AF from the diet. Inadequate food 
storage practices, little to no regulations on mycotoxin contamination, food insecurity 
and economic burdens make these populations at high risk for life-long exposure to 
harmful toxins 
Toxin enterosorption strategies using calcium montmorillonite clay (NS) to 
reduce biomarkers of exposure and toxicity have been shown to be effective in animals 
and humans (Kubena et al. 1998; Ledoux et al. 1999; Phillips et al. 1990; Pimpukdee et 
al. 2004; Schell et al. 1993a). In the following study, UPSN was utilized to investigate 
the ability of AFM1 biomarkers to rapidly indicate treatment efficacy.   
Linear biomarkers, like AFM1, are predictive of AFB1 intake and are currently 
used as the standards for assessment of population exposures. Biomarkers are important 
tools in determining the efficacy of intervention trials for the reduction of AF exposure 
                                                 
* Reprinted with permission from “Reduction in the urinary aflatoxin M1 biomarker as an early indicator 
of the efficacy of dietary interventions to reduce exposure to aflatoxins.” By Mitchell NJ, Kumi J, Johnson 
NM, Dotse E, Marroquin-Cardona A, Wang JS, Jolly PE, Ankrah NA, and Phillips TD. Biomarkers, Aug; 
18(5):391-398, Copyright 2013 by Informa UK Ltd. 
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in human populations due to the latent onset of AF related health consequences. The 
AFB1-albumin marker indicates exposure over a number of weeks, whereas the AFM1 
marker is reflective of acute AF consumption allowing detection of AFM1 24-48 hr after 
exposure. Previous work with a proposed AF binder in a human intervention trial 
showed significant decreases in both AFB1-albumin and AFM1 biomarkers following 3-
months of treatment (Wang P et al. 2008). AFM1 and the AF-mercapturic acid conjugate 
were decreased following 1 month of treatment with Oltipraz, a chemopreventative 
agent that affects phase 1 and phase 2 metabolism of AF (Wang JS et al. 1999). 
Although these biomarkers have proven useful to delineate efficacy of long-term 
interventions, shorter pilot trials are desirable, especially for use in children and other 
vulnerable groups, where appropriate dosimetry has not yet been defined. Based on the 
extant scientific literature, we postulate that daily AFM1 levels could indicate efficacy 
over a short time period. Use of this biomarker as an indicator of efficacy would allow 
for smaller, non-invasive, pilot trials that could indicate probability of an intervention to 
reduce AF toxicity with minimal harm to human participants (especially the vulnerable).  
Following positive results from the AFM1 biomarker, further human trials could be 
conducted to confirm safety, efficacy and health outcomes using long-term biomarkers.  
Our objectives in this study were to:  1) determine the ability of AFM1 
biomarkers to act as an early indicator of treatment efficacy; 2) analyze the capacity of 
UPSN to significantly reduce AFM1 levels in a short-term study in humans; and 3) 
assess the palatability of UPSN when included in Ghanaian foods.  
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3.2 Materials and methods 
3.2.1 Materials 
AFM1 was obtained from Sigma Aldrich (St. Louis, MO, USA). Immunoaffinity 
columns were purchased from VICAM (Watertown, MA, USA). NovaSil (NS) clay was 
obtained from BASF/Engelhard Chemical Corporation (Iselin, NJ, USA).  UPSN and 
calcium carbonate were purchased from Texas Enterosorbents, Inc. (Bastrop, TX). All 
materials designated for human consumption were treated with electron beam radiation 
prior to study initiation and were also analyzed for various metals and levels of 
chlorinated dibenzo-p-dioxin/furans by Columbia Analytical Services, Inc. (Houston, 
TX) (Marroquin-Cardona et al. 2011).   
3.2.2 AFB1 sorption analysis 
Isothermal analyses of AFB1 sorption onto surfaces of UPSN at equilibrium were 
performed according to methods reported by Grant and Phillips (1998) and described in 
detail by (Marroquin-Cardona et al. 2009). UPSN clay or calcium carbonate (50 ng) 
were mixed with 11 different concentrations of AFB1, all done in triplicate, for 2 hr at a 
pH of 2 and 6.5. Samples were then centrifuged and the absorbance read at 362 nm using 
a Shimadzu scanning UV visible spectrophotometer (Shimadzu Corporation, Kyoto, 
Japan). Computer-generated equilibrium isotherms were fit to the Langmuir model 
(based on r2 values and randomness of the residuals). The parameters of Qmax and Kd 
were estimated to determine the maximum sorption to the surface and the affinity of the 
sorption interaction. Single point sorption analyses instead of isotherms were conducted 
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on the calcium carbonate as the data did not fit a Langmuir model and the percent 
reduction in AFB1 was calculated for these values. 
3.2.3 Study site and design 
In recent years, studies with participants from the Ejura-Sekyedumase district of 
the Northern Ashanti Region of Ghana have proven that this community is at high risk 
for chronic AF exposure based on both AFB1-albumin and AFM1 levels (Jolly et al. 
2006; Wang P et al. 2008). Study participants were recruited from five communities in 
this district. Sociodemographic data for these communities was established previously 
(Jolly et al. 2006). All recruited participants were between 21-70 years of age. Consent 
was sought following a community meeting with study personnel. Consent documents 
were translated and explained to participants in private rooms and signed by each 
individual participant before initiation of the study. Previous research from our 
laboratory in humans has shown that 3 g/day of NS clay was the minimal effective dose 
for significantly decreasing the AFM1 biomarker (Wang P et al. 2008). This dose 
represents approximately 0.25% UPSN (w/w) of the total amount of food consumed 
daily (1200 g) by the average adult Ghanaian. Participants were selected evenly between 
the five communities (10 from each) and randomly assigned into one of two treatment 
groups. Figure 7 shows the overall study design and sample collection procedure. A 
local caterer prepared a breakfast and dinner meal for all participants daily. Participants 
were responsible for any snacks consumed and their lunch meals. Trained study 
monitors mixed each participant’s treatment into their respective food before 
consumption. Each study participant received 1.5 g of placebo (calcium carbonate) or 
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UPSN in their breakfast meal and their dinner meal. Breakfast meals consisted of a corn-
based porridge called “koko” and the dinner meals were a common soup (i.e. peanut 
soup, lamb lite soup) and corn dough called “banku”. Treatment group 1 consumed 
placebo (3 g/day) in their foods for five days followed by a two day washout period and 
consumption of 3 g/day of UPSN for an additional five days. Treatment group 2 
consumed UPSN (3 g/day) for the first five days followed by a 2 day washout period and 
an additional five days of placebo treatment (3 g/day). The crossover study design 
allowed for a smaller number of participants and each participant was used as its own 
control during data analysis to account for inter-individual variations in AF metabolism. 
Urine samples were collected at baseline, daily during treatments and at day 20. 
Overnight urine samples were collected daily, and 15 ml aliquots were stored at -20°C. 
Samples were transported cold to Noguchi Memorial Institute for Medical Research for 
biomarker analysis. Laboratory employees were blinded to treatment groups during 
analysis. Ethical clearance and institutional review board approval for this study was 
obtained from both Texas A&M University and Noguchi Memorial Institute for Medical 
Research (IRB 2009-0412 and 005/08-09).   
3.2.4 AFM1 analysis and palatability questionnaire 
Urinary AFM1 was analyzed through immunoaffinity column clean-up followed 
by HPLC coupled fluorescence detection (previously described in detail in Section 
2.2.3). Following consumption of each meal participants were asked to rate the food 
based on four criteria; 1) overall taste, 2) texture, 3) aroma and 4) would they eat the 
food again. The first three criteria had the following rating options: poor, unacceptable, 
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acceptable or good while the fourth criterion was rated yes or no. Questionnaires were 
given to participants in English or translated to the local language by study monitors. 
3.2.5 Statistical analysis 
 All statistical analysis was run on JMP 9 software (SAS Institute, Cary, NC, 
USA). AFM1 data was not normally distributed; thus the data was analyzed with a 
nonparametric test (Kruskal-Wallis). However, all data was also analyzed under 
parametric conditions (ANOVA) following a log transformation of the data. Both 
parametric and nonparametric analyses were used to compare groups by days and by 
treatment arms. A p-value <0.05 (two-tailed) was considered significant. Statistical 
significance was not changed between parametric and nonparametric testing. Data was 
analyzed with participants acting as their own controls over two different time periods 
and with AFM1 levels being compared between participants during a common time 
period. Data was also grouped by treatment for days 1-5 and grouped separately for days 
8-12 and analyzed by ANOVA. Questionnaire data was analyzed categorically with a 
chi-square test by treatments.  
3.3 Results 
3.3.1 AFB1 sorption analyses 
 The parameters of Qmax and Kd were derived for sorption of AFB1 at both pH 2 
and 6.5 onto UPSN. Isotherms are run at both a pH of 2 and 6.5 to simulate conditions 
the clay would encounter in the stomach and intestine. The sorption of AFB1 onto 
surfaces of UPSN fit the Langmuir model (r2 ≥0.92) with an L-shape pattern indicating 
saturable binding at sites similar to those shown on parent NS clay (Figure 8A). 
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Figure 7. Crossover Study Design. Participants were randomly placed into one of two groups 
consuming 3.0 g of either calcium carbonate or UPSN per day.  Following 5 days of treatment  
and 2 days of washout, groups were switched to the opposite treatment for another 5 days.
50 participants
Day 0
Group I
3.0g Placebo/d
Days 1-5 
Group II
3.0g UPSN/d 
Days 1-5
Daily urine collections;
Palatability questionnaire
Group II 
3.0g Placebo/d
Days 8-12 
Group I 
3.0g UPSN/d
Days 8-12 
Two day washout;
Treatment crossover 
Daily urine collections;
Palatability questionnaire
Recruitment and consent;
Baseline urine collection
24 26
Days 6-7 Days 6-7
Day 20 Day 20 Urine collection 
Figure 7. Crossover Study Design. Participants were randomly placed into one of two groups consuming 3.0 g of
either calcium carbonate or UPSN per day. Following 5 days of treatment and 2 days of washout, groups were
switched to the opposite treatment for another 5 days.
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As previously reported by Marroquin-Cardona et al. (2011) the theoretical Qmax values 
calculated for UPSN were 0.39 ± 0.01 mol AFB1 kg
-1 and 0.44 ± 0.05 mol AFB1 kg
-1 at 
pH 2 and 6.5, respectively (Marroquin-Cardona et al. 2011). Although the Qmax valueare 
similar, Figure 8A clearly shows a separation in the two curves for UPSN based on pH.  
This difference can be further shown by the differences in the calculated affinity values 
for both curves (Kd = 6.29x10
5 at pH 6.5 and 1.93x105 at pH 2). Figure 8A also shows 
the extrapolated isothermal curves for AFB1 interaction onto the surfaces of calcium 
carbonate (placebo). The curves for calcium carbonate do not fit the Langmuir model 
and cannot be compared with the curves obtained for UPSN. As a result, single sorption 
assays were conducted in triplicate for calcium carbonate to obtain percent reduction of 
AFB1. Maximum binding of AFB1 with calcium carbonate occurred at 4 µg at both pH 
values with only 13% bound at pH 6.5 and 5% bound at pH 2 (Figure 8B). As the 
concentration of AFB1 increases the percent bound decreases with pH 2 values dropping 
below zero. This data indicates a poor binding capacity of calcium carbonate for AFB1 
and the likely possibility that calcium carbonate is being dissolved under acidic 
conditions. 
3.3.2 Sample collection and study population 
 A total of 50 participants were recruited for this intervention trial with 25 
randomly placed into one of two treatment groups; 1) placebo days 1-5 and UPSN days 
8-12, and 2) UPSN days 1-5 and placebo days 8-12. Groups had roughly the same 
number of males and females and similar age ranges (Table 11). The overall compliance 
among study participants and sample availability for biomarker analysis was satisfactory 
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with a total of 46 participants included in data analysis (Table 11). The four participants 
who were excluded from the study either missed two urine collections or treatment doses 
in a row.      
3.3.3 Analysis of urinary AFM1 levels  
 A total of 534 urine samples were collected and analyzed for AFM1 over the 
course of the 20 day study. Mean, median and the range of AFM1 for each group at 
different stages of treatment are shown in Table 12. All samples analyzed had detectable 
AFM1, and no significant difference was found at baseline levels between the groups 
(p=0.8737). Comparisons to baseline were also assessed within each group during the 
various stages of treatment, with only day 20 values for group 2 being significantly 
lower (p=0.0277). There was a significant difference at day 20 between group 1 and 
group 2 (p=0.0055). Figure 9 shows daily mean urinary AFM1 over the full 12 days of 
treatment and demonstrates the crossover in treatments for the groups with a switch in 
AFM1 levels occurring by day 9. Comparisons between the UPSN treated groups and 
placebo groups were conducted for each time point by a one-way ANOVA of the log 
transformed data. Day 2 of the study was the only time point showing a significant 
difference between UPSN and placebo groups. Figure 10A shows the data grouped and 
analyzed using the participants as their own controls (i.e., average levels for each group 
from days 1-5 were run against average levels from days 8-12). There was no significant 
difference between placebo and UPSN treatment for group 1 (p=0.1782), however there 
was a significant difference between placebo and UPSN treatment for group 2 
(p<0.0001) (Figure 10A). Differences in dietary intake, and thus AF intake during days 
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1-5 and days 8-12 resulted in large variability between treatment arms. Thus, the data 
was also analyzed by comparing groups during the same time period (i.e., group 1 vs. 
group 2 during days 1-5 and days 8-12) (Figure 10B). The average AFM1 values were 
significantly decreased when placebo treatment was compared to the UPSN between 
groups during both days 1-5 (p=0.0011) and days 8-12 (p=0.0072) (Figure 10B). 
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Figure 8. Isothermal AFB1 sorption analysis of placebo and UPSN. A) Aflatoxin B1 adsorption
isotherms onto UPSN and calcium carbonate at pH 2 and 6.5. UPSN samples are depicted in an L-shape
curve characteristic of a saturation of binding sites by AFB1 molecules in a planar configuration
(Marroquin-Cardona et al. 2011). Samples of calcium carbonate are also depicted; however, the curves
did not fit the L-shaped pattern or the Langmuir model. B) Qmax values could not be derived for the
calcium carbonate samples, thus percent bound values were calculated at single concentration points of
AFB1.
 
Figure 8. Isothermal AFB1 sorpti  analysis of placebo and UPSN. A) Aflatoxin B1 
adso ption isotherms onto UPSN and calcium carbonate at pH 2 and 6.5. UPSN samples 
are depicted in an L-shape curve characteristic of a saturation of binding sites by AFB1 
molecules in a planar configuration (Marroquin-Cardona et al. 2011). Samples of 
calcium carbonate are also depicted; however, the curves did not fit the L-shaped pattern 
or the Langmuir model. B) Qmax values could not be derived for the calcium carbonate 
samples, thus percent bound values were calculated at single concentration points of 
AFB1.  
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There was no significant difference between groups when both were on UPSN 
treatment (p=0.0804) or placebo treatment (p=0.2546). Median urinary AFM1 had a 45% 
reduction with UPSN treatment during days 1-5 and a 55% reduction during days 8-12. 
There were no age or gender differences found with AFM1 excretion between the study 
groups. 
Table 11. Study Participant Demographics 
  Females Males Age Range Study Compliance 
Group 1 9 11 25-70 yr 20/24 
Group 2 11 15 21-46 yr 26/26 
Total 20 26 21-70 yr 46/50 
   
3.3.4 Palatability and adverse events    
 The percentage of foods that were deemed good or acceptable are listed in Table 
13. Participants never deemed any food products as unacceptable or poor during the 
study, and all participants said that they would eat the food again. Both placebo and 
UPSN treated foods received a higher percentage of “good” ratings than “acceptable” 
ratings. Pearson chi-squared tests were used to analyze the difference between “good” 
and “acceptable” ratings within each group by placebo or UPSN treatment. There were 
no significant differences between placebo and UPSN when rating for taste, aroma or 
texture. During the 10 days of treatment there were two incidents of constipation 
reported that lasted 24 and 12 hr while one participant complained of diarrhea that lasted 
for 12 hr. However, these were isolated events that occurred while the respective 
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participants were taking placebo treatment and were not associated with UPSN 
consumption.  
 
 
Table 12. Urinary AFM1 excretion 
  
AFM1 (pg/mg creatinine) 
Treatment 
stage Baseline Placebo UPSN Day 20 
      
Group1  
288 389 281 480 
 
831 ± 1279 1125 ± 2168 922 ± 1481 962 ± 1481 
 
(15-5455) (4-17155) (4-8018) (14-6952) 
      
Group2  
210 508 177 94 
 
809 ± 1226 1287 ± 2550 483 ± 973 273 ± 1617 
 
(17-4925) (4-20874) (5-8397) (10-1322) 
 
Data are median, mean ± SD, and (data range). (a) Indicates a significant 
difference (p<0.05) between the same treatment stage when group 1 is compared 
with group 2. (b) Indicates a significant difference (p<0.05) from baseline within 
the same group.   
 
 
a, b 
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Figure 9. Daily mean AFM1 levels. Points are mean values for each group per day and 
error bars represent standard error of the mean. Day zero represents baseline urine 
samples taken for participants. Group 1 (grey) was on placebo treatment days 1-5 and 
UPSN treatment days 8-12. Group 2 (black) was on UPSN treatment days 1-5 and 
placebo treatment days 8-12. * p<0.05 as compared with placebo at the same time point. 
(a) indicates the switch in treatment.    
 
3.4 Discussion  
AF-specific biomarkers currently consist of AFB1 metabolites and AFB1 adducts 
(Groopman et al. 1996; Groopman et al. 1994). Both serum the AFB1-albumin adduct 
and urinary AFM1 have shown significant correlation with dietary intake of AFs (Egal et 
al. 2005; Gan et al. 1988; Groopman et al. 1992b; Zhu et al. 1987). While the AFB1-
albumin adduct is considered to be the most stable and reliable biomarker for chronic AF 
exposure (Wild and Turner 2002), the long half-life of the biomarker requires exposures 
of one month to reach a steady state for analysis, which precludes its use in short-term 
human trials. AFM1 in urine (Zhu et al. 1987) reflects recent AFB1 exposure in humans, 
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and can be easily collected from both adults and children. Importantly, the short half-life 
makes it an excellent candidate for use in preliminary and pilot intervention trials.  
Research involving human subjects, particularly children, should be conducted in 
a manner to reduce any possibility of harm. Utilization of the AFM1 biomarker to prove 
efficacy could significantly decrease the time participants need to be treated with an 
investigational therapy and also lower overall invasiveness of such intervention trials. 
This study is the first to show that daily AFM1 concentrations can be utilized to 
determine the efficacy of an intervention trial within 5 days of treatment implementation. 
The low cost, low invasiveness of sampling and short half-life of the AFM1 biomarker, 
make daily sampling possible. This method could facilitate rapid surveillance of 
aflatoxicosis outbreaks and rapid identification of effective strategies to mitigate this 
disease. 
This work not only shows the sensitivity of AFM1 as a biomarker of intervention 
efficacy but also clearly illustrates the ability of a calcium montmorillonite clay, UPSN, 
to significantly decrease AF exposure within 5 days of treatment initiation. The 
immediate response observed in this study indicates that UPSN would be a prime 
candidate to treat populations during incidences of acute AF outbreaks. Clay as a 
toxincant enterosorbent can be delivered in various dose forms. In previous studies, NS 
clay was sterilized, encapsulated, and taken with water before each meal (Afriyie-Gyawu 
et al. 2008b). 
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Figure 10. AFM1 distribution within groups and treatment arms. The box values ranged from 25 to 75 percentiles of the total samples, the
line within it indicates the median value. The bars on both sides of a box represent values ranging from 5 to 25 and from 75 to 95
percentiles, respectively. A) Comparison of UPSN and placebo treatment within the same group. Analysis of the data in this manner
allowed for each person to be used as their own control and account for inter-individual differences in AFB1 metabolism and AFM1
excretion. B) Distribution of AFM1 levels by time points. Comparison of median AFM1 levels were compared between groups based on
time points to account for differences in daily dietary AFB1 intake. Placebo days 1-5 was compared with UPSN days 1-5 and the same was
calculated for days 8-12. **p<0.05 as compared with placebo.
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percentiles, respectively. A) Comparison of UPSN and placebo treatment within the same group. Analysis of the data in this manner 
allowed for each person to be used as their own control and account for inter-individual differences in AFB1 metabolism and AFM1 
excretion. B) Distribution of AFM1 levels by time points. Comparison of median AFM1 levels were compared between groups based on 
time points to account for differences in daily dietary AFB1 intake. Placebo days 1-5 was compared with UPSN days 1-5 and the same was 
calculated for days 8-12. **p<0.05 as compared with placebo.  
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The cost and inconvenience of encapsulation led us to consider alternate dose 
forms. Utilization of the clay as a food additive could have numerous advantages 
including lowered cost of production, decreased impact on people’s daily life, possible 
increased efficacy and improved sustainability. UPSN was developed as a more 
palatable form of the parent clay for inclusion in food products. UPSN contained a lower 
percentage of particles above 100 µm in the dry state and above 50 µm in the wet state 
versus parent NS clay (Marroquin-Cardona et al. 2011). Although X-ray diffraction 
(XRD) analysis identified quartz in the UPSN product, the relative intensity was lower 
than that of the parent clay suggesting less content of this mineral (Marroquin-Cardona 
et al. 2011). UPSN and NS had similar binding affinities for AFB1 in vitro and were 
shown to contain the same active product (calcium montmorillonite) based on XRD 
intensities (Marroquin-Cardona et al. 2011). Based on the characterization of both 
montmorillonite clays, UPSN was deemed preferable for food inclusion in the present 
study.  
 This is the first in vivo study to assess the efficacy of UPSN and the first human 
intervention study to evaluate a form of NS clay as a food additive. Only one of the two 
groups (group 2) had a significant reduction in AFM1 levels when comparing UPSN 
dosing with their placebo dose. The lack of significance in AFM1 reduction for group 1 
could be due to variations in dietary AFB1 intake from days 1-5 when compared to days 
8-12. The median exposure in placebo groups is 1.3 times higher during days 8-12 than 
days 1-5 making it hard to make meaningful comparisons between UPSN and the 
placebo treatments within the same group. Due to differences in dietary AF intake from 
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Table 13. Palatability ratings by percent 
    Rating Taste Aroma Texture 
  
Good 84.8 78.3 80.4 
Placebo 
 
Acceptable 15.2 21.7 19.6 
 
Unacceptable 0 0 0 
  
Poor 0 0 0 
      
  
Good 78.3 65.2 69.6 
UPSN 
 
Acceptable 21.7 34.8 30.4 
 
Unacceptable 0 0 0 
   Poor 0 0 0 
 
 the first half and the second half of the study, the data was also compared between 
groups over the same time points. Inter-group comparisons showed a significant 
reduction in urinary AFM1 levels in this study. A reduction rate of up to 55% in the 
median AFM1 levels could be observed in as little as 5 days of treatment. These 
reduction rates are similar to those seen in other intervention trials utilizing other dietary 
supplements (i.e. NS clay, Chlorophyllin and oltipraz) based on acute biomarkers (AFM1 
and AFB-N7-guanine) of exposure from urine (Egner et al. 2001; Wang JS et al. 1999; 
Wang P et al. 2008). In earlier research with NS, it took 3-months of treatment to see a 
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significant difference in urinary biomarkers (Wang P et al. 2008). However, in that 
study, urine samples were only taken twice throughout the 3-month period, and the large 
variability in biomarker output due to inter-individual differences of AF metabolism and 
dietary intake can lead to a lowered power of the analysis. In this study, daily sampling 
of the biomarker and pooling of the data decreased the effects of the variability of 
individual biomarker concentrations on the statistical analysis. A similar reduction in 
AFM1 metabolites over a 3-month treatment period has been associated with a 
significant decrease in AFB1-albumin adducts in humans (Wang P et al. 2008).  
 Recent reports of growth stunting associated with AF consumption (Gong YY et 
al. 2002, 2004 Turner et al. 2007) and AF contaminants occurring in children’s ready to 
use therapeutic foods has caused significant concerns for child health and acute health 
impacts from high level exposures to dietary AFs in the vulnerable and susceptible. 
Populations that lie within what has been called the “hot zone”, 40°N and S latitude, are 
the most commonly exposed to AF due to a favorable climate for Aspergillus growth and 
AF production (Cotty and Jaime-Garcia 2007b; Williams et al. 2004). A variety of 
strategies for reducing AF contamination in food and feed have been reported including 
the use of benign competitive fungal species, establishing drought resistant crops, food 
sorting and improved storage processes. However, none of these methods are suitable for 
therapy to alleviate acute aflatoxicosis and reduce lethality in the vulnerable in poor 
communities. Toxin enterosorbent intervention with UPSN clay has the capability to 
immediately impact exposure and rescue individuals suffering from acute and sub-acute 
AF exposures similar to those reported in Kenya in 2004.   
 114 
 
4. PHASE I SAFETY INTERVENTION TRIAL OF UPSN TREATMENT IN THE 
DIETS OF CHILDREN IN GHANA 
4.1 Introduction 
Stunting, wasting, and fetal growth retardation result in more than 2 million 
deaths in children under the age of 5 and account for 21% of disability-adjusted life 
years worldwide (Black et al. 2008). In 2010, it has been estimated that 171 million pre-
school children worldwide were stunted (de Onis et al., 2011). While the overall 
prevalence of stunting in developing countries has improved over the past two decades 
(from 44.4% to 29.2%), the majority of this improvement has been occurring in Asia and 
Latin America. The rate in Africa (40%), however, has remained mostly stagnant and is 
not expected to improve drastically over the next 10 years (de Onis et al. 2012). 
Although stunting is primarily attributed to nutritional and protein deficiencies, AF has 
also been associated with growth faltering in Sub-Saharan Africa (Gong YY et al. 2002, 
2003, 2004; Okoth and Ohingo 2004; Shuaib et al. 2010; Turner et al. 2003, 2007; Wang 
E et al. 1992). Current strategies implemented to alleviate growth faltering and 
subsequent physical and mental deficits include food and micronutrient supplementation. 
These complementary foods, sometimes referred to as ready-to-use therapeutic foods 
(RUTFs), are designed to supplement the typical diet and often consist primarily of 
maize, groundnuts (peanuts), and other protein sources, such as soybeans (Bhutta et al. 
2008; Hendricks KM 2010; Lartey et al. 1999). Recently, there have been reports of AF 
contamination in similar homemade complimentary foods (Weanimix) in Ghana, West 
Africa (Kumi et al. 2011). 
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 Due to dietary exposures in African countries such as Guinea, Kenya, Benin, 
Togo, Senegal, and the Gambia, approximately 85% to 100% of children have detectable 
levels of serum or urinary AF biomarkers (Gong et al., 2003, 2004; Polychronaki et al., 
2008; Turner et al., 2000, 2003, 2005; Wild et al., 1990, 1993). Therefore, it is clear that 
intervention strategies directed at the mitigation of child exposures are needed in areas 
where risk of AF consumption is high and malnutrition is common. Based on detailed 
studies conducted in animals and humans, it was determined that ingestion of UPSN at 
levels efficacious for reducing AFB1 biomarkers would be reasonably safe in children.  
In the following clinical trial, safety and efficacy of UPSN was assessed for children at 
risk for AF exposure from the Ejura-Sykedumase district of Ghana. The study followed 
a Phase I, double blind, placebo-controlled trial over a two-week time period. The results 
from this research will be utilized to design future studies investigating long-term 
protection of children at high risk for AF exposure and the potential of this material for 
short-term therapy during outbreaks of acute aflatoxicosis.         
4.2 Materials and methods 
4.2.1 Materials 
UPSN was manufactured through a refinement process of the parent calcium 
montmorillonite, NS, by Texas Enterosorbents. UPSN was examined for various 
environmental contaminants, including dioxins and heavy metals to ensure compliance 
with federal and international standards. Metal and dioxin analysis of both NS and 
UPSN was reported to be similar and well under the tolerable daily intake (TDI) or 
provisional tolerable daily intake (PTDI) set forth by various food safety councils of 
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international organizations such as the World Health Organization (WHO) and the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) (Marroquin-Cardona et al. 
2011). UPSN was sterilized by electron beam irradiation to ensure safety from any 
possible bacterial or viral contamination prior to trial initiation.   
HPLC grade methanol, phosphate buffered saline, and AFM1 standard were 
purchased from Sigma Aldrich (Saint Louis, MO, USA). Ultrapure deionized water 
(18.2 MΩ) was generated within the lab using an Elga™ automated filtration system 
(Woodridge, IL, USA). Immunoaffinity columns were purchased from VICAM 
(Watertown, MA, USA).  
4.2.2 Study site and participant recruitment 
           Study participants were recruited from six communities in the Ejura-
Sekyedumase district of the Ashanti Region of Ghana. The six communities included 
Dromonkuma, Hiawoanwu, Kotokoliline, Nkwanta, Ejurafie, and Kasei. These 
communities are in rural areas where inhabitants are primarily subsistence farmers. All 
recruited participants were between 3-9 years of age. Consent was sought from the 
parents or legal guardians following a community meeting with study personnel. 
Consent documents were translated and explained to each participant, then signed by 
each participant’s guardian prior to initiation of the study. Participants were randomly 
assigned to one of three treatment groups. Figure 11 represents the overall study design 
and treatment arms. The three treatment arms consisted of a placebo group, which 
received 0.75 g calcium carbonate twice daily, a low-dose group which received 0.375 g 
UPSN twice daily, and a high-dose group which received 0.75 g UPSN twice daily. A 
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placebo-controlled group was deemed necessary in this research since clinical reference 
ranges for hematology and serum biochemistry values are not currently well established 
for African children (Zeh et al. 2012). Thus, the placebo group was used as a reference 
when determining safety of UPSN. Doses were weighed into identical packages at 
Noguchi Memorial Institute for Medical Research (NMIMR) prior to the study to ensure 
that monitors and participants would be blinded to their treatment. Trained study 
monitors mixed each participant’s treatment into their breakfast and dinner meals before 
consumption. Breakfast meals consisted of a corn-based porridge called “koko” or soup 
and the dinner meals typically consisted of a common soup (i.e. peanut soup, lamb lite 
soup) and corn or cassava dough called “banku” and “fufu”, respectively. These meals 
were supplied by the individual households. Participants provided blood samples (3 cc) 
on the morning prior to initiation of treatment (Day 0) and on day 15 (the morning after 
their last treatment dose). Blood samples were collected by trained phlebotomists at the 
Ejura District Hospital. Aliquots of the blood samples were used for hematological 
analysis and the remaining amount was centrifuged. The resulting serum was collected 
and kept at -20°C. Urine samples were collected by parents the morning of Day 0 
(baseline), halfway through the study (day 7), and the morning after the final dose (day 
15). Following collection, urine samples were stored at -20°C and together with the 
serum samples were transported to NMIMR for analysis. The study design followed the 
guidelines for a double-blind randomized Phase I clinical trial. Ethical clearance and 
Institutional Review Board approval for this study were obtained from both Texas A&M 
University and NMIMR in Accra, Ghana (2011-0684 and 043/11-12, respectively).
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Figure 11. Phase I safety trial design. Flow chart delineating the study design and procedures for a 2-week clinical 
trial with UPSN in Ghana. 
 
 
Figure 11. Phase I safety trial design. Flow chart delineating the study design and procedures for a 2-week clinical trial 
with UPSN in Ghana.
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4.2.3 Toxicity and adverse events monitoring 
             Based on the existing scientific literature describing consumption of 
dioctahedral smectite clays in adults and children, no severe toxicity was expected as a 
result of UPSN treatment. However, research staff and medical personnel were on-site 
throughout the study period to monitor for potential adverse effects and to remove 
participants from the study in the event of such an effect. Daily diary worksheets and 
symptom checklists were provided to study monitors as assessment tools for adverse 
events monitoring and were completed twice daily following ingestion of each treatment 
dose. Adverse events are described as percentages of total number of adverse event 
reports out of the total number of completed daily diary worksheets per treatment group. 
In the event of an adverse treatment effect or unrelated condition at any time during the 
study, medical treatment was available to participants from the district hospital at no cost 
to the participant. Any symptoms were assessed according to the following criteria: Mild 
(grade 1), slightly bothersome and relieved with symptomatic treatment; Moderate 
(grade 2), bothersome and interfered with activities and only partially relieved with 
symptomatic treatment; Severe (grade 3), prevented regular activities and not relieved 
with symptomatic treatment. Any participant experiencing severe incidences were 
advised to seek immediate medical attention. Physical examination and laboratory 
analysis were performed for persistent symptoms. Any symptoms that were linked to the 
UPSN treatment by the study physician would result in immediate discontinuation of the 
treatment; however this did not occur during the study. 
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4.2.4 AFM1 analysis, hematology, and serum biochemistry 
Urinary AFM1 was analyzed through immunoaffinity column clean-up followed 
by HPLC coupled fluorescence detection (previously described in detail in Section 
2.2.3). Whole blood measurements consisted of hemoglobin, total white cell count and 
platelet count. Whole blood analysis was conducted with a flow cytometer (Abx 
micro60, Block Scientific, Bohemia, NY, USA). Serum albumin, alkaline phosphatase 
(ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-
glutamyl transpeptidase (GGT), total protein, total bilirubin, urea, creatinine, 
triglycerides, sodium (Na+), potassium (K+), chloride (Cl-), calcium (Ca2+), and 
magnesium (Mg2+) were measured using a Flexor E, automatic blood analyzer (Vital 
Scientific, Netherlands). 
4.2.5 Statistical analysis 
         Statistical analysis was conducted with JMP 10 software (SAS Institute, NC, 
USA). The ultimate goal of this study was to determine if the ingestion of UPSN clay 
was safe in children; therefore, statistical evaluation focused on comparisons between 
treatment arms, as well as values within a group at baseline and at day 15. A Chi-square 
test was used for analysis of side-effect/toxicity data between treatment groups. As 
expected, AFM1 biomarkers of exposure data was not normally distributed and was log 
transformed prior to analysis. Paired t-test and ANOVA statistical tests were conducted 
on both AFM1 data and biochemical parameters for comparisons among treatment 
groups. A two-tailed p-value<0.05 was considered statistically significant. Correlation 
analyses were performed for serum biochemical parameters and AFM1 levels. R-squared 
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values were based on a standard linear regression model; p-values and correlation 
coefficients were calculated by a Pearson correlation test.                  
4.3 Results 
4.3.1 Study participant characteristics and compliance 
In total, 63 children were enrolled in the clinical trial. There were no significant 
differences in mean age, gender, weight, or other general physical parameters such as 
blood pressure between treatment groups (Table 14). Adherence to the two-week study 
protocol was excellent, with all 63 participants completing the study. Only one 
participant missed an evening dose of treatment throughout the 28 doses/participant 
administered. This participant was in the low-dose UPSN group and was diagnosed with 
and treated for malaria that same day. General acceptance by the parents and children 
was exceptional.  
4.3.2 Adverse events and side effects 
The two dose levels of UPSN (0.75 and 1.5 g/day) were tolerable in the 
participants throughout the study. Adverse symptoms reported during the two-week 
study were primarily of a gastrointestinal nature and included vomiting and diarrhea. 
Table 15 is a tally of individual adverse events reported throughout the course of the 
study. It is important to note that, in some cases, reports were made multiple times by the 
same participant. For example, all reported events in the high-dose group originated 
from one individual who received medical attention from the district hospital following 
2 consecutive days of vomiting. This participant was diagnosed and treated for malaria 
by doctors at the district hospital, but was allowed to stay in the clinical trial per the 
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physician’s recommendation. Vomiting ceased after initiation of malarial medication. In 
total, there were 3 children diagnosed and treated for malaria during the study. This is 
equivalent to 4.8% of our study population, which is actually a lower prevalence rate 
than reported for the area (> 75 per 1,000) by the WHO (World Malaria Report 2012). 
The symptoms reported by individuals with malaria accounted for 9 out of the total 13 
adverse events (69.2%) reported. The placebo, low-dose, and high-dose groups 
experienced side effects at a rate of 0.3% (2/588), 0.8% (5/588), and 1% (6/588), 
respectively. Severities of side effects were generally reported as mild to moderate and 
either no treatment or self-treatment was effective in alleviating symptoms. Severe cases 
of vomiting requiring immediate medical attention occurred only in those participants 
later diagnosed with malaria. Importantly, there were no significant differences observed 
in number of adverse events between treatment groups (p>0.37) or in severity of 
symptoms reported (p>0.43). 
4.3.3 Hematological, blood chemistry, and serum mineral effects  
Hematological analysis of blood samples showed no significant difference 
between treatment arms, although lymphocytes and monocytes were above the normal 
range across all treatment groups at both day 0 and day 15 (Table 16). Hematological 
values in the placebo group were not significantly different from either the low-dose or 
high-dose UPSN groups at day 0 or day 15. These levels were also not significantly 
different within each treatment group when comparing day 15 to baseline values.  
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Table 14. Demographics and Physical Parameter 
  
Treatment group 
Demographic Characteristics Placebo Low-dose High-dose 
Participants 
 
21 21 21 
Gender 
          Male 
 
13 14 14 
      Female 
 
8 7 7 
Age (years)
 a
 
 
5.8 ± 1.6 5.4 ± 1.8 5.7 ± 1.9 
Body weight (kg)
 a
 
 
20.0 ± 4.8 21.0 ± 8.5 18.9 ±5.2 
Height (cm)
 a
 
 
107.2 ± 13.2 107.9 ± 16.3 105.8 ± 15.1 
Systolic blood pressure (SBP) (mmHg)
 a
 87.7 ± 8.0 91.3 ± 10.9 92.3 ± 11.0 
Diastolic blood pressure (DBP) (mmHg)
 a
 44.6 ± 7.3 45.6 ± 9.1 47.2 ± 10.2 
aMean ± SD; Note: all data are baseline vales.  
 
 
Results of serum biochemistry analyses are provided in Table 17. No significant 
differences were observed within groups between day 0 and day 15 for albumin, ALP, 
AST, GGT, total bilirubin, urea, or triglycerides. ALT values were significantly higher 
after treatment for all groups (p< 0.0003), including the placebo group. The placebo 
group also exhibited significantly lower (p< 0.01) total protein levels following 
treatment, however, this was not the case for the UPSN treated groups. At day 15, the 
low-dose UPSN group had significantly lower creatinine levels compared to baseline 
(p<0.05), however this observation was not dose-dependent. Comparison of serum 
biochemistry parameters between the placebo group and the low-dose or high-dose 
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UPSN groups did not indicate significant differences at day 0 or day 15 (Table 17). 
Although average total bilirubin levels were within range in all treatment groups 
throughout the study, a wide range of values were detected (0.2-35.5 μmol/L) and these 
values were positively correlated, with urinary AFM1 concentration at day 0 (Figure 
12A). Upon comparison of all treatment groups at day 15, the association was lost 
(Figure 12B). Interestingly, when AFM1 decreased or increased from day 0 to day 15, 
there was a corresponding decrease or increase in bilirubin levels 62% of the time; 
indicating that bilirubin levels may have a positive association with AFM1 excretion in 
children. 
Median, mean, and normal U.S. pediatric ranges for the serum minerals assessed 
are outlined in Table 18. Serum Na+ and Cl- significantly increased (p< 0.01) over the 
course of the study in all groups. All groups exhibited significantly decreased Ca+ levels 
following the study. A reduction in serum Mg2+ was seen in the UPSN high-dose group 
(p< 0.01). There was also a small reduction in the mean Mg2+ of the UPSN low-dose 
group, however it was not significantly different (p>0.27). However, levels in all groups 
remained well within the normal U.S. range. No other mineral level comparison between 
day 0 and day 15 was significantly different.  
4.3.4 AFM1 biomarker levels in urine 
Throughout the study, 100% of urine samples contained detectable levels of 
AFM1. AFM1 concentration ranged from 0.5-5443.7 pg/mg creatinine. The mean at day 
0 was 297.8 pg/mg creatinine. AFM1 levels were not significantly different by gender or 
correlated with age (data not shown). Although treatment groups were not significantly 
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different at baseline or day 15 of treatment, the high-dose UPSN group exhibited 
significantly (p=0.216) lower AFM1 levels on day 7 than both the placebo and low-dose 
group (Figure 13A-C). When all data values from day 7 and 15 were pooled by 
treatment group the high-dose group showed an overall statistically significant 
(p=0.0063) 70% reduction in AFM1 levels when compared to control (Figure 14). 
 
Table 15. Adverse Events Reported 
 
Treatment Group 
 
 
Placebo Low Dose High Dose Sum  
Symptom Reported 
    Other 0
a
 0   2 * 2 
Indigestion 0 0 0 0 
Nausea 0 0 0 0 
Vomiting 2    3 *    4 * 9 
Constipation 0 0 0 0 
Diarrhea 0 1 0 1 
Flatulence  0 0 0 0 
Loss of Appetite 0 1 0 1 
Abdominal Discomfort 0 0 0 0 
Heartburn 0 0 0 0 
Dizziness 0 0 0 0 
Insomnia 0 0 0 0 
Bloating 0 0 0 0 
Total Incidence (%) 2 (0.3) 5 (0.8) 6 (1) 13 (0.7) 
     Severity 
    Mild 2 2 5 9 
Moderate 0 2 1 3 
Severe 0 1 0 1 
        aIndicates number of times an adverse event was reported.  
     *Indicates participant was diagnosed with malaria by health official 
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Table 16. Hematological Analysis 
 
Treatment Group 
Normal clinical 
range (US) Reference 
 
Placebo 
 
Low Dose 
 
High Dose 
    
 
Baseline After 
 
Baseline After 
 
Baseline After 
    Hemoglobin (g/dL) 11.3 ± 0.8 11.4 ±1.1 
 
11.5 ± 0.9 11.7 ± 1.3 
 
11.0 ± 1.5 11.3 ± 1.5 
 
11.0-14.5 
 
A 
WBC  8.2 ± 2.0 7.4 ± 1.2 
 
7.8 ± 2.0 7.9 ± 1.8 
 
8.5 ± 3.4 8.2 ± 2.7 
 
3.4-12.0 
 
A 
Platelet  275.3 ± 73.9 303.0 ± 112.4 
 
296.0 ± 85.0 349.9 ± 142.7 
 
266.0 ± 80.4 280.9 ± 117.3 
 
150.0-450.0 
 
A 
Lymphocytes (%) 55.2 ± 10.9 56.9 ± 8.1 
 
52.6 ± 7.9 51.8 ± 9.6 
 
52.9 ± 11.2 53.5 ± 9.4 
 
28.0-48.0 
 
B 
Monocytes (%) 10.6 ± 3.2 11.0 ± 3.9 
 
12.3 ± 3.7 13.0 ± 3.9 
 
10.4 ± 3.0 10.9 ± 3.3 
 
3.0-6.0 
 
B 
Granulocytes (%) 34.2 ± 12.1 31.9 ± 7.4 
 
35.1 ± 8.4 35.2 ± 10.7 
 
36.6 ± 11.0 35.6 ± 9.1 
 
32.0-76.0 
 
B 
Data are mean ± SD; A) Mayo Clinic pediatric reference values B) Children’s hospitals and clinics of Minnesota reference values; Reference ranges are 
combined for males and females WBC and Platelet values are in (X 1000/mm3). 
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Table 17. Serum biochemistry 
 
Treatment Groups 
Normal  
Clinical  
Range (US) Reference  
 
Placebo 
 
Low Dose 
 
High Dose 
    
 
Baseline After 
 
Baseline After 
 
Baseline After 
    
 
49 47.2 
 
48.5 47.9 
 
49.6 48.4 
    Albumin (g/L) 47.0 ± 9.0 46.9 ± 2.8 
 
48.5 ± 3.1 47.2 ± 2.3 
 
46.2 ± 11.1 47.6 ± 6.0 
 
35.0-50.0
 
A 
 
15.9-56.0 39.7-51.0 
 
42.5-53.0 42.2-51.6 
 
11.1-57.4 25.2-56.2 
   
 
591.9 596.2 
 
479 620.5 
 
521.3 581.9 
   
ALP (U/L) 559.1 ± 185.7 532.0 ± 355.6 
 
427.2 ± 
242.3 572.3 ± 332.6 
 
488.5 ± 215.8 584.9 ± 314.7  
 
149.0-468.0 
 
A 
 
176.9-1039.4 6.3-1164.3 
 
17.3-843.4 6.1-1102.2 
 
13.1-907.6 24.7-1189.1 
   
 
13.2 27.1 
 
17.2 27.6 
 
17.7 24.6 
   ALT (U/L) 14.4 ± 6.0 30.2 ± 11.3 * 
 
19.3 ± 8.6 28.9 ± 7.2 * 
 
20.2 ± 20.0 29.3 ± 15.1 * 
 
7.0-55.0 
 
A 
 
4.3-27.1 13.7-51.4 
 
7.5-46.5 20.8-45.8 
 
3.0-87.3 12.4-68.3 
   
 
39.8 41.2 
 
38.3 42.1 
 
38.4 40.4 
   AST (U/L) 41.8 ± 13.2 44.9 ± 12.3 
 
42.3 ± 8.4 43.7 ± 10.8 
 
40.2 ± 14.1 41.4 ± 10.0 
 
8.0-60.0
 
A 
 
16.8-66.3 31.4-73.3 
 
30.9-59.5 29.8-74.3 
 
12.6-85.9 20.6-57.3 
   
 
15 16.6 
 
10.6 14 
 
13.2 15 
   GGT (U/L) 16.6 ± 8.0 17.0 ± 6.8 
 
13.9 ± 8.6 16.0 ± 7.3 
 
14.1 ± 9.0 17.0 ± 11.7 
 
7.0-29.0
 
A 
 
1.7-42.0 6.1-31.4 
 
6.4-43.2 7.4-35.5 
 
0.5-37.2 2.8-48.7 
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Table 17. Continued 
 Treatment Groups  
Normal 
Clinical 
Range (US)  Reference 
 Placebo  Low Dose  High Dose     
 Baseline After  Baseline After  Baseline After     
 
5.5 8.1 
 
6.2 7.5 
 
6.7 6.1 
    Total Bili(µmol/L) 7.1 ± 7.1 8.5 ± 4.9 
 
7.8 ± 5.4 7.9 ± 3.4 
 
8.4 ± 8.1 8.3 ± 7.4 
 
1.7-17.1 
 
A 
 
0.2-28.1 0.6-22.4 
 
0.5-25.4 1.8-15.9 
 
1.1-35.5 0.2-29.9 
    
 
80.5 76.3 
 
77.8 77.2 
 
79.8 80.9 
    Total Protein (g/L) 78.8 ± 8.8 77.0 ± 3.3 * 
 
78.2 ± 6.0  77.4 ± 4.3 
 
79.8 ± 31.0 78.0 ± 8.6 
 
63.0-79.0 
 
A 
 
43.6-87.2 70.8-82.5 
 
70.2-89.8 70.1-86.1 
 
21.3-194.2 47.8-89.6 
    
 
2.9 2.7 
 
2.8 2.7 
 
3.1 2.8 
    Urea (mmol/L) 2.7 ± 0.8 2.9 ± 0.6 
 
2.8 ± 0.8 2.6 ± 0.6 
 
2.9 ± 1.2 2.9 ± 1.0 
 
2.5-7.1 
 
A 
 
0.8-3.8 2.1-4.5 
 
1.5-4.6 1.6-3.7 
 
0.6-5.2 1.6-6.0 
    
 
58.1 53.3 
 
61.7 54.3 
 
64.4 59.1 
    Creatinine(µmol/L) 54.6 ± 16.4 54.3 ± 6.2 
 
62.4 ± 10.1 55.7 ± 9.5 * 
 
60.7 ± 17.9 56.5 ± 9.0 
 
50.0-110.0 
 
C 
 
5.4-71.1 40.2-65.1 
 
38.7-77.0 42.4-78.5 
 
18.5-90.4 34.1-74.2 
    
 
0.8 1.1 
 
1 1 
 
0.9 1.1 
    Triglycerides 
(mmol/L) 1.0 ± 0.7 1.3 ± 0.8 
 
1.3 ± 0.7  1.2 ± 0.7  
 
1.6 ± 3.0 1.3 ± 0.6 
 
<1.02 
 
A 
 
0.2-2.6 0.4-3.5 
 
0.5-3.0 0.7-3.8 
 
0.2-14.1 0.5-3.2 
    Data represent median, mean ± SD, and range; A) Mayo Clinic pediatric reference ranges C) Royal College of Physicians and Surgeons of Canada 
ranges; Reference ranges are combined male and female values   
* Denotes significant difference between baseline and after treatment 
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4.4 Discussion 
Chronic childhood AF exposure has gained interest over the past decade as a 
potential variable in the complex milieu of biological and environmental factors that lead 
to stunting, wasting, and suppressed immunity. In particular, Sub-Saharan Africa has 
been identified as an area at high risk for AF exposure as well as growth stunting. 
Investigations from the Ejura district in the Ashanti Region of Ghana have demonstrated 
on-going, high level AF exposure over the past decade (Jolly et al. 2006, 2011; Mitchell 
NJ et al. 2013; Wang P et al. 2008). A prevalence of up to 54.9% has been reported for 
stunted and/or wasted children from another district of the Ashanti Region (Inungu 
1995). Although the high rates observed in this population are primarily thought to occur 
as a result of inadequate nutrition and protein intake, multiple variables likely contribute 
to the etiology of disease. Chronic AF exposure in this community could be one such 
contributing factor, particularly following administration of nutritional supplements such 
as homemade “weanimix”, which consists of groundnuts, beans, and maize (0.5:0.5:4). 
A recent assessment of the weaning foods produced in this community, intended for 
children between the ages of six months and two years, showed AF contamination in 
100% of samples with levels as high as 500 ppb (Kumi et al. 2011). Urine samples 
collected from children before and after 21 days of homemade weanimix consumption 
revealed increased levels of AFM1 biomarkers, indicating that while it is an important 
nutritional supplement in this region, weanimix can also cause heightened AF exposure 
(Kumi et al. 2011). Therefore, an intervention strategy to reduce childhood exposure in 
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these populations, while maintaining the use of these important nutritional supplements, 
is of particular interest.  
Enterosorption therapy may be a valuable tool in low-economic, high risk areas, 
where food insecurity results in a limited variety in the diet and continued consumption 
of poor quality foods (Phillips et al. 2008; Shephard 2003). Clinical trials utilizing 
similar dioctahedral smectite clays at doses as high as 6 g/day for the treatment of acute 
diarrhea in children resulted in limited adverse effects; of which mild constipation was 
the most severe event reported (Dupont et al. 2009; Lexomboon et al. 1994; Madkour et 
al. 1993; Szajewska et al. 2006). Similarly, results from the current study indicate that 
administration of dietary UPSN powder at concentrations from 0.75-1.5 g/day in healthy 
children (ages 3-9 years) for 14 days resulted in minimal side effects. Neither, dose-
dependent toxic effects nor severe clinical symptoms were related to UPSN consumption 
in the present study. Hematologic parameters indicated that UPSN treatment did not 
impair immunity or promote an inflammatory response (George-Gay and Parker 2003).  
ALT values were increased in all treatment groups at day 15; however there were 
not significant differences between the low-dose or high-dose UPSN groups, and 
placebo. These values were also within normal pediatric reference ranges reported by the 
United States Mayo Clinic (Table 17). Additionally, all other liver toxicity parameters 
(i.e. ALP, AST, bilirubin, and GGT) were not increased at day 15 in any treatment 
groups. Therefore, the cause of an increase in ALT values over the duration of the study 
remains unclear. Na+ and Cl- levels were also significantly increased over the study 
period, however this was observed in the placebo group as well as the UPSN treated 
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groups. This indicates that these changes were most likely due to a change in dietary 
consumption of Na+ and Cl-, possibly through higher intake of salt during the study 
period. The levels for Cl- were still within normal reference range, while some Na+ 
values were out of range based on the United States pediatric values as seen in Table 18 
(Mayo 2013).  
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Figure 12. Correlation of log transformed total bilirubin
and log transformed AFM1 values for all participants at
day 0 (A) and day 15 (B).
 
Figure 12. Correlati n of log transformed total bilirubin and log transformed 
AFM1 values for all participants at day 0 (A) and day 15 (B). 
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Increases in Ca2+ have been observed following administration of the parent NS 
product (Afriyie-Gyawu et al. 2005) and UPSN (Marroquin-Cardona et al., 2011) in rats, 
which was attributed to dissolution of calcite and exchangeable Ca2+ ions from 
montmorillonite. However, in the present study total Ca2+ levels were decreased in all 
treatment groups including the placebo (calcium carbonate). Calcium carbonate, and to a 
lesser extent NS clay, typically act as calcium supplements, thus it is likely that this 
overall reduction in serum levels is a result of dietary changes during the intervention 
trial. 
Mg2+ was the only serum micronutrient that dose-dependently decreased with 
UPSN treatment. The mean concentrations in the high-dose group were significantly 
lower than the placebo group on day 15 following treatment and the low-dose group, 
while not significantly different, demonstrated a decreasing trend from the placebo. 
However, it is important to note that all levels remained within normal range throughout 
the study. Furthermore, significant modulation in serum Mg2+ concentrations have not 
been observed in any other animal or human study with UPSN or parent NS 
(Gelderblom et al. 1996a). Decreased absorption and retention of Mg2+ was observed in 
a pig model following ingestion of 1% of a sodium montmorillonite clay (Schell et al., 
1993). Mg2+ plays an important role in many human metabolic functions, acting as a co-
factor in enzymatic reactions that involve adenosine triphosphate (ATP). Levels are 
controlled by the kidneys and GI tract and appear to be closely linked to calcium, 
potassium, and sodium metabolism (Reinhart 1988). Therefore, the change in Mg2+ 
observed here could have resulted from changes in calcium or sodium metabolism and 
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not directly from UPSN treatment. An alternative explanation for the lowered serum 
Mg2+ observed is a direct sequestration of Mg2+ by UPSN in the gut through cation 
exchange activity of the clay, thus reducing the availability of Mg2+ for absorption from 
the gut. Longer safety trials controlling for intake of essential dietary nutrients are 
warranted to determine whether UPSN could interfere with micronutrient or mineral 
absorption in children. 
Although changes in serum bilirubin have been reported following exposure to 
AF in animal species (Clifford and Rees, 1967; Clark et al., 1987) to our knowledge 
there have been no correlations made between AF exposure and bilirubin levels in 
humans. AF-alb, while a valuable AF assessment tool in the serum, is a long-term 
biomarker of exposure and is not known to fluctuate with recent exposure as rapidly as 
the urinary biomarker. For this reason, urinary AFM1 is a better marker to correlate with 
rapidly changing serum components, such as bilirubin, which can modulate considerably 
in one day. As stated previously, AF has been shown to elevate total bilirubin and ALP 
levels in animal models. Since growth stunting has been reported to be common in most 
forms of chronic liver disease (Sokol and Stall, 1990), it will be important to assess liver 
function parameters in future studies involving children, growth-stunting, and AFs. 
Additionally, since direct bilirubin can be measured in the urine of individuals 
experiencing liver malfunction, this may be an excellent non-invasive biomarker to 
monitor in clinical AF studies.  
Although the range of AFM1 excretion was similar the average levels were 
significantly lower in this study than those seen in adults from the same population in 
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Table 18. Serum minerals 
 
Treatment Groups 
Normal  
Clinical  
Range (US) Reference 
 
Placebo 
 
Low Dose 
 
High Dose 
    
 
Baseline After 
 
Baseline After 
 
Baseline After 
    
 
132.2 138.2 
 
135.3 138.1 
 
128.5 135.6 
    Na (mmol/L) 130.6 ± 6.8 139.2 ± 5.5 * 
 
133.6 ± 8.0 138.8 ± 3.8 * 
 
129.3 ± 9.1 136.8 ± 3.1 * 
 
135.0-145.0 
 
A 
 
115.3-141.4 132.2-153.4 
 
114.3-146.2 134.5-150.3 
 
112.1-149.9 132.7-143.3 
    
 
3.7 4 
 
3.8 3.9 
 
3.7 4.1 
    K (mmol/L) 3.8 ± 0.4 4.0 ± 0.4 
 
3.8 ± 0.4 4.1 ± 0.5 
 
3.8 ± 0.5 4.1 ± 0.4 
 
3.6-5.2 
 
A 
 
3.0-4.8 3.3-5.0 
 
2.7-4.5 3.2-5.7 
 
3.1-4.8 3.3-4.7 
    
 
97.3 101.2 
 
98.8 102.4 
 
96.2 100.4 
    Cl (mmol/L) 97.4 ± 4.2 101.2 ± 4.0 * 
 
97.7 ± 5.6 101.5 ± 2.5 * 
 
96.6 ± 5.1 100.3 ± 2.1 * 
 
102.0-112.0 
 
A 
 
89.4-105.3 90.1-108.4 
 
83.0-106.8 96.0-104.8 
 
87.8-106.3 95.4-105.2 
    
 
2.4 2.1 
 
2.3 2.2 
 
2.3 2.1 
    Ca (mmol/L) 2.4 ± 0.2 2.2 ± 0.3 * 
 
2.3 ± 0.1 2.2 ± 0.2 * 
 
2.3 ± 0.2 2.1 ± 0.3 * 
 
2.4-2.7 
 
A 
 
1.9-2.7 1.8-2.8 
 
2.0-2.6 1.2-2.6 
 
2.0-2.6 1.5-2.5 
    
 
0.9 0.8 
 
0.9 0.8 
 
0.8 0.8 
    Mg (mmol/L) 0.8 ± 0.1 0.8 ±0.1 
 
0.9 ± 0.1 0.8 ± 0.1 
 
0.8 ± 0.1 0.8 ± 0.1 * 
 
0.7-1.0 
 
A 
 
0.5-1.0 0.6-1.0 
 
0.7-1.0 0.6-1.0 
 
0.7-1.1 0.6-0.9 
    Data represent median, mean ± SD, and range; A) Mayo Clinic pediatric reference ranges; Reference ranges are combined male and 
female values.  
* Denotes statistical significance between baseline and after treatment.   
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October of 2010 (Mitchell NJ et al. 2013). This finding may be explained by the fact that 
this intervention trial was carried out during the wet season, whereas the adult study took 
place at the beginning of the dry season, which typically correlates with increasing AF 
exposure (Turner et al. 2000; Wild et al. 2000). Also, the variance in excretion levels 
could be attributed to the difference in food intake, metabolism, and urinary output 
between children and adults. The high-dose UPSN group showed a significant decrease 
in AFM1 excretion when compared to baseline levels for that group and when compared 
to controls (70%). This decrease in AFM1 is higher than the percentages previously 
reported following NS and UPSN consumption in adults (58.7 and 55.0%, respectively) 
(Mitchell NJ et al. 2013; Wang P et al. 2008). The variation could be attributed to 
different inclusion levels of clay from the adult and children studies. Percent reduction in 
the adult clinical trials was based on an intake of 3 g clay/day while intake for the 
current study was 1.5 g/day. Although the amount of UPSN consumed in this clinical 
trial was half that of the adult study, it could account for a higher percentage of the total 
daily food intake, and thus the total daily AF intake. It is difficult to determine the actual 
daily caloric intake for this population, but this should be considered in future work 
when determining appropriate dose levels for vulnerable populations.        
The results from this Phase I clinical trial indicate that UPSN consumption by 
children (ages three to nine years) is safe at a dose up to 1.5 g/day for two weeks. 
Inclusion of UPSN in weaning foods could also significantly decrease the amount of 
AFB1 absorbed through the gastrointestinal wall, thereby reducing adverse effects of AF 
exposure and enhancing the quality, efficiency and safety of nutritional supplements.   
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Figure 13. Dose effects of UPSN intervention of urinary AFM1 excretion over the duration of
the study. The box plots show distributions of AFM1 levels in each group across time points.
The box values range from 25 to 75 percentiles of the total samples, the line within the box
indicates the median value. The bars on both sides of a box represent values ranging from 5 to
25 and 75 to 95 percentiles, respectively. * Indicates statistical significance (p<0.05).
 
Figure 13. Dose effects of UPSN intervention of urinary AFM1 excretion over 
the duration of the study. The box plots show distributions of AFM1 levels in 
each group across time points. The box values range from 25 to 75 percentiles of 
the total samples, the line within the box indicates the median value. The bars on 
both sides of a box represent values ranging from 5 to 25 and 75 to 95 
percentiles, respectively. * Indicates statistical significance (p<0.05). 
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Figure 14. Comparisons of treatment groups following pooling of the AFM1 data for day 7
and day 15. The box values range from 25 to 75 percentiles of the total samples; the line
within the box indicates the median value. The bars on both sides of a box represent
values ranging from 5 to 25 and 75 to 95 percentiles, respectively. *Indicates statistical
significance (p<0.05).
 
i ure 14. Comparisons of treatment groups following p oling of the AFM1 data 
for day 7 and day 15. The box values range from 25 to 75 percentiles of the total 
samples; the line within the box indicates the median value. The bars on both 
sides of a box represent values ranging from 5 to 25 and 75 to 95 percentiles, 
respectively. *Indicates statistical significance (p<0.05).  
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5. TOXICOKINETICS OF AFB1 AND FB1 COMBINED EXPOSURE AND 
SORPTION WITH UPSN CLAY IN A RODENT MODEL 
5.1 Introduction 
Naturally occurring foodborne carcinogens, such as AFB1 and FB1, are 
predominantly investigated as independent compounds. However, complex mixtures of 
mycotoxins occur in the environment and could induce additive, antagonistic or 
synergistic interactions when present together (Carpenter et al. 1998). Research has 
demonstrated that multiple mycotoxins can co-contaminate crops and foods intended for 
both animal and human consumption (Almeida et al. 2012; Kimanya et al. 2008; Sun G 
et al. 2011). Although research investigating the health effects due to co-exposure of 
these two mycotoxins is limited, several studies have elucidated their additive and 
synergistic capability. Since AFB1 and FB1 commonly co-contaminate foods, any 
therapeutic approach that could mitigate both mycotoxins would be highly attractive and 
more cost-effective than a combination of approaches. In particular, populations most at 
risk for exposure to both mycotoxins also suffer from food insecurity and poor economic 
conditions. Thus, a remediation strategy for such communities must function to reclaim 
contaminated foods in their entirety and cause minimal interference to daily life. UPSN 
is from the family of smectites that has been shown to sorb AFB1 in vitro and in 
numerous animal and human models, thereby decreasing biomarkers of exposure in the 
urine and blood and protecting animals from toxic endpoints (Beaver et al. 1990; Colvin 
et al. 1989; Edrington et al. 1996; Phillips et al. 1988; Pimpukdee et al. 2004). Recently, 
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in vitro analyses indicated that UPSN efficaciously bound FB1 as well as mixtures of 
AFB1 and FB1 (Brown KA et al. 2012).  
The objectives of this study were: 1) to determine whether a dual protection 
would be feasible in a mammalian gastrointestinal system and 2) to assess the difference 
in UPSN efficacy when a mixture of AFB1 and FB1 is present, as opposed to a single 
toxin exposure.  
5.2 Materials and methods 
5.2.1 Materials 
High Performance Liquid Chromatography (HPLC) grade methanol and 
acetonitrile, as well as reagent grade hydrochloric acid, formic acid, sodium phosphate 
monobasic, sodium borate, sodium cyanide, dibasic potassium phosphate, and pH 
buffers (4.0, 7.0, and 10.0) were purchased from VWR (Atlanta, GA). O-
phthaldialdehyde (OPA), AFM1, and FB1 analytical standards were purchased from 
Sigma-Aldrich (Saint Louis, MO). FB1 specified for animal treatment was purchased 
from the PROMEC Unit of the South African Medical Research Council (Tygerbreg, 
South Africa). UPSN was obtained from Texas Enterosorbents (Bastrop, TX). Ultrapure 
deionized water (18.2 MΩ) was generated within the laboratory using an Elga™ 
automated filtration system (Woodridge, IL). 
5.2.2 Animal housing, diet, and treatments 
Five-week old male Fischer-344 rats were purchased from Harlan (Houston, TX) 
and allowed to acclimate for one week before being randomly divided into twelve 
treatment groups consisting of six animals per group (Table 19). Briefly, the treatment 
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groups included an absolute control, positive controls (dosed with AFB1, FB1 or a 
mixture of the two), and groups treated with a one-time toxin dose in addition to one of 
three levels of UPSN clay (0.25, 0.5, or 2% w/w feed consumption). Control animals (no 
UPSN) were maintained on a nutritionally complete powdered feed (Teklad rodent diet 
8604, Harlan) and water ad libitum. Animals that were placed in the 0.25, 0.5, or 2% 
UPSN treatment groups received Teklad 8604 powdered feed homogenously mixed with 
UPSN at the respective percentages and water ad libitum. Animal maintenance, 
husbandry, and treatment protocols involving AFB1 and FB1 exposures were reviewed 
and approved by the Institutional Animal Care and Use Committee at Texas A&M 
University. Following the one week acclimation period animals were gavaged with 
0.125 mg AFB1/kg b.w. and/or 25 mg FB1/kg b.w. These levels were minimal doses to 
provide sufficient levels of urinary AFM1 and FB1 for quantitation (Robinson et al. 2012; 
Sarr et al. 1995). Aqueous gavage solutions administered to UPSN treatment groups also 
contained UPSN at an amount equivalent to one day’s intake. Based on an average daily 
feed consumption of 20 g the doses were as follows: the 0.25% group was gavaged with 
0.05 g, 0.5% were given 0.1 g, and 2% were given 0.4 g UPSN, respectively. Following 
gavage, animals were housed in metabolic cages (NalgeneTM) and urine was collected at 
12, 24, 36, 48, and 72 hr. Samples were stored at -20°C for AFM1 and FB1 biomarker 
analyses. Animals were euthanized after 72 hrs, blood samples collected, and serum 
stored at -20°C until AFB1-albumin analysis. Liver and kidney weights were also 
recorded and expressed as a percentage of the total body weight.  
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5.2.3 Analysis of urinary AFM1 
AFM1 concentrations in the urine were analyzed using immunoaffinity column 
purification using methods previously described in Section 2.2.3. However, here 1 ml of 
rat urine was adjusted to an acidic pH with 1.0 M ammonium formate (pH 4.5) and the 
volume increased to 10 ml with water. Quantification of AFM1 was based on peak area 
and retention time as compared to external standards run between every 5 samples. The 
limit of detection for urinary AFM1 using this method was 4.8 pg. Creatinine analysis 
was performed on all urine samples at the Texas Veterinary Medical Diagnostic 
Laboratory (College Station, TX) to adjust for variations in urine dilution. 
 
Table 19. Study treatment groups 
Treatment groups  0% UPSN 
0.25% 
UPSN 
0.5% 
UPSN 
2.0% 
UPSN 
0.125 mg AFB
1
/kg b.w. 6 6 6 6 
25 mg FB
1
/kg b.w. 6 6 6 6 
25 mg FB
1
/kg b.w. + 0.125 mg AFB
1
/kg 
b.w. 
6 6 0 6 
Absolute Control 6 0 0 0 
 
5.2.4 Analysis of urinary FB1 
Urine samples from 3 animals in the same treatment group were pooled for 
analysis. Following centrifugation, a 300 μl aliquot of supernatant was loaded into a pre-
equilibrated VICAMTM FumoniTest immunoaffinity column and passed through by 
gravity. After washing with 10 ml of PBS, FB1 was eluted three times with 0.5 ml of 
20% methanol in 10 mM hydrochloric acid directly onto a pre-conditioned Waters Oasis 
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HLB cartridge (3 cc/60 mg, 30 μm particle size). The HLB cartridge was sequentially 
washed with 2 ml water and 2 ml 30% aqueous methanol, and then eluted three times 
with 0.6 ml of 2% formic acid in methanol. Eluents were evaporated to dryness under 
nitrogen gas while incubated at 35°C. Dry residues were reconstituted with 150 μl of 
50% aqueous methanol.  
HPLC-fluorescence analysis was carried out on an Agilent 1100 liquid 
chromatography system (Agilent Technologies, Santa Clara, CA). FB1 molecules were 
derivatized with o-phthaldialdehyde (OPA) prior to fluorescence detection (Xu et al. 
2010). To avoid degradation of the derivatives, an on-line automatic injector thoroughly 
mixed 20 μl of OPA reagent with the sample for one minute immediately prior to each 
injection. Chromatographic separations were performed on a Luna C18 (2) column 
(Phenomenex Torrance, CA; 5 μm particle size, 250 x 4.6 mm), maintained at 35°C. 
Molecules were resolved with a linear gradient starting from 0.1 M sodium phosphate 
monobasic (pH 3.4): methanol (35/65, v/v) to 0.1 M sodium phosphate monobasic (pH 
3.4): methanol (20/80, v/v) over 13 min, with a flow rate of 1.0 ml/min and injection 
volume of 100 μl. The OPA derivative was monitored at an emission wavelength of 440 
nm and excitation wavelength of 330 nm. The limit of detection for this method was 20 
pg.  
5.2.5 Analysis of serum AFB1-albumin adduct 
Serum from all AFB1 and AFB1/FB1 treatment animals was assessed for AFB1-
albumin levels 72 hr following gavage. The methodology to complete this analysis was 
adopted as previously reported (Qian G et al. 2013b; Riley et al. 1994). Briefly, 150 μL 
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of serum was digested with pronase (pronase:total protein, 1:4, w:w) for 3 hr at 37°C. 
The digest was further purified by a solid phase cartridge, evaporated, reconstituted, and 
injected into an Agilent 1200 HPLC system for quantification by fluorescence signal. 
Excitation and emission wavelengths were 405 and 470 nm, respectively. The limit of 
detection was 0.4 pg/mg albumin. Serum AFB1-albumin adduct concentrations were 
adjusted by total serum albumin content.    
5.2.6 Statistical analysis 
Serum levels of AFB1-albumin adduct and urinary AFM1 and FB1 are expressed 
as mean ± standard deviation (SD). Data was not normally distributed and was therefore 
log transformed for statistical analysis. Comparisons of these parameters between treated 
groups and the control group were conducted using one-way analysis of variance 
(ANOVA) followed by a student’s t-test to compare between each of the 12 treatment 
groups. A p-value of less than 0.05 was considered statistically significant.    
5.3 Results 
5.3.1 Organ and body weights 
Relative weight gain over the acclimation and treatment periods of the 
current study were not significantly different between absolute control and treated 
animals. Average weight gained during the acclimation period was 30.1 g. Animals 
weighed on average 145.3 g, 72 hr following gavage. Comparisons of organs 
between treatment groups were conducted with the somatic indices for each organ. 
There were no significant differences observed between treatment groups for liver 
or kidney, the two primary target organs known to be affected by FB1 and AFB1. 
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Average percent body weight values for liver and kidney were 4.77% ± 0.24 and 
0.46% ± 0.04, respectively (data not shown).   
5.3.2 Urinary AFM1 levels in AFB1 treatment groups 
Mean urinary AFM1 was calculated based on six rats per treatment group. 
Absolute control animals receiving an equal volume (0.75 ml) gavage of ultra-pure water 
did not have detectable AFM1 metabolites in the urine at any of the collection time 
points. Excretion of AFM1 peaked between 12 and 24 hr following AFB1 treatment. Five 
out of six rats were completely void of AFM1 by the 36 hr timepoint (Figure 15A). The 
positive control group displayed the highest average concentration of AFM1 (201 ng/mg 
creatinine) at the 12 hr time point. Comparisons of AFM1 levels between UPSN 
treatment groups and positive controls showed a marked decrease in overall excretion of 
AFM1 metabolites. UPSN treatment reduced AFM1 biomarkers in a dose-dependent 
manner with the largest reduction observed in the 2% treatment group. UPSN at 0.25% 
reduced AFM1 excretion by 88%, 94%, and 85% at 12, 24, and 36 hr time points, 
respectively (Figure 15B). Reduction of biomarkers in the 0.5% UPSN treatment group 
were 91%, 96%, and 85% at 12, 24, and 36 hr time points (Figure 15B). AFM1 levels in 
the 2% UPSN treatment group were reduced by 97%, 99%, and 58% at 12, 24, and 36 
hr, respectively. The decrease in AFM1 observed in the UPSN treatment groups was 
highly significant (p<0.001) at 12 and 24 hr. The 0.25% and 0.5% UPSN groups were 
also significantly different from the 2% UPSN group (p=0.0045 and 0.0190, 
respectively), but were not significantly different from each other (Figure 15A). 
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5.3.3 Urinary AFM1 levels in AFB1/FB1 treatment groups  
AFM1 excretion patterns were different between AFB1 treatment groups and 
AFB1/FB1 mixture groups. AFM1 excretion by the co-exposure group peaked at 12 hr 
and was almost undetectable by 24 hr. The highest average AFM1 concentration in the 
urine was 118 ng/mg creatinine at 12 hr in animals dosed with the AFB1/FB1 mixture 
(Figure 15C). This value is approximately 2 times lower than the average concentration 
in animals dosed with AFB1 alone. UPSN treatment dose-dependently reduced AFM1 
excretion in animals exposed to the AFB1/FB1 mixture. However, the percent reductions 
observed in the mixture groups were lower than those in the AFB1 control groups. 
Compared to AFB1/FB1 positive controls, the 0.25% UPSN group exhibited AFM1 
decreases of 66% and 32% at 12 and 24 hr, respectively. At the same time points, 0.5% 
UPSN reduced AFM1 by 88% and 43%, while 2% UPSN reduced levels by 95% and 
76% (Figure 15D). AFM1 levels were non-detectable in any groups treated with UPSN 
by the 36 hr timepoint. AFM1 excretion levels observed during UPSN inclusion were 
significantly different from the AFB1/FB1 control group for the 0.5% and 2% UPSN 
only at the 12 hour time point (p=0.0124 and 0.0016, respectively). The 0.25% UPSN 
group did not excrete significantly lower AFM1 than the AFB1/FB1 controls at 12 hr, and 
excreted levels significantly higher than the 2% UPSN group (p=0.0072) (Figure 15C). 
Although the UPSN treated groups had lower AFM1 output at 24 hr than the control 
group, the difference was not statistically significant. 
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5.3.4 Urinary FB1 levels in FB1 treatment groups  
 Urine samples were also analyzed for FB1 with HPLC-coupled fluorescence 
detection. Mean FB1 levels were calculated from six animals per treatment group. 
Absolute control animals did not have detectable levels of FB1 present in their urine at 
any time point assessed. As expected, the highest levels of FB1 excretion occurred 12 hr 
post-gavage, decreasing rapidly, and reaching non-detectable levels by 36 hr (Figure 
16A). At 12 hr, mean urinary excretion for animals dosed with FB1 alone was 722 ng/mg 
creatinine. Addition of UPSN clay at the 2% w/w level significantly decreased the 
amount of FB1 excreted at 12 and 24 hr (p=0.0437 and 0.0150, respectively). Although 
not significant, 0.25% UPSN decreased overall excretion of FB1 as well. Mean levels of 
FB1 excreted by the 0.25% and 2% UPSN groups at 12 hr were 425 and 384 ng/mg 
creatinine, respectively, and 177 and 281 ng/mg creatinine at 24 hr. Overall reduction of 
the FB1 biomarker for the 0.25% UPSN inclusion group was 41% at 12 hr and 61% at 24 
hr, compared to the positive control group. UPSN inclusion at the 2% level reduced 
urinary FB1 by 80% and 98% at 12 and 24 hr (Figure 16B).  
5.3.5 Urinary FB1 levels in AFB1/FB1 treatment groups 
Mean urinary levels of FB1 were 453 and 78 ng/mg creatinine at 12 and 24 hr post-
gavage, respectively, in the AFB1/FB1 co-treated positive control samples. A dose-
dependent reduction in urinary FB1 was observed for the UPSN treated AFB1/FB1 
groups, with the 2% UPSN group exhibiting the largest difference from the positive 
control group (Figure 16C). The FB1 biomarker in the 0.25% UPSN group was reduced 
by 24 and 27% at 12 and 24 hr after gavage and by 40 and 50% for the 2% UPSN group, 
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respectively (Figure 16D). Reduction in FB1 was significant in the 2% UPSN group at 
12 hr (p=0.0137), but not at 24 hr (p=0.1452). The reduction of urinary FB1 excretion 
observed in the 0.25% UPSN group was not statistically significant, with p=0.0910. 
5.3.6 Area under the curve (AUC) calculations 
Figure 17 shows the differences in kinetics for total AFM1 and FB1 excretion in 
the urine by calculations of area under the curve (AUC) for each treatment group. Based 
on AUC, approximatley 75% of the total AFM1 excreted was detected within the first 24 
hr after AFB1 exposure in the positive control group. The 0.25% UPSN group excreted 
the equivalent of 9% of the total AFM1 that was excreted by the AFB1 treated positive 
control group (Figure 17A). Based on the total AUC, the 0.5 and 2% UPSN groups 
excreted the equivalent of 6 and 2% of the amount of AFM1 excreted by the AFB1 
treated positive control, respectively. The mean excretion of AFM1 biomarkers was 
significantly different (p=0.0002) between animals dosed with AFB1 alone and animals 
receiving both AFB1 and FB1. The AUC value for AFM1 excretion in the AFB1/FB1 
control animals was approximately 3 times smaller than the AUC for the AFB1 control 
animals (Figure 14A). Based on AUC values, the 0.25%, 0.5%, and 2% UPSN groups 
excreted the equivalent of 37%, 16%, and 7% of the AFM1 excreted by the AFB1/FB1 
positive controls.     
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Figure 15. Mean excretion pattern of AFM1. A) 0.125 mg AFB1/kg b.w. treated groups with 0, 0.25, 0.5, and 2% UPSN. B) Table of 
percent reduction between AFB1 treated positive control group (no clay) and each AFB1/UPSN group at time points 12, 24, and 36 hr 
following gavage. C) AFB1/FB1 mixture groups with 0, 0.25, 0.5, and 2% UPSN. D) Table of percent reduction between AFB1/FB1 treated 
positive control group (no clay) and each AFB1/FB1/UPSN group at time points 12, 24, and 36 hr following gavage. * Indicates a 
significant difference between the positive control group and the UPSN treated group at a specific time point (p<0.01). ** Indicates a 
significant difference between the positive control group and ALL UPSN groups at a specific time point (p<0.01).  
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Approximately 76% of the total FB1 excreted by the FB1 treated positive control 
group was excreted within the first 24 hr after gavage. Based on the AUC calculations, 
the 0.25% UPSN group excreted the equivalent of 54% of the total FB1 excreted by the 
FB1 treated control group. The 2% UPSN group excreted the equivalent of 27% of the 
total FB1 excreted by the FB1 treated control group (Figure 17B). Similar to the change 
in kinetics of AFM1 excretion after AFB1/FB1 co-exposure, total FB1 excreted in 
AFB1/FB1 combination groups was significantly lower than total FB1 excreted in the FB1 
treated controls (p=0.0173). Total AUC values indicated an approximate two-fold 
reduction in the amount of FB1 excreted by the AFB1/FB1 combination group compared 
to the positive control group. Based on the AUC calculations, the 0.25% and 2% UPSN 
groups excreted the equivalent of 72 and 53% of the total FB1 excreted by the AFB1/FB1 
positive controls (Figure 17B). UPSN treatment was less effective in reducing AFM1 and 
FB1 urinary biomarkers after AFB1/FB1 co-exposures than after exposure to either AFB1 
or FB1 alone.  
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Figure 16. Mean excretion pattern of FB1. A) 25 mg FB1/kg b.w. treated groups with 0, 0.25, and 2% UPSN. B) Tabl  of percent reduction 
between FB1 treated positive control group (no clay) and each FB1/UPSN group at time points 12 and 24 hr following gavage. C) 
AFB1/FB1 mixture groups with 0, 0.25, and 2% UPSN. D) Table of percent reduction between AFB1/FB1 treated positive control group 
(no clay) and each AFB1/FB1/UPSN group at time points 12 and 24 hr following gavage. * Indicates a significant difference between the 
positive control group and the UPSN treated group at a specific time point (p<0.05). 
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5.3.7 AFB1-albumin analysis  
Analysis of AFB1-albumin adducts in the serum was conducted following 
euthanasia (72 hr after gavage). Means and standard deviations were calculated based on 
three animals per group. Compared to positive control groups, all three UPSN 
concentrations significantly reduced AFB1-albumin adduct levels (all p-values<0.0001). 
UPSN concentrations of 0.25% and 0.5% were also significantly different (p<0.0001) 
compared to the 2% group, but not to each other (Figure 18A). The mean AFB1-albumin 
concentration was 632 pg/mg albumin for the positive control group (AFB1 treatment 
alone), whereas serum from the 0.25%, 0.5%, and 2% UPSN groups contained 101, 104, 
and 36 pg/mg albumin, respectively. The percent reduction in AFB1-albumin levels by 
UPSN treatment group are shown in Figure 18B. Animals that were gavaged with a 
combination of AFB1/FB1 had significantly higher AFB1-albumin levels (p=0.0061) than 
the AFB1-treated controls. However, UPSN clay was still capable of significanlty 
decreasing the AFB1-albumin biomarker in a dose-dependent manner (Figure 18A). In 
the AFB1/FB1 combination group, the mean AFB1-albumin level was 1,112 pg/mg 
albumin.The adduct concentrations in the 0.25%, 0.5%, and 2% UPSN groups co-
exposed to AFB1/FB1 were significantly different from each other (242, 126, and 37 
pg/mg albumin, respectively).              
5.4 Discussion 
Previous isothermal data from our laboratory indicated that NovaSil clay (a 
calcium montmorillonite) can tightly sorb AFB1 and reduce the bioavailability of AFB1 
in the gastrointestinal tract of animals and humans (Phillips et al. 1995, 2008). 
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Importantly, clay treatment resulted in lower levels of well-established short and long-
term biomarkers of AF exposure in the urine and serum, i.e. AFM1 and AFB1-albumin 
adducts (Wang P et al. 2008). Recent studies demonstrated that NovaSil clay also 
reduced biomarker levels of FB1 in rats and humans (Robinson et al. 2012). A uniform 
particle size NovaSil clay (UPSN) was produced to maintain purity and consistency 
from batch to batch for use in human populations. In preliminary work, UPSN was 
shown to retain the binding properties of the parent product (NovaSil) (Marroquin-
Cardona et al. 2011). Binding analysis performed with heat-collapsed UPSN suggests 
that AFB1 and FB1 binding is saturable and occurs largely within the interlayer regions 
of the clay (Brown KA et al. 2012; Grant and Phillips 1998) providing preliminary 
evidence that both mycotoxins may compete for the same binding sites on surfaces of 
UPSN.  
In the present study, inclusion of UPSN montmorillonite clay during AF 
exposure decreased the excretion of AFM1 in the urine and the production of the AFB1-
albumin adduct in the serum of rats. The overall excretion of AFM1 was similar to that 
reported in a study utilizing Fischer-344 rats in which the majority of AFM1 excreted in 
the urine occurred within the first 12 hr following gavage of animals with AFB1. 
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Figure 17. Area under the curve for AFM1 and FB1 excretion. A) Area under the curve (AUC) for toxicokinetic excretion of AFM1 in
urine. Black bars are indicative of total AUC for rats treated with 0.125 mg AFB1/kg b.w. and 0, 0.25, 0.5, or 2% UPSN. Gray bars are
indicative of total AUC for rats treated with the AFB1/FB1 mixture and 0, 0.25, 0.5, or 2% UPSN. B) AUC for pharmacokinetic
excretion of FB1 in urine. Black bars are indicative of total AUC for rats treated with 25 mg FB1/kg b.w. and 0, 0.25, 0.5, or 2% UPSN.
Gray bars are indicative of total AUC for rats treated with the AFB1/FB1 mixture and 0, 0.25, 0.5, or 2% UPSN. * Indicates a
significant difference between the single toxin treatment and the mixture treatment with the same inclusion percent of UPSN (p<0.01).
 
 
Figure 17. Ar a under the curve for AFM1 and FB1 excretion. A) Are  under the curve (AUC) for toxicokinetic 
excretion of AFM1 in urine. Black bars are indicative of total AUC for rats treated with 0.125 mg AFB1/kg b.w. and 0, 
0.25, 0.5, or 2% UPSN. Gray bars are indicative of total AUC for rats treated with the AFB1/FB1 mixture and 0, 0.25, 
0.5, or 2% UPSN. B) AUC for pharmacokinetic excretion of FB1 in urine. Black bars are indicative of total AUC for 
rats treated with 25 mg FB1/kg b.w. and 0, 0.25, 0.5, or 2% UPSN. Gray bars are indicative of total AUC for rats 
treated with the AFB1/FB1 mixture and 0, 0.25, 0.5, or 2% UPSN. * Indicates a significant difference between the 
single toxin treatment and the mixture treatment with the same inclusion percent of UPSN (p<0.01).  
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 Inclusion of 0.5% of a calcium montmorillonite resulted in a reduction of AFM1 
excretion by 95%, while in the current study, 0.5% UPSN inclusion resulted in a 94% 
total reduction in AFM1 (Sarr et al. 1995). A study utilizing dogs, demonstrated that 
calcium montmorillonite treatment, via food inclusion, following AFB1 gavage could 
lower urinary excretion of AFM1 by as much as 65% (Bingham et al. 2004). Species 
differences in absorption, metabolism, length of digestion, clay dose dissemination, and 
treatment regimen could all possibly account for the differences in efficacy seen between 
these studies. While dogs will consume an entirety of a meal in one sitting, this is not 
typically the case in rodents, especially following gavage, which can be a stressful 
procedure. Thus, it was deemed necessary to include UPSN in the gavage solution for 
the rodent model to ensure adequate time in the GI tract to interact with AFB1 before 
adsorption into the vascular system. The difference in binding efficacy obtained in the 
current study could be ascribed to the route of exposure (i.e., gavage vs. dietary) and 
other physiological conditions prevailing in the gut of rodents.  
Although extensive research focusing on the binding capacity of calcium 
montmorillonite for AF has been conducted, it is only recently that its sorption capability 
for FB has been addressed. Robinson et al. (2012) demonstrated a significant decrease in 
FB biomarkers of exposure following treatment with clay in both rats and humans. In the 
rodent model given 2% clay, FB1 excretion in the urine was reduced by 20% at 24 hr 
post-gavage and 50% at 48 hr post-gavage (Robinson et al. 2012). In the current study, 
the reduction of FB1 biomarkers following inclusion of UPSN at 2% was higher (97%) 
after 24 hr. The protocols for these two studies were similar; however, the current study 
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collected urine samples at more frequent time intervals and the samples were pooled (3 
animals/analysis) within treatment groups. It is also important to note, that in this study a 
refined form of calcium montmorillonite (UPSN) was used which was not the same clay 
used in the study by Robinson et al. (2012). While there is no evidence that UPSN would 
have a higher capacity to bind FB, the isothermal analysis has not been conducted to 
verify this hypothesis, and thus could still be considered a factor in the higher reduction 
of urinary metabolites. 
The present study verifies the results reported for other rodent based metabolic 
studies indicating that treatment with UPSN can reduce the excretion of AFM1 and FB1 
in the urine following exposure to the mycotoxins separately. Since AFB1 and FB1 can 
co-occur under natural conditions (Almeida et al. 2012; Kimanya et al. 2008; Sun G et 
al. 2011), this could enhance risk due to possible synergistic and/or additive effects. The 
mixture of AFB1 and FB1 resulted in a slightly lowered efficacy of UPSN in reducing 
these mycotoxins. Based on AUC calculations, the 2% UPSN group reduced the total 
amount of AFM1 excreted by 98% in the AFB1 treated group alone, and 93% in the 
AFB1/FB1 treated group. AUC values indicated that 2% UPSN decreased total FB 
excretion by 73% in the FB1 treated group and only reduced by 47% in the AFB1/FB1 
mixture. The reduced efficacy of UPSN binding observed in the mixture groups could be 
an indicator of competition for binding sites on the clay. It is evident from this data that 
although UPSN can bind both AFB1 and FB1, it will preferentially bind AFB1 
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Figure 18. Serum AFB1-albumin concentrations. A) Mean serum AFB1-albumin levels for
the AFB1 and AFB1/FB1 treated groups. *Indicates a significant difference between positive
control group and UPSN treated group (p<0.001). ** Indicates a significant difference
between the AFB1 and AFB1/FB1 group (p<0.05). B) Table of percent reduction between
positive control group (no clay) and each UPSN group.
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during co-exposures. This hypothesis is further supported by the fact that there were 
more molecules of FB (3.46x10-5 mole/kg) available for binding than molecules of AF 
(4.01x10-7 mole/kg). Inclusion of 2% UPSN clay could protect humans or animals 
against the toxic effects of AFB1 when there is a mixture of mycotoxins present, 
however it may not be sufficient to completely eliminate the effects from FB1 exposure. 
In contrast to AFB1, a non-genotoxic threshold exists for FB1, (JECFA 2001) suggesting 
that the impaired adsorption may well reduce levels in vivo below that which would 
result in any adverse biological effects. This is of relevance in populations where 
exposure levels of FB1 exceed the provisional tolerable daily intake (PMTDI) proposed 
by JECFA (2001), and UPSN intervention could play an important role in reducing the 
risk of exposure. More research, however, needs to be conducted to determine a 
sufficient level of UPSN inclusion in the diet that could positively impact exposure and 
relevant physiological and/or biological endpoints for combined AFB1 and FB1 toxicity. 
Apart from the effect of UPSN, the amount of AFM1 and FB1 excretion in the 
urine was significantly lower when the toxins were dosed together than when either was 
dosed alone in control groups.  Since AFB1 is more toxic than FB1 the relative reduction 
in their absorption from the gut should also be considered. In addition, it is know that 
AFB1 is absorbed at a high rate, whilst FB1 is poorly absorbed ranging from 1 to 6% in 
non-ruminants (Gan et al. 1988; Scholl P et al. 1996). Studies, utilizing trans-epithelial 
electrical potential suggest that mycotoxins modulate the Na+ co-transport involved in 
sugar and amino acid transport carrier systems (Grenier and Appelgate 2013). It is not 
known whether the uptake of AFB1 and FB1 also co-interact via these mechanisms, 
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although the current study implies that they countered each other’s’ absorption from the 
gut. The modulating role of FB1 on lipid metabolism with the disruption of sphingolipid, 
phospholipid, cholesterol, and fatty metabolism has been reported, resulting in toxic 
effects including an increase in oxidative damage to different cellular constituents 
including the cellular membrane (Abel and Gelderblom 1998; Gelderblom et al. 2001; 
Riley et al. 2001). These different adverse biological parameters are likely to disrupt 
membrane integrity, which led to the hypothesis that the intestine is a possible target for 
FB toxicity (Bouhet and Oswald 2007). This could explain the poor absorption of FB1 
and, in the current study, the disrupted absorption of AFB1, which provides interesting 
scenarios regarding the co-exposure of these carcinogens. Both the in vivo interactive 
liver AFB1/FB1 models utilize AFB1 as the cancer initiating treatment with FB1 as the 
promoter in a separate treatment regimen. The present study implies that the combined 
treatment is likely to reduce the cancer promoting properties of FB1.  
Although the urinary biomarkers were reduced when AFB1 and FB1 were co-
treated, the blood AFB1-albumin biomarker was increased in the presence of FB1. 
Multiple pathways of detoxification and activation occur during metabolism of AFB1 
involving many different cytochrome P-450 enzymes (CYP-450). In particular, the 
AFM1 and AFB1-albumin products are considered to be involved in two separate 
pathways (detoxification and activation, respectively) but can be products of the same 
enzymes (Massey et al. 1995). In rats, the formation of AFM1 is catalyzed 
predominantly by CYP1A1 and 1A2, while the production of the AFB1 8,9-epoxide 
occurs through catalysis with CYP1A2, CYP2A3, CYP2B7, CYP3A3, and CYP3A4 
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with the latter isoform having the highest affinity for AFB1 (Massey et al. 1995). A 
higher level of the AFB1-albumin adduct suggests an increased production of the most 
toxic and carcinogenic metabolite, AFB1 8,9-epoxide in the presence of FB1. In earlier 
work, it was shown that FB1 induced the activity of CYP1A1, 3A1 and 4A1 in rats 
following a 6 day intraperitoneal treatment (Martinez-Larranaga et al. 1996). This 
induction may be responsible for the higher level of the AFB1-albumin adduct observed 
in this study. Thus, the carcinogenic potency of AFB1 is likely to increase in the 
presence of FB1. More studies are warranted to support this conclusion and the 
consequences of combinations of toxins in the diet. 
Results from this study provide evidence for an economical and sustainable 
intervention to reduce exposure to both AF and FB from contaminated diets. Interesting 
interactive effects were noticed related to the combined treatment of the mycotoxins in 
the absence of UPSN, resulting in a 50% and 60% reduction in FB1 and AFB1 
adsorption. The metabolic conversion of AFB1 could also be altered resulting in an 
increased conversion into the 8,9 epoxide and AFM1 presumably due to the selective 
induction of CYP isoforms by FB1. While more research is warranted to find an optimal 
inclusion level for UPSN, the prospect of utilizing this clay as a binder for both toxins is 
promising. This could facilitate important applications to selectively reduce levels below 
the carcinogenic thresholds for initiation and promotion of hepatocellular carcinoma.  
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6. SUMMARY 
 Chronic exposure to dietary AFs remains a public health concern in communities 
consuming large quantities of maize and/or peanut based foods. AF is a known 
carcinogen primarily targeting the liver. In addition to HBV infection, AF has been 
implicated as a major risk factor for the development of HCC in Western Africa and 
Southeast Asia. Importantly, HBV and AF co-exposure causes a synergistic potency in 
HCC risk (calculated to be approximately 30 times higher than with either factor alone). 
In addition, a recent risk assessment study estimated that AF-induced HCC (without 
HBV) accounted for 2,150 to 9,300 annual cases of HCC in Africa. Reports of acute 
incidences of aflatoxicosis, resulting in the deaths of 125 people in Kenya, have verified 
the common occurrence and high levels of AF contamination present in the developing 
world. Even the young are at risk for exposure from ingestion of contaminated breast 
milk and weaning foods.  
The young of all species are more susceptible to the effects of AF than adults. AF 
exposure in the young of various animal species has resulted in growth inhibition and 
faltering. Associations of growth stunting and AF consumption in children in Benin have 
created interest in interventions to reduce the negative effects on child health. Research 
from Ghana, in particular, has indicated a high frequency and level of exposure to AF in 
a farming community located in the Ashanti region. Similarly, a recent estimate of 
dietary AF consumption in Ghana was calculated to be one of the highest in Africa, due 
to the high maize content of the diet (Shephard et al. 2008). The burden of AF exposure 
from the diet in developing countries is a significant problem in the young (and the 
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vulnerable). Moreover, a variety of diverse intervention strategies have not proven to be 
sustainable and practical. Given the complicated cultural, economic, and logistical 
aspects that need to be considered when implementing an intervention, a comprehensive 
survey was conducted in different regions of Ghana to determine risk factors for 
exposure in this particular country.     
An initial objective of our work was to assess AF exposure through biomarker 
analysis from urine samples across different regions of Ghana, which have different 
dietary habits due to cultural, economic, and demographic circumstances. Participant 
urine samples tested positive for a short-term biomarker (AFM1) in 40% of the 
population. This level was significantly lower than observed in samples from the Ejura-
Sekyedumase district in the Ashanti region of Ghana (Obuseh et al. 2010). It is 
important to note that the AFM1 biomarker can fluctuate with changes in the diet, and 
only predicts AF exposures from day to day due to its short half-life. The Greater Accra 
and Central regions of Ghana had the highest percentages of their populations above the 
median level of AFM1, and should be considered as areas of importance for 
interventions. The most notable commonality between these two regions is location; 
both regions are coastal areas and have the highest population density of all the regions. 
Other socio-economic factors, such as gender, age, level of education, and number of 
persons in a household did not appear to affect AF load. Additionally, food preparation 
practices had no effect on overall AF exposure in the participants from this study. Thus, 
education and food sorting/washing, although important for other environmental and 
foodborne contaminants, may need complimentary practices to significantly reduce AF 
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contamination of foods in Ghana. As suspected, consumption of maize was a significant 
risk factor in AFM1 excretion. More than 60% of the participants reported eating maize 
or maize-based products every day. This was higher than peanuts or millet, two other 
important crops that are susceptible to AF contamination. Thus, intervention strategies in 
Ghana should be focused on maize crops and maize-based foods. An appropriate 
intervention should be effective across all economic classes, genders, and age groups, 
and needs to compliment food preparation practices already present in the area. Use of 
an AF sorbent like calcium montmorillonite clay could prevent bioavailability of the 
foodborne toxin that is still present following sorting and washing of contaminated 
grains.  
In numerous animals, NovaSil clay has been shown to be highly effective in 
mitigating the toxic effects of AF exposure from the diet. A three-month intervention 
trial in humans, demonstrated the efficacy of NovaSil to reduce the bioavailability of 
AFs from contaminated food (Wang P et al. 2008). Use of biomarkers of exposure to 
determine the efficacy of intervention trials has long been the standard for AF research 
due to the latent onset of AF related disease. However, previous interventions have 
indicated that it takes at least one-month to observe significant decreases in biomarker 
levels following initiation of treatments. Costly and time consuming trials are not 
plausible for application in the vulnerable, i.e. infants, children, and pregnant females 
due to safety and dosimetry concerns for new products and the requirement for short-
term, Phase I studies prior to long-term interventions. In other work, a short-term (two-
week) cross-over trial was conducted to evaluate the efficacy of the AFM1 biomarker 
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and the significance of clay (UPSN) delivery in food, instead of capsules. Although 
AFM1 excretion is positively correlated with AFB1 intake, the day to day variability of 
this biomarker complicates statistical analysis. However, the cross-over study indicated 
that collecting daily urine samples and pooling the data over five days was effective in 
showing significant reductions of AF exposure in a preliminary trial. Urinary AFM1 was 
reduced by 55% in the UPSN (refined NovaSil) treated group when compared to the 
placebo within five days. Interestingly, the cross-over design clearly indicated the switch 
in treatment groups using the AFM1 biomarker. Future work to alleviate aflatoxicosis in 
children during periods of severe drought could be conducted over short periods of time 
with the use of daily AFM1 biomarkers to indicate individual exposure and efficacy of 
the clay-based therapy. This would significantly reduce the risk of utilizing experimental 
treatments for children when dosimetry has yet to be determined in a vulnerable 
population. It is also important to note that this work also provided evidence that UPSN 
can significantly reduce the bioavailability of AF within five days. Thus, it is the only 
intervention strategy yet reported that has the potential to decrease morbidity and 
mortality in young humans and animals during AF outbreaks.               
Safety and efficacy of reducing AF-induced biological endpoints has also been 
demonstrated in multiple animal models. Afriyie-Gyawu et al. (2008) reported no 
adverse events related to NovaSil consumption in adults over a three-month period. 
Following treatment with NovaSil for three months, serum levels nutrient and non-
nutrient minerals were measured, with NovaSil having a dose-dependent effect on 
strontium (Sr) only. In further work, a Phase I safety evaluation of UPSN in children was 
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conducted to determine dosimetry and potential adverse events in order to translate this 
technology to rural communities in Ghana. Malnutrition and growth faltering result in 
more than 2 million deaths in children per year; importantly, the introduction of 
nutritional supplements in Africa has not had a significant impact on these outcomes. 
Many supplements utilized in Ghana, particularly for the very poor, are homemade 
porridges that contain high contents of maize and peanuts. In a survey of 36 households, 
samples of homemade supplements from the Ejura-Sekyedumase district tested positive 
for AF, with more than 80% of them above the FDA action level of 20 ppb (and one as 
high as 500 ppb). However, discontinuing these supplements could lead to increased 
mortality and morbidity in children from malnutrition. Utilization of UPSN in such 
foods could significantly decrease the effects from AF while maintaining the nutritional 
benefits. At our study site in Ejura, treatment of participants (3-9 years of age) with 
either 0.75, 1.5 g/day UPSN, or calcium carbonate (placebo) did not result in any severe 
adverse events. The most common complaint was vomiting; however the majority of 
those cases were diagnosed with malaria. Hematology and serum biochemistry 
parameters did not show a significant difference between UPSN and placebo groups. 
Only magnesium (Mg) showed signs of a dose-dependent decrease following the two-
week ingestion of UPSN. Those participants consuming the high-dose of UPSN also had 
a significant decrease in AFM1 excretion when compared to the placebo group. Results 
from this work are promising for the future use of UPSN in nutritional supplements 
destined for children. Work needs to be conducted to verify the reduction of Mg in the 
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serum and further determine a minimal effective dose that would be safe for use in 
children.  
The continued work in Ejura has recently indicated that this population is co-
exposed to another important mycotoxin, FB. The homemade nutritional supplements 
from this area all contained FB and 56% of urine samples from adults tested positive for 
an FB1 biomarker (Robinson et al. 2012). FB, like AF, is known to highly contaminate 
maize and initial work with both toxins demonstrated either an additive or synergistic 
effect in cellular toxicity and development of HCC in animal models. Therefore, an 
intervention that can alleviate both AF and FB from the diet would have a dual benefit to 
the population in Ejura-Seykedumase. In our work, NovaSil clay was effective, albeit to 
a much lesser extent than with AF, to reduce the FB1 biomarker in the urine of rats and 
humans. However, the binding capacity was significantly diminished following 
dehydroxylation and denaturing of the interlayer space of the clay (Brown et al. 2013), 
similar to the effects seen with AF. Thus, it was hypothesized that both AF and FB were 
capable of binding to the interlayer surfaces of the montmorillonite and were competing 
for binding sites. In other work, a metabolic study in rats was undertaken to delineate 
efficacy of UPSN in an animal model when both AFB1 and FB1 are present. UPSN 
significantly reduced urinary biomarkers of both AFB1 and FB1 when dosed separately. 
Interestingly, when in combination, UPSN lost some of its efficacy for both mycotoxins, 
although it still appeared to bind AFB1 preferentially over FB1. This would indicate that 
UPSN can be effective in reducing the bioavailability of both mycotoxins; however 
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competition for binding sites may reduce its efficacy and should be considered in future 
intervention trials.  
In summary, AF and FB exposure in Western Africa is seemingly unresolved due 
to food insecurity and climate. Although AF is known to contribute to the morbidity and 
mortality from HCC in the area, it is likely that its impact is even more significant on 
public health through its negative effects on immunity, growth, and nutrient utilization. 
Co-exposure to FB is likely to only exacerbate the issue, as it is known to cause 
cytotoxic and chronic inflammatory problems. Practical and effective intervention 
strategies focused on alleviating the exposure in poor communities and communities at 
high risk for both mycotoxins are critically needed. Inclusion of UPSN in the diets of 
such populations could be a sustainable approach to reduce the health effects of these 
mycotoxins in the vulnerable, thus positively impacting the health of humans and 
animals in the developing world.    
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